Authoritative reviews and expert opinion Industry focused, peer reviewed
• The future of toxicity testing • Epigenetic therapies for non-oncology indications • In silico understanding of infectious agents • Lyotropic liquid crystal systems in drug delivery
December 2010 Volume 15 Nos. 23&24/24
www.drugdiscoverytoday.com
ABOVE & BEYOND
Uncover a New Order in Quantitation Revolutionizing LCMS quantitation...again Mass spectrometry is entering a new dimension in quantitative power. MRM3 offers enhanced fragmentation to your MRM analysis, bringing your quantitation to a new level of selectivity. Watch the background noise vanish from complex matrices with no need to develop costly and time-consuming sample separation procedures. Finally, there is a workflow with the vision to match your own. MRM3...only with the AB SCIEX QTRAP® 5500 System. For more information, visit www.absciex.com/qtrap5500
For Research Use Only. Not for use in diagnostic procedures. © 2010 AB SCIEX. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license.
CONTENTS 1
December 2010 Volume 15 · Numbers 23/24 pp. 983–1114
REVIEWS FOUNDATION
997 The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform Sunita J. Shukla, Ruili Huang, Christopher P. Austin and Menghang Xia
GENE TO SCREEN
1008 Epigenetic therapies for non-oncology indications Jonathan D. Best and Nessa Carey
1015 Pharmacoproteomics: a chess game on a protein field Angelo D’Alessandro and Lello Zolla
INFORMATICS Cover Story The leading story of this issue of Drug Discovery Today, by Sunita J. Shukla, Ruili Huang, Christopher P. Austin and Menghang Xia highlights the US Tox21 collaborative program and how it has brought about a change in approach in toxicity testing of chemical compounds. Standard in vivo testing is being superseded to an extent by higher throughput in vitro assay techniques. This approach is prioritizing compounds for further mechanism of action studies and the development of models to predict adverse events in humans.
1024 Connecting the dots: role of standardization and technology sharing in biological simulation Samik Ghosh, Yukiko Matsuoka and Hiroaki Kitano
POST SCREEN
1032 Lyotropic liquid crystal systems in drug delivery Chenyu Guo, Jun Wang, Fengliang Cao, Robert J. Lee and Guangxi Zhai
1041 Developments towards antiviral therapies against enterovirus 71 Kan X. Wu, Mary M.-L. Ng and Justin J.H. Chu
1052 PubChem as a public resource for drug discovery Qingliang Li, Tiejun Cheng, Yanli Wang and Stephen H. Bryant
1058 Heparin/heparan sulphate-based drugs Neha S. Gandhi and Ricardo L. Mancera
1070 Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives Maribel Navarro, Chiara Gabbiani, Luigi Messori and Dinorah Gambino
Put your research ahead of the curve Experience SciVerse - the new platform for ScienceDirect and Scopus users - with: Integrated search across ScienceDirect, Scopus and the scientific web, ranked by relevance and without duplication New applications that enhance search and discovery, allowing you to search methodologies and protocols, view search terms highlighted in full sentences and see the most prolific authors for search results
Experience it for yourself at www.info.sciverse.com/preview
Open to accelerate science
CONTENTS 2
DRUG DISCOVERY TODAY Editorial Editor: Steve Carney Assistant Editor: Kirsty Strawbridge Content Development Manager: Joanna Aldred Journal Manager: Basil Nyaku Publisher: Jaap van Harten Editorial Enquiries: Drug Discovery Today Elsevier 32 Jamestown Road, London, NW1 7BY, UK Tel: +44 (0)20 7424 4200 Fax: +44 (0)1865 853067 Email:
[email protected]
EDITORIAL 983 Aneuploidy and adult neurogenesis in Alzheimer’s disease: therapeutic strategies Philippe Taupin ADVISORY EDITORIAL BOARD Jurgen Bajorath University of Bonn, Germany Walter Blackstock Experimental Therapeutics Centre, Singapore David Brayden University College Dublin, Ireland Paul Caron Vertex Pharmaceuticals, USA David Cavalla Arachnova, UK David Clark Argenta Discovery, UK Dalia Cohen Rosetta Genomics, USA Donald Daley Argenta Discovery, UK Sean Ekins ACT LLC and Collaborations in Chemistry, USA Hans-Peter Fischer GeneData, Switzerland Peter Ghazal University of Edinburgh, UK Christopher M. Hill Organon, UK Nick Hird Takeda Chemical Industries, Japan Enoch Huang Pfizer, USA Thomas Joos University of Tuebingen, Germany Vincent H.L. Lee Chinese University of Hong Kong, Hong Kong David Lewin Yale University, USA Christopher A. Lipinski Melior Discovery, USA Lorenz Mayr Novartis, Switzerland Nick Meanwell Bristol-Myers Squibb, USA BK Muralidhara Pfizer Global Biologics, St. Louis, USA Mark Murcko Vertex Pharmaceuticals, USA Fajun Nan Shanghai Institute of Materia Medica, China Pradeep Nathan Experimental Medicine, GSK and University of Cambridge Gitte Neubauer Cellzome, Germany Eric Neumann Teranode, USA Tim Peakman UK Biobank, UK Norton Peet Aurigene, USA Manuel Peitsch Novartis, Switzerland Kurt Rasmussen Eli Lilly and Co. Ltd. USA Janice Reichert Tufts Center for the Study of Drug Development, USA John Reidhaar-Olson Hoffmann–La Roche, USA Mike Romanos GlaxoSmithKline, UK Raymond C. Rowe Intelligensys, UK Andreas Russ University of Oxford, UK Esther Schmid Pfizer, UK Jonathan Sheldon Inforsense, UK Michael Snyder Yale University, USA Susie Stephens Eli Lilly and Co. Ltd., USA Robert Strausberg The J. Craig Venter Institute, USA Donny Strosberg Scripps Florida, USA Yuichi Sugiyama University of Tokyo, Japan David Szymkowski Xencor, USA Nick Terrett Ensemble Discovery, USA Vladimir Torchilin Northeastern University, Boston, USA Mark Whittaker Evotec OAI, UK Hans Winkler Johnson and Johnson, Belgium Limsoon Wong Laboratories for Information Technology (LIT), Singapore X.F. Steven Zheng Robert Wood Johnson Medical School, USA
PERSPECTIVE FEATURE
985 The MPTP marmoset model of Parkinsonism: a multi-purpose non-human primate model for neurodegenerative diseases Ingrid H.C.H.M. Philippens, Bert A. ‘t Hart and German Torres
991 Securing reliability and validity in biomedical research: an essential task Thomas Wilckens
MONITOR 1079 Cellular Delivery of Therapeutic Macromolecules (CDTM) International Symposium 2010: lessons and progress from inter-disciplinary science Mark Gumbleton and Arwyn T. Jones
ABSTRACTS 1080 Delegate abstracts
FORTHCOMING ARTICLES: Angiotensin II Receptors and Drug Discovery in Cardiovascular Disease By Chiranjib Dasgupta and Lubo Zhang Creativity, Innovation and Lean Sigma: a controversial combination? By Craig Johnstone, Garry Pairaudeau and Jonas A. Pettersson The graphical representation of ADME-related molecule properties for medicinal chemists By Timothy J. Ritchie, Peter Ertl and Richard Lewis Characteristics of orphan drug applications that fail to achieve marketing approval in the US By Harald E. Heemstra, Hubert G.M. Leufkens, R.P.Channing Rodgers, Kui Xu, Bettie C.G. Voordouw and M.Miles Braun
The 4 e-journals from Drug Discovery Today
Orders, claims, and journal enquiries:
Advertising Enquiries
please contact the Regional Sales Office nearest you:
Commercial Sales Department, Elsevier, 32 Jamestown Road London, NW1 7BY, UK. Tel: +44 (0) 20 7611 4357 Fax: +44 (0) 20 7611 4463 Email:
[email protected]
St. Louis: Elsevier, Customer Service Department, 11830 Westline Industrial Drive, St. Louis, MO 63146, USA; phone: (877) 8397126 [toll free within the USA]; (+1) (314) 4537076 [outside the USA]; fax: (+1) (314) 5235153; e-mail:
[email protected]
Amsterdam: Elsevier, Customer Service Department, PO Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) (20) 4853757; fax: (+31) (20) 4853432; e-mail: JournalsCustomerServiceEMEA @elsevier.com
Tokyo: Elsevier, Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 HigashiAzabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail:JournalsCustomerServiceJapan @elsevier.com
Singapore:
Global Director of Sales Kevin Partridge Tel: +44 1865 84 3717 Email:
[email protected]
Online Access to Drug Discovery Today
New England Vikki Macomber 508-928-1255
[email protected]
Full-text online access to Drug Discovery Today is provided free of charge as part of an individual’s or laboratory’s paid print subscription copy. Subscribers may claim their access by registering at https://cs.sciencedirect.com/activate/ddt/members. Free abstracts to all articles are provided to non-subscribing institutes. Full text articles are also available via Pay Per View.
Mid West & South East Inez Hererro Redman 585-678-4395
[email protected] North/South West Lori Young 347-751-5796
[email protected] California Elizabeth Loennborn 970-300-2557
[email protected]
Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis for institutions. Issues are sent by standard mail to all destinations. Claims for missing issues will be met, free of charge, if made within three months of the date of dispatch. Please send notices of change of address at least eight weeks in advance, including both old and new addresses.
Europe
Abstracting & Indexing
Asia
Biochemistry and Biophysics Citation Index BIOSIS/Biological Abstracts CAB Abstracts International Chemical Abstracts Current Contents (Life Science) EMBASE/Excerpta Medica Index Medicus International Pharmaceutical Abstracts Life Sciences Collection Medline/MEDLARS Online Science Citation Index SciSearch/Science Citation Index Expanded Also covered in the abstract and citation database SCOPUS® Full text available on ScienceDirect®
Wendy Xie +86 10 8520 8827
[email protected]
Photocopying Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For more information on how to seek permissions visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK)/(+1) 215 239 3804 (USA).
Check if you have full-text access at www.sciencedirect.com, or search abstracts and recommend to your information specialist or librarian today. Free abstracts to all articles provided to non-subscribing institutes. Full text articles are also available via Pay Per View.
USA
Elsevier, Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: JournalsCustomer
[email protected]
Copyright Statement © 2010 Elsevier Ltd. All rights reserved. This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd, and the following terms and conditions apply to their use:
Available online-only to Institutional subscribers via ScienceDirect. For more information go to www.drugdiscoverytoday.com
North Europe Daniela Georgescu + 31 20 485 2611
[email protected] South Europe James Kenney + 44 20 7424 4216
[email protected]
The latest developments in drug discovery – direct to your inbox Keep up with our Editor’s choice of latest papers across the literature in drug discovery by signing up for e-alerts to our Editor’s Choice newsletter at http://www.drugdiscoverytoday.com/echoice.htm.
For more information about Drug Discovery Today and for the best guide to the latest innovations in drug discovery, visit www.drugdiscoverytoday.com For a full list of Elsevier products, visit www.elsevier.com
Advertising Artwork Production & Materials Tracey Miller Tel: +44 (0)1865 843808 Email:
[email protected]
Marketing Enquiries Francesca Webb Tel: +44 1865 843244 Email:
[email protected]
Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.
Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
USA mailing notice Drug Discovery Today (ISSN 1359-6446) is published 24 times a year by Elsevier Science (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Periodical postage rate paid at Rahway, NJ and additional mailing offices. POSTMASTER: send address changes to Drug Discovery Today, 11830 Westline Industrial Drive, St. Louis, MO 63146, USA AIRFREIGHT AND MAILING in the USA by Mercury International Ltd, 365, Blair Road, Avenel, NJ 07001, USA
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
EDITORIAL
editorial Philippe Taupin
Aneuploidy and adult neurogenesis in Alzheimer’s disease: therapeutic strategies The confirmation that neurogenesis occurs in the adult brain and neural stem cells (NSCs) reside in the adult central nervous system (CNS) of mammals reveals that the adult brain has the potential for self-repair. Neurogenesis occurs in discrete regions of the adult mammalian brain, the subventricular zone and the dentate gyrus (DG) of the hippocampus, in various species, including humans. Newly generated neuronal cells in the adult brain originate from a pool of residual NSCs. Adult NSCs contribute to the physiology and pathology of the nervous system [1]. Recent studies show that neurogenesis is enhanced in the brain of patients with Alzheimer’s disease (AD) [2]. Enhanced neurogenesis in the brain of AD patients would contribute to regenerative attempts in the CNS, to compensate for the neuronal loss. 1359-6446/06/$ - see front matter ß 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2010.04.001
AD is a neurodegenerative disease associated with learning and cognitive deficits, and for which aging is the main risk factor. The hippocampus is the main region of the brain affected by the disease. There are two forms of the disease: the late onset form (LOAD) diagnosed after age 65 and the early onset form (EOAD) diagnosed at a younger age. Genetic background and acquired and environmental risk factors are causative factors for LOAD, whereas EOAD is primarily an inherited disease. The presence of the apolipoprotein E varepsilon 4 allele (ApoE4) in the genetic makeup of the individuals is the best-established genetic risk factor for LOAD. Mutations in the amyloid precursor protein (APP), the presenilin-1 (PSEN-1) and the presenilin-2 (PSEN-2) genes have been identified as causative for EOAD. Amyloid plaques, composed of deposits of amyloid proteins, and neurofibrillary tangles, composed of aggregated hyperphosphorylated Tau proteins, are the histopathological hallmarks of AD [3]. AD is also characterized by neurodegeneration and aneuploidy in the adult brain [4]. The increase of aneuploid nerve cells in regions of degeneration in the AD brain contributes to the development of the disease. In regions of degeneration, cell cycle re-entry and DNA duplication, without cell division, are at the origin of aneuploid nerve cells in the brain of patients with AD [5]. These cells are fated to die and may undergo a slow death process, underlying the process of neurodegeneration in AD [6]. The ApoE, PSEN-1, PSEN-2 and TAU genes are located on chromosomes 19, 14, 1 and 17, respectively. Aneuploidy for chromosomes carrying genes involved in AD promotes the formation of amyloid plaques, neurofibrillary tangles and neurodegeneration in the brain of patients with AD, LOAD or EOAD depending on the genetic and/or risk factors involved. Dividing cells are the most likely to generate aneuploid cells [7]. Hence, neurogenesis holds the potential to generate new neuronal cells that are aneuploid in the neurogenic regions of the adult brain. Aneuploid new neuronal cells and aneuploid newly generated neuronal cells that would not proceed with their developmental program in the adult brain would be a contributing factor of the pathogenesis of AD in the neurogenic regions. Aneuploidy, for chromosomes carrying genes involved in AD, in newly generated neuronal cells of the adult brain would further promote the pathological process of AD, particularly in the hippocampus [8]. Adult neurogenesis is a relatively low frequency event in the adult brain; it is estimated that 0.004% of the granule cell www.drugdiscoverytoday.com
983
EDITORIAL
Editorial
population is generated per day in the DG of adult macaque monkeys [1]. The hippocampus is one of the neurogenic regions of the adult brain and one of the regions of the brain the most affected in AD. Aneuploid newly generated neuronal cells originating from the nondisjunction of chromosomes during cell division may have their lifespan shortened or may survive for extended period of time. They would contribute to the pathogenesis of AD by promoting the formation of amyloid plaques, neurofibrillary tangles, neurodegeneration and aneuploidy, locally. This suggests that, despite being a low frequency event, the generation of aneuploid new neuronal cells in the hippocampus, in particular, may play a critical contribution to the pathology of AD. Mutated forms of PSEN-1 are detected in interphase kinetochores and centrosomes of dividing cells, where they may be involved in the segragation and migration of chromosomes during cell division [9]. The hyperphosphorylation of Tau by kinases leads to the dissociation of Tau and tubulin and to the breakdown of microtubles causing the disruption in the mitotic spindle, which promotes aneuploidy during mitosis [10]. Hence, genetic and/or risk factors involved in AD would promote the generation of aneuploid new neuronal cells in the adult brain. Enhanced neurogenesis in the hippocampus of patients with AD, and more generally conditions that promote neurogenesis, would contribute to an increase of aneuploidy newly generated neuronal cells in the adult brain. This reveals that adult neurogenesis may be involved in the pathogenesis of AD. In all, adult neurogenesis may contribute not only to regenerative attempts in the nervous system, but also to the pathogenesis of neurological diseases and disorders, particularly in AD. The
984
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
contribution of aneuploid newly generated neuronal cells of the adult hippocampus to the pathogenesis of AD opens new avenues and perspectives for our understanding of and for treating the disease. Therapeutic strategies will aim at specifically targeting aneuploid newly generated neuronal cells of the adult brain, to limit their potential deleterious effects in patients with AD, without disrupting the regenerative capacity of adult neurogenesis. References 1 Taupin, P. (2006) Neurogenesis in the adult central nervous system. C. R. Biol. 329, 465–475 2 Jin, K. et al. (2004) Increased hippocampal neurogenesis in Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 101, 343–347 3 Querfurth, H.W. et al. (2010) Alzheimer’s disease. N. Engl. J. Med. 362, 329–344 4 Kingsbury, M.A. et al. (2006) Aneuploidy in the normal and diseased brain. Cell. Mol. Life. Sci. 63, 2626–2641 5 Yang, Y. et al. (2003) Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J. Neurosci. 23, 2557–2563 6 Yang, Y. et al. (2007) Cell division in the CNS: protective response or lethal event in post-mitotic neurons? Biochim. Biophys. Acta 1772, 457–466 7 Torres, E.M. et al. (2008) Aneuploidy: cells losing their balance. Genetics 179, 737– 746 8 Taupin, P. (2009) Adult neurogenesis, neural stem cells and Alzheimer’s disease: developments, limitations, problems and promises. Curr. Alzheimer Res. 6, 461–470 9 Li, J. et al. (1997) Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 90, 917–927 10 Kim, H. et al. (1986) The binding of MAP-2 and tau on brain microtubules in vitro: implications for microtubule structure. Ann. N. Y. Acad. Sci. 466, 218–239
Philippe Taupin School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland email:
[email protected]
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
PERSPECTIVE
feature The MPTP marmoset model of Parkinsonism: a multi-purpose non-human primate model for neurodegenerative diseases Aging societies face an increasing prevalence of neurodegenerative disorders for which no cure exists. The paucity of relevant animal models that faithfully reproduce clinical and pathogenic features of neurodegenerative diseases is a major cause for the lack of effective therapies. Clinically distinct disorders, such as Alzheimer’s and Parkinson’s disease, are driven by overlapping pathogenic mechanisms that converge onto vulnerable neurons to ultimately cause abnormal clinical outcomes. These similarities, particularly in the early phases of neurodegeneration, might help identify appropriate animal model systems for studying of cell pathology. While reviewing some of the cellular mechanisms of disease progression, we discuss the MPTP-induced model of Parkinsonism in marmoset monkeys as a model system for construct, face and predictive validity in neurodegenerative studies.
Overlapping pathogenic mechanisms and modeling neurodegenerative states Aging Western societies face a steadily increasing prevalence of neurological diseases caused by a progressive degenerative process within the central nervous system (CNS). Neurodegenerative disorders as diverse as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD) have for a long time been regarded as different pathological entities because of their specific clinical symptoms, unique cell pathology and response to drug treatment. These diseases, however, exhibit overlapping pathogenic mechanisms that are conspicuously present throughout the brain parenchyma (Fig. 1). For instance, specific defects in cellular repair
mechanisms and inability to maintain neuronal (e.g. Ca2+) homeostasis can threaten cell function and viability, particularly in genetically prone individuals [1]. The etiology of AD, PD, ALS and HD seems to be woven by similar molecular threads: the aggregation and deposition of microscopically visible abnormal proteins that are causally linked to cellular stress and inflammation. It is not clear, however, how abnormal proteins lead to synaptic damage and then faulty neurotransmission. Understanding the mechanism of toxicity of aggregation-prone proteins for each of these diseases represents the most compelling research endeavor in the neurosciences. Unfortunately, it has come as an acute disappointment that most first clinical trials of therapies designed to mitigate the
1359-6446/06/$ - see front matter ß 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2010.08.009
toxicity of mutant or aggregation-prone proteins have failed to help patients. Furthermore, the paucity of relevant animal models that faithfully reproduce clinical and pathogenic features of neurodegenerative states have also failed to identify basic intracellular events that are causal for the human disease. An exception to this exasperating situation might be the toxininduced model of idiopathic PD (Box 1). The observation in the early 1980s of early-onset Parkinsonism in some Californian drug users who inadvertently injected themselves with 1methyl-4-phenyl-4-propionoxy-piperidine (MPPP, desmethylprodine; a synthetic opioid with effects similar to those of morphine and pethidine) led to the identification of 1-methyl-4phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) as a www.drugdiscoverytoday.com
985
Features PERSPECTIVE
Ingrid H.C.H.M. Philippens1,2,*, Bert A. ‘t Hart1,3 and German Torres2
PERSPECTIVE
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
GLOSSARY 2+
2+
Features PERSPECTIVE
Disturbed Ca homeostasis [34] Regulation of intracellular Ca is vital for proper CNS function. However, relatively high Ca2+ levels during aging might be responsible for agedependent vulnerability to cell injury. In neurodegenerative diseases, neuronal Ca2+regulation is compromised by depletion of energy supply owing to metabolic arrest and loss of mitochondrial function. This invariably leads to synaptic dysfunction, impaired protein plasticity and overall cell degeneration. Excitotoxicity [33] In excitotoxicity, cell death is initiated by the overstimulation of excitatory amino acid receptors by high glutamate concentrations, leading to high intracellular Ca2+ levels. Excitotoxicity also generates ROS accompanied with ATP depletion. Excitotoxicity has been implicated in progressive neurodegenerative disorders through a process in which otherwise healthy neurons are unable to withstand non-lethal glutamate concentrations. Glia activation [12,35] Glia cells play an active part in neurodegenerative processes. After harmful signals to neurons, microglia produce substances (such as cytokines) that keep certain neurodegenerative processes in a constant state of inflammation. There is evidence that clusters of microglia abound in the senescent brain, thus suggesting that activation and proliferation of these cell types could account for age-related neurodegenerative states. Mitochondrial dysfunction [3] Mitochondria organelles, the source for most of the cell’s adenosine triphosphate (ATP) supply, are responsible for regulating membrane potentials and cellular metabolism through Ca2+-dependent autonomous channels. Mitochondrial dysfunction contributes to protein misfolding and aberrant oxidative stress and plays a central part in age-related neurodegeneration. Oxidative stress [10,32] An imbalance in redox homeostasis causes toxic effects on proteins, lipids and DNA strands through the production of ROS. Oxidative stress is one of the key mechanisms involved in neurodegenerative diseases. The primary sources of ROS are mitochondrial dysfunction and microglia oxidative burst. Protein aggregation [5] Several age-related neurodegenerative diseases are associated with protein aggregation or misfolding. It is still unclear whether the protein aggregation is generally toxic or the result of a protective mechanism initiated by injured neurons; however, in inherited forms of neurodegeneration, misfolded proteins often lead to an earlier onset and more severe clinical phenotype than sporadic forms. The current understanding is that microscopic aggregates are protective and that monomers and/or oligomeric precursors of the aggregates are pathological. drug derivative with discrete neurotoxic properties. Subsequent studies in non-human primates (e.g. squirrel monkeys, rhesus macaques and common marmosets) confirmed that injections of MPTP lead to a gross depletion of dopamine (DA) neurons in the substantia nigra pars compacta. This depletion causes a spectrum of movement disorders, including the clinical triad of resting tremor, rigidity and bradykinesia. In general, these initial findings have led to the development of the MPTP-induced model of
Parkinsonism in marmoset monkeys (Callithrix jacchus), which is currently used as a valid preclinical model of idiopathic PD. It should be noted that rodents are a less useful model for neurodegenerative studies because rats are not sensitive to systemic MPTP treatment and DA cell death in mice usually does not lead to the full spectrum of Parkinsonian symptoms. The aim of this review is to list several pathological similarities of the marmoset MPTP-based model with a broad spectrum of neurodegenerative diseases
BOX 1
The MPTP model of neurodegeneration Since the discovery of MPTP, this drug has become the preferred toxin to induce Parkinsonism in laboratory animals. MPTP selectively damages DA neurons, which invariably leads to impaired DA neurotransmission. The toxin is highly lipophilic and after systemic administration rapidly crosses the blood–brain barrier to cause cellular havoc. Within the CNS, MPTP is converted into MPDP+ in astrocytes by the enzyme monoamine oxidase-B; it then spontaneously oxidizes into the metabolite MPP+. MPP+ is released into the extracellular space by an as yet unknown mechanism. MPP+ is taken up by DA neurons vi a the DA transporter. Inside the neuron, MPP+ can be stored either in the vesicular monoamine transporter or mitochondria. MPP+ impairs mitochondrial respiration pathways by inhibiting complex 1 of the electron transfer chain. In this context, MPTP toxicity can be efficiently counteracted by riluzole (a drug already approved for the treatment of ALS [30]) when used in models of DA neuron degeneration [29,31]. Thus, the MPTP model of neurodegeneration can be used for rapid drug discovery and as an in vivo screening assay for drugs and nutritionals that reduce the risk of excitotoxic damage to neurons. 986
www.drugdiscoverytoday.com
(Fig. 2) and to discuss the possibility of using this non-human primate as an alternative model system for preclinical neuroprotective drug development.
Mitochondrial defects and neurodegenerative diseases Early indications for the role of mitochondrial dysfunction (see Glossary) in neurodegenerative states [2] came from studies showing that increases in mitochondrial oxidative stress and/ or accumulation of protein aggregates could produce a devastating pathological and clinical phenotype [3]. This possibility was further supported by the discovery that MPTP inhibits the first enzyme complex of the mitochondrial electron transfer chain (complex I) in brains and platelets of patients with PD [4]. Moreover, the finding that systemic administration of the lipophilic complex I inhibitor rotenone could recapitulate many of the symptoms of PD further highlighted the interrelationship of mitochondrial proteins, oxidative stress and DA cell function [5]. Since then, mitochondrial defects have been implicated in a variety of clinical cases, commonly involving cell networks that have high energy requirements such as those found in the CNS. For example, recessive mutations in the genes encoding DJ-1 and PTEN-induced kinase 1, both localized to mitochondria (or at least to the outer mitochondria membrane), have recently been linked to familial forms of PD [6,7]. Furthermore, several pathogenic mitochondrial DNA (mtDNA) base substitution mutations and mtDNA deletions and insertions have been identified in a variety of other neurodegenerative diseases. For instance, cortical mtDNA deletion levels are elevated in both AD and HD, and AD brains show increased oxidative damage in their mtDNA [8]. Similarly, oligomerized amyloid-b peptide, a large component of plaque pathology in the AD brain, seems to trigger mitochondrial fission or fragmentation via S-nitrosylation of dynamin-related protein [9]. Collectively, these observations rekindle the debate over mechanistic theories of neurodegenerative diseases and also revive interest in oxidative stress as an underlying mechanism for the selective demise of certain neurons. It is worth noting that mitochondrial-based diseases commonly have a delayed onset and a progressive course, very much like those seen in a broad range of neurodegenerative disorders. This is now being studied in the marmoset monkey model of PD, which might provide insights into several novel mechanisms for mitochondrial pathology.
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
[(Figure_1)TD$IG]
PERSPECTIVE
Oxidative stress and brain pathology Oxidative stress (e.g. reactive oxygen species, or ROS) can damage proteins overtly prone to changes in redox-signaling pathways [10]. Fortunately, the burden of ROS production is largely [(Figure_2)TD$IG] neutralized by a complex anti-oxidant
arsenal of enzymatic scavengers including superoxide dismutase, catalase and glutathione peroxidase; however, these protective mechanisms are often weakened by chronic oxidative stress, particularly during senescence. Thus, it is generally accepted that a crucial
PD ALS AD
MPTP
MS HD Drug Discovery Today
FIGURE 2
MPTP causes brain damage with phenotypes overlapping those caused by different etiologies. Neurons are particularly vulnerable to both the toxic effects of MPTP and aggregation of misfolded proteins. Each of these toxic effects converges on pathways that cause motor deficits or dementia. The common characteristics of these neurodegenerative disorders suggest parallel approaches to drug therapy.
balance between ROS production and antioxidant defenses determines the degree of oxidative stress in the aging nervous system [10]. Neurodegenerative diseases might, therefore, represent the effects of a chronic imbalance between ROS production and ROS clearance. Is there any supporting evidence for this working hypothesis? Indeed, alterations in mitochondrial respiratory capacity and agedependent increases in oxidative damage are seen in AD, PD, HD and ALS [11]. The relative contribution of oxidative stress to neurotoxicity is not yet clear, but one possibility is that AD, PD, HD and ALS all share early common mechanisms of oxidative pathology, which later become specific to certain brain regions with different clinical end points. Nonetheless, the observation that diverse brain pathologies show oxidative damage reinforces the central role of mitochondrial metabolism and subsequent energy-dependent ROS production in neurodegenerative states. This link provides a useful framework for understanding disease progression in the marmoset monkey model of PD. www.drugdiscoverytoday.com
987
Features PERSPECTIVE
FIGURE 1
Schematic diagram depicting several pathogenic features found in a broad range of neurodegenerative diseases. The features in the inner circle are responsible for the initial cellular insult that causes failure of neuronal homeostasis. The features in the outer circle are responsible for the maintenance and progression of disease pathology. In some cases, such as in inherited PD or HD, the pathogenic process can originate from the outer circle. All of these intracellular processes of disease are potential targets for drug therapy.
PERSPECTIVE
Microglia activation and neurodegenerative diseases
Features PERSPECTIVE
For decades, glia cells were thought to have only a passive, supporting role in the CNS. It is now becoming increasingly clear, however, that glia cells, particularly microglia, have an active role in inflammatory response signaling events. For instance, microglia cells continuously survey the brain for injury and infection, both during development and during adulthood. Microglia cells promptly migrate to areas of injury and release cytokines such as tumor necrosis factora, interleukin-1b and interleukin-6, which dramatically increase the excitability of nearby neurons. Similar migratory patterns of microglia are found in AD, PD and multiple sclerosis (MS) patients, where they often interact with neurons and surrounding blood vessels. Whether these interactions are helpful or harmful in these clinical conditions is a matter of debate. Regardless, several in vitro studies have demonstrated co-localization of activated microglia cells with amyloid fibrils and a-synuclein aggregates remarkably similar to that seen in neural tissue extracted from patients afflicted with protein-folding-related diseases. This observation implies that aberrant folded proteins might directly injure the synapses and neurites of neurons, in addition to activating microglia cells. Thus, microglia activation as seen in certain neurodegenerative states might result from changes in protein metabolism that occur before widespread cell death ensues, the characteristics of which are often disease specific. Abnormally high levels of activated microglia have also been associated for decades with senescence, thus indicating that the inability to maintain glia cell homeostasis is sufficient to cause common end points in both aging and neurodegenerative states [12]. Work in nonhuman primates also implicates microglia activation as an early step for many of the underlying mechanisms that provoke neuronal death in AD, PD and MS. For example, injections of MPTP into marmoset monkeys selectively damages DA cells in the substantia nigra pars compacta, a pathogenic event that is immediately followed by the clustering of microglia around injured neurons [13]. Of interest, activated microglia in MPTP-treated monkeys remain considerably elevated in the midbrain one year after MPTP exposure [14]. This observation suggests that activation of microglia in areas of injury might be more protracted than previously thought. Furthermore, in an autoimmune model of MS in marmoset monkeys, degeneration of white matter seems to be indirectly mediated by infiltrated inflammatory 988
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
cells, whereas degeneration of grey matter in the same non-human primate is ascribed to highly concentrated recruitment of microglia cells [15]. Of interest, in a superoxide dismutase mutant mouse model of ALS, neurodegeneration can be mitigated by inhibiting the actions of microglia cells, suggesting that – in this particular case, at least – degeneration could be triggered by the abnormal release of microglia-derived cytokines that bind and perturb cell-surface receptors and/ or channels rather specifically [16]. Although the ‘microglia cascade hypothesis of degeneration’ offers a broad framework to explain certain pathological features of AD, PD and MS, it is currently hampered by a lack of detailed mechanistic understanding.
Aggregation and deposition of abnormal proteins Several age-related degenerative diseases, including AD, HD, dementia with Lewy bodies and PD, are associated with aggregation and accumulation of misfolded proteins, the characteristics of which are often disease specific [5]. For instance, in AD, the aberrant deposition of amyloid-b occurs in the form of fibrils or extracellular plaques, whereas in HD, the polyglutamine-containing protein accumulates in the form of nuclear and cytoplasmic inclusions. In PD, the toxic protein is represented by a-synuclein that ‘seeds’ the brain to produce intracellular Lewy bodies [17,18]. It should be noted that the ability of proteins to form highly organized aggregates is not restricted to the few proteins associated with recognized clinical disorders but seems to be a generic propensity of all polypeptide chains. Studies in animal models of AD and PD further support the ability of proteins to change conformation and form small, soluble aggregates that assume toxic states with a wide range of cellular targets. For example, microinjections of fibrillar amyloid-b into the aged marmoset brain induces typical pathogenic aspects of AD [19]. In addition, rat studies show that intracerebral injections of misfolded asynuclein cause degeneration of vulnerable neurons that recapitulate the pathogenic features often seen in sporadic PD [20]. Finally, mice systematically treated with MPTP spontaneously develop protein aggregates that could be equally toxic to the nervous system [18]. Despite the rapid advance in the molecular dissection of protein folding and misfolding, including the identification of several pathogenic proteins, it is not yet known whether clearance of soluble aggregates correlate with disease improvement. There is still considerable work to be done, particularly in non-human primate models of
neurodegenerative diseases, to determine whether therapeutic agents can prevent aggregates from forming or dismantling those already rooted in the brain parenchyma.
Modeling certain pathogenic features of neurodegeneration Animal models offer a useful experimental platform for target identification (e.g. pathogenic mechanism) and validation (e.g. face validity) of candidate drugs (Table 1). Target identification in neurodegenerative diseases is a major challenge, however, because a ‘spider web’ of pathological events – acting separately or synergistically – exist in certain individuals who are at risk of developing a specificdegenerative phenotype (Fig. 1). Furthermore, the multiple and diverse cellular mechanisms that characterize most neurodegenerative diseases conspire to develop an all-inclusive animal model that mimics the most obvious symptoms of the brain disease. Non-human primates, in particular the marmoset monkey, bridge this gap by providing an appropriate animal model for construct, face and predictive validity (‘face validity’ refers to the perceived similarity of the symptoms observed in the model and in the human disorder). More importantly, the close genetic, anatomical, physiological and immunological synteny of marmoset monkeys with humans makes them the preferred species for replicating brain diseases. Besides the anatomical and physiological similarities with humans, behavioral and cognitive deficits, which frequently represent the main source of disability in patients, can be assessed very accurately in the marmoset monkey [21]. There are, however, substantial ethical hurdles and acute differences associated with using monkeys for mimicking neurodegeneration in humans. For instance, potential side-effects associated with invasive approaches to disease replication (e.g. intracerebral injections of pathogenic molecules such as amyloid-b or a-synuclein) considerably limit the use of marmoset monkeys for certain clinical studies. In regards to MPTP, this toxin does not produce dementia with Lewy bodies, amyloid-b or polyglutamine-containing proteins, which are common pathological features of neurodegenerative disorders. Thus, the MPTP-treated marmoset monkey can only serve as a template model for understanding disease mechanisms and potential new drug treatments, rather than predicting different clinical manifestations of a particular brain disorder. This difference in essence relates back to the difficulty of finding an all-inclusive animal
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
PERSPECTIVE
TABLE 1
Neuroprotective compounds used in MPTP-based pathologies, which are also currently approved for preclinical phases of several neurological studies Mechanism of action
Target
Application
Status
Reference
Coenzyme Q10
Anti-oxidant Mitochondrial energy enhancer
Oxidative stress Mitochondrial dysfunction
PD, HD AD
Research
[24]
Creatine
Mitochondrial energy enhancer
Brain atrophy Inclusion formation
ALS, HD, PD
Research
[2]
Apocynin
Anti-oxidant Anti-inflammatory
Oxidative stress Microglia activation
ALS, MS, stroke, PD
Research
[25]
Minocycline
Anti-inflammatory anti-apoptotic
Microglia activation Apoptosis
PD, MS, HD, AD, ALS
Research
[24]
Lipoic acid
Anti-oxidant Anti-inflammatory
Mitochondrial decay Oxidative stress
PD, AD, HD
Research
[26]
EGCGa
Anti-oxidant Anti-inflammatory
Oxidative stress
PD, stroke, AD, ALS
Research
[27,28]
Memantine
NMDAb antagonist
Excitotoxicity
PD, AD
Approved/research
[29]
Riluzole
NMDAb antagonist Ca2+ channel blocker
Excitotoxicity
ALS PD
Approved/research
[30,31]
Rasagiline
Monoamine oxidase-B inhibitor Anti-apoptotic GDNFc activation
b-amyloid, glutamate Apoptosis
PD AD
Approved/research
[24]
a
Epigallocatechingallate N-methyl-D-aspartate c Glial-cell-line-derived neurotrophic factor
model that could point the way to common therapeutic approaches. In this regard, it is certainly conceivable that some of the therapeutic drugs listed in Table 1 could be applied [(Figure_3)TD$IG]
across multiple neurodegenerative diseases. Indeed, memantine 10 mg twice daily has been used to treat several neurological diseases, including those associated with excessive glu-
tamate release (e.g. AD and PD with dementia [22]). Both AD and PD with dementia, regardless of their respective protein aggregate profiles and anatomical lesion loci, are often accom-
FIGURE 3
Magnetic resonance spectroscopy (MRS) imaging analysis of the MPTP-treated marmoset brain [23]. MRS imaging permits in vivo analysis in a regionally specific manner of brain metabolites relevant to neuronal density (N-acetylaspartate, or NAA). In these studies, we hypothesized that in the same MPTP-treated animal, the ratios of NAA to total creatine (tCr, the standard denominator in MRS ratio analyses) would be decreased. This pattern would reflect diminished neuronal viability to MPTP toxicity. Left panel: T2-weighted axial brain section oriented to the SN and reference area in the cortex (COR). Right panel (upper): Representative spectrum from one voxel is shown with peaks identified for NAA and tCr. Right panel (lower): Relative changes in NAA/tCr ratios (means SEM) across defined times (weeks) in the marmoset SN. Note that modafinil (already approved for narcolepsy) also minimizes MPTP-based toxicity. Significant differences compared to baseline (*) and between treatments (§) (one-way ANOVA followed by Bonferroni post hoc tests; P 0.05). www.drugdiscoverytoday.com
989
Features PERSPECTIVE
b
PERSPECTIVE
Features PERSPECTIVE
panied by non-motor complications, such as dementia, sleep disturbances, depression and psychotic symptoms, which invariably worsen their prognoses. This strategy provides rationale for the use of drugs for wider applications than conditions in which cholinergic (for AD) or DA (for PD) are considerably impaired. Furthermore, as better in vivo imaging methods become more widely available in non-human primates (Fig. 3), ambiguities related to cholinergic, glutamatergic or DA function in the brain of living marmoset monkeys suffering from MPTP toxicity will probably become better elucidated [23]. Nevertheless, the well-established MPTP model of idiopathic PD in marmoset monkeys recapitulates most of the core pathogenic mechanisms of the human condition, including mitochondrial dysfunction, oxidative stress, and activation and proliferation of microglia [14]. Furthermore, the neuronal cell loss and neurodegenerative cascade of events after MPTP administration are stable over time, thus providing a window of opportunity for testing pharmacological therapies that modify the temporal and kinetic states of brain pathology. These useful characteristics of MPTP, when applied to the marmoset monkey, can provide relevant mechanistic and therapeutic information that could be used to delay or perhaps even arrest the disease before the more typical symptoms emerge and the damage caused by the neurodegenerative state becomes irreversible.
Concluding remarks Despite the advances in clinical pharmacology and state-of-the-art of animal modeling, innovative approaches to neurodegenerative states are still needed. Rather than placing a lot of effort in the creation of disease-specific animal models, we propose that research efforts should focus on the implementation of a generic model that covers core principles of pathogenetic processes. The MPTP-treated marmoset monkey, for instance, resembles human PD with respect to pathology, biochemistry, symptomatology and response to treatment. Thus, knowledge gained from this animal model will aid in the development of drug therapies for several forms of neurodegenerative diseases.
Acknowledgement The authors would like to thank Henk van Westbroek for his excellent technical assistance regarding the artwork.
990
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
References 1 Lin, M.T. and Beal, M.F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787–795 2 Beal, M.F. (2003) Bioenergetic approaches for neuroprotection in Parkinson’s disease. Ann. Neurol. 53 (Suppl. 3), S39–S47 3 Petrozzi, L. et al. (2007) Mitochondria and neurodegeneration. Biosci. Rep. 27, 87–104 4 Dawson, T.M. and Dawson, V.L. (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302, 819–822 5 Dauer, W. and Przedborski, S. (2003) Parkinson’s disease: mechanisms and models. Neuron 39, 889–909 6 Bonifati, V. et al. (2003) DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 24, 159–160 7 Valente, E.M. et al. (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1158–1160 8 Gu, G. et al. (2002) Mitochondrial DNA deletions/ rearrangements in Parkinson disease and related neurodegenerative disorders. J. Neuropathol. Exp. Neurol. 61, 634–639 9 Cho, D.H. et al. (2009) S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324, 102–105 10 Alexi, T. et al. (2000) Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. Prog. Neurobiol. 60, 409–470 11 Simonian, N.A. and Coyle, J.T. (1996) Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36, 83–106 12 Streit, W.J. et al. (2008) Microglial degeneration in the aging brain – bad news for neurons? Front. Biosci. 13, 3423–3438 13 Kanaan, N.M. et al. (2008) Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys. Glia 56, 1199–1214 14 Barcia, C. et al. (2004) Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46, 402–409 15 Merkler, D. et al. (2006) Differential macrophage/ microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol. 16, 117–123 16 Liang, X. et al. (2008) The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 64, 304–314 17 Taylor, J.P. et al. (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991–1995 18 Gibrat, C. et al. (2009) Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alphasynuclein inclusions. J. Neurochem. 109, 1469– 1482 19 Geula, C. et al. (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4, 827–831 20 Recchia, A. et al. (2008) Generation of a alpha-synucleinbased rat model of Parkinson’s disease. Neurobiol. Dis. 30, 8–18 21 Philippens, I.H.C.H.M. (2008) Non-human primate models for Parkinson’s disease. Drug Discov. Today Dis. Models 5, 105–111
22 Burn, D.J. (2010) The treatment of cognitive impairment associated with Parkinson’s disease. Brain Pathol. 20, 672–678 23 van Vliet, S.A. et al. (2008) Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res. 1189, 219–247 24 LeWitt, P.A. (2006) Neuroprotection for Parkinson’s disease. J. Neural Transm. Suppl. 71, 113–122 25 ’t Hart, B.A. et al. (1990) Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. Free Radic. Biol. Med. 9, 127–131 26 Maczurek, A. et al. (2008) Lipoic acid as an antiinflammatory and neuroprotective treatment for Alzheimer’s disease. Adv. Drug Deliv. Rev. 60, 1463–1470 27 Mandel, S.A. et al. (2008) Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther. 14, 352–365 28 Koh, S.H. et al. (2006) The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci. Lett. 395, 103–107 29 Lipton, S.A. (2007) Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr. Drug Targets 8, 621–632 30 Aggarwal, S. and Cudkowicz, M. (2008) ALS drug development: reflections from the past and a way forward. Neurotherapeutics 5, 516–527 31 Obinu, M.C. et al. (2002) Neuroprotective effect of riluzole in a primate model of Parkinson’s disease: behavioral and histological evidence. Mov. Disord. 17, 13–19 32 McGeer, P.L. and McGeer, E.G. (2008) Glial reactions in Parkinson’s disease. Mov. Disord. 23, 474–483 33 Salin´ska, E. et al. (2005) The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 43, 322–339 34 Mattson, M.P. (2007) Calcium and neurodegeneration. Aging Cell 6, 337–350 35 Gao, H.M. and Hong, J.S. (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 29, 357–365
Ingrid H.C.H.M. Philippens Department of Immunobiology, Biomedical Primate Research Centre, Lange Kleiweg 139, 2288 GJ Rijswijk, The Netherlands Bert A. ‘t Hart Department of Immunobiology, Biomedical Primate Research Centre, Lange Kleiweg 139, 2288 GJ Rijswijk, The Netherlands German Torres Department of Neuroscience and Histology, New York College of Osteopathic Medicine of New York Institute of Technology, Old Westbury, NY 11568, USA
[email protected]
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
PERSPECTIVE
feature Securing reliability and validity in biomedical research: an essential task The buzzword ‘translational’ dominates concepts to optimize value creation from science. This article discusses the impact of ‘old’ and contemporary data on hypothesis generation in relation to human physiology and in the effort to optimally implement translational sciences. I outline how dogmas and errors, sometimes perpetuated over decades, impact contemporary research and drug discovery projects. As a consequence and to improve value creation from science, a reevaluation of old data (i.e. of the validity and reliability of research with regard to human physiology) seems necessary. In line with this, the compliance of newly generated hypotheses, assays and tools with a conceptual focus on human physiology as the gold standard seems essential. To achieve improved research success, several measures need to be initiated and guided by industrial and academic leaders in concert to have an impact on the quality of research in the very near future. There is no ‘holy grail’, but in general terms, a constructive but critical approach – not just to contemporary biomedical research – seems mandatory to avoid the errors of the past and enable solutions to evolve dynamically.
A recent article in the Financial Times proposed ‘drug research needs serendipity’ [1]. What seems rather more needed is an incentive to identify and question pre-existing errors and dogmas, some of which have evolved over decades, and to re-evaluate essential data, which build the foundation of our contemporary research with respect to their relevance to human biology. This requirement could be defined as ‘transcriptional science’ (TS). I will use this paraphrase to describe a conceptual approach analogous to translational science, simply because in biology, transcription is the rate-limiting step for translation, and, if it goes awry, it can lead to false or irrelevant products. To this author, translational science means that human physiology is positioned in the
centre of all biomedical sciences to enable the right questions to translate biomedical research into new therapeutics [2–4]. Thus, the reliability and validity (Table 1) of a given study needs to be assessed a priori. What, however, assures the reliability and validity of the data that are used to delineate translational hypotheses and generate the related experimental designs? An old Chinese saying implicates one aspect: old data should not be neglected but might require reconsideration in a new context (Fig. 1). In general, the quality and value of a study are only as good as the design of the study and, equally importantly, the previous data and related interpretations on which the new hypothesis will be built. This is where the idea of
1359-6446/06/$ - see front matter ß 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2010.10.004
TS steps in: TS aims to exclude data and related interpretations, which poorly relate to human conditions, whether generated in vitro or in vivo, for both hypothesis generation and the design of new studies. If possible, TS will re-evaluate data and extract the content that can be used for translational databases or hypothesis generation, a task that obviously requires manual data analysis and (re)interpretation. TS should serve as an essential prerequisite and quality control for translational research and related drug discovery projects; otherwise, errors will inevitably be perpetuated and invalidate all efforts made in translational sciences. TS requires that researchers approach their own work and the work of others (as well as the related interpretations) most critically, from ancient reports to www.drugdiscoverytoday.com
991
Perspective FEATURE
Thomas Wilckens
PERSPECTIVE
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
TABLE 1
Definitions. Validity and reliability (partially adopted from Wikipedia.org and L.T.F. Gamut, Logic, Language, and Meaning: Introduction to logic, p. 115): Reliability does not imply validity. Both terms are used in test theories and relate to the logic and accuracy of a test, i.e. an experimental design and the related results, if adapted to biomedical research. A reliable measure is measuring something consistently, but one may not be measuring what is being intended to be measured. For example, while there are many reliable tests of specific biological reactions, not all of them would be valid for predicting, for example a glucose response to different stressors. In terms of accuracy and precision, reliability is analogous to precision, while validity is analogous to accuracy. An example often used to illustrate the difference between reliability and validity in the experimental sciences involves a common bathroom scale. If someone who is steps on a scale 10 times and gets readings of 25, 50, 100, 125, etc., the scale is not reliable. If the scale consistently reads ‘‘65’’, then it is reliable, but not valid. If it reads ‘‘80’’ each time, then the measurement is both reliable and valid. This is what is meant by the statement, ‘‘Reliability is necessary but not sufficient for validity.’’ Reliability requires better comparable experiments, while validity asks the question if the experiment is tailored to appropriately answer the questions being asked; i.e. if the experiment is valid in logic terms. In the dynamic context of increasing knowledge in biomedical research, both, reliability and validity of an experiment may require adjustment to the current status of science. I.e. in retrospective reliability and validity may need to be newly assessed for a given experiment, which may enable new hypothesis generation and even conclusions based on data generated earlier.
Perspective FEATURE
modern biomedical research and contemporary work. Obviously, the quest for an approach that assures higher validity and reliability of data used for translational science implies that there are many dogmas and perpetuated errors in our scientific literature and community. Indeed, they do exist and might even have become stronger with time. Some of them seem to erode (i.e. drug-target selectivity as a predictor of desired therapeutic effects has been questioned), and the fact that most compounds are acting on multiple targets is implying new concepts [5]. Similarly, the animal models that are the cornerstones of a research field are being challenged [6].
The cortisol story Here, just one example, which I consider of major impact for our contemporary therapeutic concepts and drug discovery related to a plethora of pathological conditions, will be briefly discussed to demonstrate some interrelationships between various mechanisms that can contribute to the constitution of a dogma. Before getting into details, it should be mentioned that I am not questioning the undisputable negative effects of chronic excessive stress or hypercortisolism. However, that acute cortisol release enables coping with a variety of stressors to defend homeostasis and even enhances immunity [7] challenges the general view of the effects that ‘glucocorticoids’
[()TD$FIG]
as a drug class might have on immunity and inflammation from a teleological viewpoint. I argue that the almost standardized approach – that is, the interpolation of effects mainly generated by the use of synthetic glucocorticoids, which cannot be used in physiological concentrations per definition, or the supraphysiological use of cortisol, often in conjunction with the neglect of appropriate experimental design (there is no physiological state without cortisol present) – has perpetuated a false dogma: glucocorticoids as a drug class are, in general, considered to be immunosuppressive and anti-inflammatory, although the ‘class’ comprises compounds with highly different physiological and pharmacological profiles. Cortisone therapy fell out of favor in the 1950s because of undesired effects observed in high non-physiological doses. The voices of Hench’s contemporary colleagues, who emphasized that low, physiological replacement-like dosing regimens (i.e. lower than those currently considered low dose and using the endogenous cortisol, not prednisone or prednisolone) benefit patients and all the negative effects were due to the very high pharmacological regimens, were overheard [8,9]. When the patents for cortisone expired, new compounds were generated, which aimed to limit some of these undesired effects [10]. In this context, it is almost ironic that lowdose corticosteroid therapy with synthetic compounds, mainly prednisolone, has become a new standard [11].
Drug Discovery Today
FIGURE 1
On Ko Chi Shin, ‘The new ideas reside within the old.’ Confucius (551–479 BC). As this saying indicates, to (re-)investigate and understand old ideas is essential for innovation. 992
www.drugdiscoverytoday.com
Thus, in the very early days of corticosteroid research, dexamethasone (DEX) – a very potent, high-affinity synthetic steroid, which behaves completely differently to the endogenous hormone cortisol – became the gold standard. Fig. 2 summarizes how DEX differs from cortisol, with the sole exception that it also binds to the glucocorticoid receptors (GRs), but not the mineralocorticoid receptor (MR), which cortisol binds to with a higher affinity than the GRs. It was postulated that the sum of DEX’s effects on various targets would eventually reflect the physiological functions of cortisol; although the logic behind this concept has already been questioned, more than ten years ago, the wellsupported arguments had little to no impact [12,13]. The complex interactions of the GRs and a proposed regulation at the tissue level have been described recently [14]. In line with this, a variety of microarray studies have documented that the standard GR and MR agonists induce and repress an overlapping but not identical portfolio of genes: in human liver cells, for example, of a total of 300 genes that are variously regulated by cortisol or corticosterone (both binding to the MRs) and DEX (only GRs), only 25 are equivalently regulated by all three of the gold standard agonists (M. Cidlowski, personal communication). Thus, the interpolation from one compound to the other as a ‘class effect’ seems obsolete, not least because we know that targets like nuclear receptors might dynamically and highly specifically respond to different ligands [15]. A recent and elegant study, however, has demonstrated that minor changes in low physiological corticosteroid concentrations have a major impact on experimental arthritis (i.e. a decrease in local cortisol prevents bone destruction), which is in stark contrast with all clinical experiences with glucocorticoid treatment
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
PERSPECTIVE
Perspective FEATURE
[()TD$FIG]
FIGURE 2
Selected differences affecting function: cortisol binding globulin; (a) metabolism by 11b-HSD; intracellular activation/recycling; binding to GR (five isoforms), MR (two isoforms); (b) GR and MR dimer formation; heterodimer formation occurs physiologically; receptor affinity; receptor–ligand interactions (conformational changes induced by ligand); receptor–ligand co-activator, repressor assembling; (c,d) transrepression/transactivation (differences between all GR ligands); liganddependent change of conformation and related effects. Endogenous cortisol differs from synthetic glucocorticoid receptor ligands (in particular, dexamethasone) at almost every step along the activation and metabolism pathways. Figure modified, with permission, from Ref. [14].
www.drugdiscoverytoday.com
993
PERSPECTIVE
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Perspective FEATURE
in rheumatoid arthritis [16]. Interestingly, although this contention would have immediate consequences for cortisol research related to inflammation and immunity, the authors highlight other results as their major finding, rather than the conflict with current views. It seems there is a bias to stay within the accepted conceptual framework. Similar observations (i.e. a ‘white hat bias’) have been made in obesity research. In general, there seems to be a trend to interpret data within the mainstream framework of a research community [17]. The impact of this dramatic perpetuation of the bias in cortisol research on biomedical research and related drug discovery is best documented by the fact that the putative pro-inflammatory function and essential role of endogenous cortisol in cardiovascular disease, stroke and, possibly, many other diseases might have been overlooked for 50 years [18]. That DEX and similar synthetic glucocorticoids do not activate the MR, which is protected from occupation with cortisol in some, but not all, tissues by a cortisol-catabolizing enzyme [19], might explain why some of these proposed proinflammatory actions of cortisol via the MR [20] were overlooked for decades. The opportunities that will arise from these new discoveries could affect inflammatory conditions such as arthritis, asthma or even metabolic diseases [19,20]. It is also easy to imagine the immense consequences this observation could have had on public health if it had been discovered 40 years ago.
A dogma can evolve from various influences, including patenting interests and the standardization of mainstream thinking and experimental designs; protected by converging commercial and academic interests, it might predominate over decades of research and drug development. In the following paragraphs, some ideas are presented to avoid a similar situation and create new value from existing data.
Data integration and interpretation: improving content How could better ‘content’ in translational terms be achieved? Often, scientists will uncritically or in a biased manner extrapolate experimental conditions and related results from recent highprofile publications to design their studies because it is neither common nor appropriate to question the publications of scientific leaders. This procedure ensures that views and designs that, in retrospect, seem irrelevant from a translational, ‘human physiology first’ viewpoint are perpetuated. The new study, consequently, might result again in data with little physiological relevance, no matter how elegantly and elaborately it is performed. This consequence often seems to be overlooked by the editors and reviewers of leading journals, in which cuttingedge technologies sometimes dominate the evaluation of a manuscript over the generation and foundation of the hypothesis per se.
In conjunction with this constellation, systems biology [21], systems chemical biology [22], bioinformatics, semantics and other tools that aim to support translational science in general [23] also rely on the quality of data entered into the relevant database. As outlined above, however, these data might be confounded if they are not manually evaluated. Thus, all computational methods are certainly helpful to extract and organize data; however, they cannot replace content ranking by the human brain, which is still superior in validating complex data constellations and experimental designs. Creating transcriptional (i.e. high-confidence content) databases might seem an insurmountable obstacle in light of the exponential growth of data. However, if each project were to start with a standardized approach to ranking and interpreting data in hypothesis generation, with respect to their relevance to the in vivo dynamics of human physiology, improved validity and reliability of contemporary research seems feasible. The standards for such a content ranking approach need to be generated first, which is challenging because even defining which questions should be asked and identifying common denominators in a given field of research might seem too complex. Nevertheless, it is anticipated that even simple standards and ranking tools could improve the quality of new data considerable. There must be both academic and commercial interest in further developing
[()TD$FIG]
Identification of physiologically relevant data
Identification of physiologically irrelevant data
Definition of standardized translational/physiological experimental designs
Validated physiological relevant databases
Incorporation of semantic computational technologies with individual content ranking
Repetition of key experiments under physiological conditions
“Transcriptional Science”:
• Ensuring reliability and validity • Ensuring physiological content • Re-evaluation of existing data • Validation of existing data • Identification & elimination of dogmas Selected benefits:
• New views and theories • New uses for existing compounds • New therapeutic concepts • Optimized use of resources • Enabling open disputation? Drug Discovery Today
FIGURE 3
Transcriptional science: an essential prerequisite to enable translational sciences. If uncritically adopted, existing physiologically questionable or irrelevant data, related interpretations and dogmas will unequivocally be perpetuated and invalidate translational science a priori, including all financial investment. 994
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Experimental design and standardization: biomarkers and more When is an experiment physiologically relevant? It would be prudent to try to give a simple answer, but a direct consequence of this question is the fact that we need more standardized and truly physiologically relevant model systems to make data better comparable and, in particular, to rank them in a physiological context. First questions that come to mind are ‘When is an experiment reflecting male or female conditions?’ and ‘How relevant is this after all?’ In relation to the discussion above, small changes of cortisol dramatically impact on cellular functions (i.e. induce opposing functions in physiological concentrations) [26]. Findings like this force thought-provoking questions, such as ‘How many in vitro assays, not just in this field, are of physiological relevance at all?’ Ultimately, TS implies that experiments that built the foundation of previous drug discovery programs and studies in progress must still be analyzed with respect to their physiological relevance, but they might also need to be repeated (e.g. to include new control conditions), perhaps often. At first, repeating ‘old’ studies might have little appeal for researchers driven by their hunt for impact factor scores. If appropriately addressed, however, the identification of new, more physiological functions for any given physiological pathway could open new and unexpected avenues for innovative treatments. This would ensure progress for both science and the scientist. In addition to efforts to make data comparable, in particular for drug discovery, new standards for experiments might need to be agreed; generally defined and accepted biomarkers are one first approach. Regulatory authorities might require such initiatives sooner or later, but the consolidation of biomedical research forces a more efficacious use of resources now. If one only analyses the investments made in cortisol research since the patent expired in the 1950s (which was a major driver for new compounds at the time) and discovery projects based on data with limited translational relevance, it becomes obvious what resources could be released if our scientific approaches included a more aggressive evaluation of the existing fundaments on which
we build our views and opinions, which often are prematurely interpreted as the truth (Fig. 3).
Transcriptional science, an integral part of translational sciences and its culture In his review, titled ‘Translational research: forging a new cultural identity’, Barry Coller identified several challenges ahead, including the willingness to embrace change in general and to induce a new culture of scientific disputation [27]. Ensuring the reliability and validity of data generated in the paradigm of translational sciences will primarily require the implementation of a new culture in biomedical research, not another new terminology like ‘transcriptional sciences’, to assess data and scientific hypothesis more openly and with constructive criticism. Concepts such as endogenous angiogenic factors would not have been developed successfully if people like Judah Folkman had not resisted the opposition to their ideas and questioned dogmas throughout their careers. Scientists in the industry and academia will have to appreciate that critical comments might help to improve the impact of their work, if the criticism is conveyed in an appropriate and constructive manner, ideally before the work is started. Open discussions and converging expertises are the only measures that will ultimately ensure a higher return of investment for societies. ‘Open content ranking forums’, established by publishers for specific areas of research, might be one approach worth exploring. Within companies, specific IT solutions for in-house content ranking by the companies’ scientists, enabling them to participate proactively, could be developed. ‘Constructive devil’s advocates’ (i.e. experts in challenging designs and ideas) could be trained and become part of project teams to promote a better success (translation) rate. In general, eliminating misleading concepts and experiments at the right time with the right questions should be rewarded – for example, by progression of a project to a milestone – both in academia and the industry. In addition, negative data or data that do not fit our current views should be more appreciated. Challenging dogmas or falsifying accepted or new theories does not really exist as a research goal, although it is an equally logical and rewarding approach to generating knowledge [28]. After all, science gets exciting when things do not fit and new ground is touched. There is no holy grail to achieve a better return on investment in biomedical research related to personal effort and funding, but there are many ad hoc opportunities to improve the reliability and
validity of experimental designs and extract additional value from old knowledge. To unfold this potential and secure progress in finding new cures for unmet needs, however, will require a concerted approach that can only be initiated and guided by leaders from academia and industry in concert. References 1 Shawitz, D. and Taleb, N. (2008) Drug research needs serendipity. Financial Times 2 Littman, B.H. et al. (2007) What’s next in translational medicine? Clin. Sci. (Lond.) 112, 217–227 3 Nathan, D.G. (2005) The several Cs of translational clinical research. J. Clin. Invest. 115, 795–797 4 Fitzgerald, G.A. (2005) Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nat. Rev. Drug Discov. 4, 815–818 5 Mestres, J. and Gregori-Puigjane, E. (2009) Conciliating binding efficiency and polypharmacology. Trends Pharmacol. Sci. 30, 470–474 6 Martin, B. et al. (2010) ‘‘Control’’ laboratory rodents are metabolically morbid: why it matters. Proc. Natl. Acad. Sci. U.S.A. 107, 6127–6133 7 Dhabhar, F.S. (2009) Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 16, 300–317 8 Jefferies, W.M. (1955) The present status of ACTH, cortisone and related steroids in clinical medicine. N. Engl. J. Med. 253, 441–446 9 Jefferies, W.M. (1967) Low-dosage glucocorticoid therapy: an appraisal of its safety and mode of action in clinical disorders, including rheumatoid arthritis. Arch. Intern. Med. 119, 265–278 10 Jefferies, W.M. (1996) Safe Use of Cortisol. Charles C Thomas Publisher Ltd 11 Hoes, J.N. et al. (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 66, 1560–1567 12 Wilckens, T. (1995) Glucocorticoids and immune function: physiological relevance and pathogenic potential of hormonal dysfunction. Trends Pharmacol. Sci. 16, 193–197 13 Wilckens, T. and De Rijk, R. (1997) Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today 18, 418–424 14 Gross, K.L. and Cidlowski, J. (2008) Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol. Metab. 19, 331–339 15 Margolis, R.N. et al. (2009) Chemical approaches to nuclear receptors in metabolism. Sci. Signal. 2 mr5 16 Buttgereit, F. et al. (2009) Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum. 60, 1998–2007 17 Cope, M.B. and Allison, D. (2010) White hat bias: examples of its presence in obesity research and a call for renewed commitment to faithfulness in research reporting. Int. J. Obes. (Lond.) 34, 84–88 18 Funder, J.W. (2009) Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53, 286–290 19 Cooper, M.S. and Stewart, P.M. (2009) 11{beta}Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic
www.drugdiscoverytoday.com
995
Perspective FEATURE
this kind of knowledge base and content ranking, which is essential for informed decision making in any problem in biomedical sciences. Some aspects of the problem (i.e. too many neglected data) have been acknowledged [24], but the solution might require ‘competitive collaboration’, not only within the pharmaceutical industry [25] but also including academia.
PERSPECTIVE
PERSPECTIVE
Syndrome, and Inflammation. J. Clin. Endocrinol. Metab. 94, 4645–4654 20 Rickard, A.J. and Young, M.J. (2009) Corticosteroid receptors, macrophages and cardiovascular disease. J. Mol. Endocrinol. 42, 449–459 21 Krishna, R. et al. (2007) Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development. J. Clin. Pharmacol. 47, 738–743 22 Oprea, T.I. et al. (2007) Systems chemical biology. Nat. Chem. Biol. 3, 447–450
Perspective FEATURE 996
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
23 Ruttenberg, A. et al. (2007) Advancing translational research with the Semantic Web. BMC Bioinformatics 8 (Suppl. 3), S2 24 Editorial, (2009) Data’s shameful neglect. Nature 461, 145 25 Bingham, A. and Ekins, S. (2009) Competitive collaboration in the pharmaceutical and biotechnology industry. Drug Discov. Today 14, 1079–1081 26 Lim, H.Y. et al. (2007) Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 122, 47–53
27 Coller, B.S. (2008) Translational research: forging a new cultural identity. Mt. Sinai J. Med. 75, 478–487 28 Popper, K. (1934) The Logic of Scientific Discovery, Springer, Vienna
Thomas Wilckens Jakob-Klar-Str. 7, 80796 Mu¨nchen, Germany
[email protected] [email protected]
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
A synopsis of the Tox21 initiative and a focus on the NIH Chemical Genomics Center’s efforts within this program using in vitro methods and quantitative high-throughput screening.
Sunita J. Shukla, Ruili Huang, Christopher P. Austin and Menghang Xia NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3370, USA
The US Tox21 collaborative program represents a paradigm shift in toxicity testing of chemical compounds from traditional in vivo tests to less expensive and higher throughput in vitro methods to prioritize compounds for further study, identify mechanisms of action and ultimately develop predictive models for adverse health effects in humans. The NIH Chemical Genomics Center (NCGC) is an integral component of the Tox21 collaboration owing to its quantitative high-throughput screening (qHTS) paradigm, in which titration-based screening is used to profile hundreds of thousands of compounds per week. Here, we describe the Tox21 collaboration, qHTS-based compound testing and the various Tox21 screening assays that have been validated and tested at the NCGC to date. Introduction Traditionally, the toxicological evaluation of environmental chemicals has largely relied on animal models that have been used to extrapolate to potentially harmful events in humans. These models have been developed to evaluate specific toxicological endpoints, such as oral, dermal and ocular toxicity; immunotoxicity; genotoxicity; reproductive and developmental toxicity; and carcinogenicity. Although these animal models have provided useful information on the safety of chemicals, they are relatively expensive, low throughput and sometimes inconsistently predictive of human biology and pathophysiology. Recently, several major new initiatives have begun to utilize in vitro methods and a variety of new technologies to develop in vitro signatures and computational models predictive of in vivo response. These initiatives should enable researchers to identify a battery of in vitro assays that will detect perturbations in cellular pathways that are expected to contribute to or result in adverse health effects [1]. Furthermore, these initiatives represent a welcome movement away from traditional in vivo high-dose hazard studies [1]. To appreciate the scientific and technological advancements that are shaping toxicity testing today, it is important to appreciate where this new paradigm fits in the context of historical testing.
Reviews FOUNDATION REVIEW
Foundation review: The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform Dr Sunita J. Shukla is currently a postdoctoral fellow at the NIH Chemical Genomics Center (NCGC). She is currently working under the guidance of Dr Menghang Xia in developing in vitro toxicity-based assay screening using a quantitative high-throughput screening platform. Furthermore, she is also working under the guidance of Dr Doug Auld in the area of assay development and high-content screening. Dr Shukla is the first recipient of the Humane Society/Procter and Gamble Fellowship honoring the advancement of alternatives to animal testing. Before joining NCGC, she received her Ph.D. in Human Genetics, with a focus on pharmacogenetics of anticancer agents, from the University of Chicago in the lab of Dr M. Eileen Dolan in 2007. Additionally, she received a Master of Public Health degree at Saint Louis University with a focus on Epidemiology and Environmental/ Occupational Health in 2001. She has authored or co-authored 13 peer-reviewed publications. Dr Christopher Austin is director of the NIH Chemical Genomics Center (NCGC) and senior advisor to the Director for Translational Research at NHGRI. The NCGC is an ultra-highthroughput screening, informatics and chemistry center that develops novel compounds as probes of biology and starting points for development of new drugs for rare and neglected diseases, profiles small-molecule libraries for biological and toxicological activities and develops new paradigms to increase the efficiency and genome-wide reach of assay, screening, chemistry and informatics technologies. Dr Austin received his A.B. from Princeton and M.D. from Harvard, trained in neuroscience and genetics at Harvard, and came to NIH in 2002 from Merck. Dr Menghang Xia is group leader of cellular toxicity and signaling at the NIH Chemical Genomics Center (NCGC). Dr Xia and her research group are currently focused on the target-specific and mechanism-based toxicological studies, in collaboration with the Biomolecular Screening Branch at the National Toxicology Program (NTP) and National Center for Computational Toxicology at the US Environmental Protection Agency (EPA). Her group has developed and validated a battery of in vitro toxicological assays using a quantitative high through screening platform, and investigated the mechanism of action of chemicals in multiple cellular signaling pathways. Dr Xia received her Ph.D. from State University of New York at Buffalo, did postdoctoral training at University of California at San Francisco, and joined NCGC in 2005 from Merck.
Corresponding author:. Xia, M. (
[email protected]) 1359-6446/06/$ - see front matter. Published by Elsevier B.V. doi:10.1016/j.drudis.2010.07.007
www.drugdiscoverytoday.com
997
accepted vision for future toxicology testing, calling for the development and use of in vitro models in human cells of toxicological response based on automated high-throughput screening (HTS) of pathway-based cellular assays related to toxicity and computational modeling [12]. The report envisioned that initially, such less expensive and higher throughput assays could be used to evaluate the modes of action of chemicals for more comprehensive testing programs and that eventually these data would enable the rapid and mechanism-based prediction of in vivo biological responses [2,13,14]. To move this research agenda forward, the NTP partnered with the NIH Chemical Genomics Center (NCGC) in 2005 to pilot the chemical, biological and informatics processes required for the transition from predominantly in vivo to in vitro toxicology. In 2006, this partnership was expanded to include the EPA. In 2008, in recognition of successful proof-of-principle studies [3,15] and galvanized by the NRC report, the ‘Tox21’ collaboration was formally established via a Memorandum of Understanding among the agencies (http://ntp.niehs.nih.gov/) and publication of a policy paper from the senior leadership of the three organizations [16]. The Tox21 collaboration takes advantage of the complementary strengths of the three partners (Fig. 1). The NTP, a trans-Department of Health and Human Services program headquartered at the NIH National Institute of Environmental Health Sciences, has enormous experience in experimental toxicology. The NCGC, a trans-NIH program administered by the National Human Genome Research Institute, has unparalleled capacity and expertise in in vitro assays, titration-based screening and informatics. The EPA National Center for Computational Toxicology, part of the EPA’s Office of Research and Development, has deep computational
998
www.drugdiscoverytoday.com
lT na tio
The advent of technological innovations in molecular and cellular biology prompted the National Toxicology Program (NTP) to propose a new Roadmap in 2004, ‘A National Toxicology Program for the 21st Century’ [10], focusing on three main areas: refining traditional toxicology assays, developing rapid mechanism-based predictive screens and improving the overall utility of data for making public health decisions. This Roadmap placed an increased emphasis on the use of alternative assays for identifying key pathways and molecular mechanisms linked to disease [10]. The US Environmental Protection Agency (EPA) started its ToxCast program in 2006 to address many of the same issues [11]. When these programs were in their early stages, a 2007 report from the National Research Council (NRC) entitled Toxicity Testing in the 21st Century (Tox21) enunciated what has become a widely
y nc ge nA tio gy ec olo rot es xic tat al P To ter d S nt en nal me ite l C tio Un iron na puta v tio En Na Com for
Toxicity testing in the 21st century and the US Tox21 partnership
Na
Reviews FOUNDATION REVIEW
Since its inception, toxicity testing has relied on animal models treated at maximum tolerated dose levels, with the results extrapolated to human health outcomes at lower doses. This approach dates back to the 1950s, when the use of more specific or mechanistic animal models, and knowledge of the underlying mechanisms for any particular toxicological response, were relatively unknown [2]. Such in vivo testing is costly, time consuming and low throughput [3]. The complete toxicological profiling of one chemical in standard in vivo assays consisted of the following toxicity tests: acute, subchronic and chronic toxicity; reproductive toxicity; developmental toxicity, ocular and skin irritation, hypersensitivity, phototoxicity and toxicokinetic studies [4]. Despite the disadvantages associated with testing in animals, the majority of the understanding regarding chemical toxicity has come from data obtained in such systems [5]. Even extensive animal testing does not provide a mechanistic understanding of toxicity and knowledge concerning adverse risks to humans is still inadequate [6]. Hence, a need for more mechanistic data and a ‘theoretical framework for rational decision making’ was noted in the early 1980s [6]. More recently, there have been numerous studies highlighting intra- and inter-species differences in mammals, including humans. Williams and Weisburger [7] pointed out that intraspecies differences among different mouse strains affect the severity and incidence of neoplasms, making extrapolation of various cancers from mice to humans difficult. Inherent resistance to spontaneous and malignant tumors in nonhuman primate models has also led to variations in the manifestation of disease across these species [8]. In addition to inter- and intra-species differences in disease models, other species-specific differences that affect disease outcome and extrapolations include differences in basal metabolic rate, metabolic pathways, cancer type (sarcomas in mice versus carcinomas in humans), genetic aberrations associated with tumors, and telomere biology, especially with regard to humans and mice [9]. In addition to physiologic differences, the difference in observed high-dose toxicity in rodents and low-dose risks in humans will require knowledge of physiological differences with regard to mode, tissue of exposure, mechanism of action and knowledge of previous in vitro data regarding the agent in question.
es
Traditional toxicity testing methods
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
ox Na ico of tion log En al I yP vir ns on titu rog me te ram nta lH ea lth Sc ien c
REVIEWS
National Human Genome Research Institute
NIH Chemical Genomics Center Drug Discovery Today
FIGURE 1
The Tox21 collaboration. The Tox21 collaboration brings together the experimental toxicology expertise of the NTP, high-throughput screening technology at the NCGC and computational toxicology expertise at the EPA.
toxicology expertise [14]. This combined expertise has enabled rapid implementation of the NRC vision, the application of novel methodologies to evaluate a large number of chemicals in a range of in vitro assays in a short period of time [17]. Although realization of the NRC vision might ultimately require a research effort on the scale of the Human Genome Project [18], success of this effort would be transformational for toxicology testing for environmental and pharmaceutical chemicals, providing cheaper, faster and more accurate assessment of the toxicological potential of new chemicals.
Role of the NCGC in the Tox21 collaboration The NCGC was established in 2004 as the first assay development, screening, informatics and chemistry center of what was to become the NIH Roadmap Molecular Libraries Probe Production Center Network. The Molecular Libraries Initiative, a component of the NIH Roadmap for Medical Research, was born from the need for new approaches to determine function and therapeutic potential of human genes on the heels of the Human Genome Project and to accelerate the pace at which basic research is translated into small-molecule therapeutics [17] (http://nihroadmap.nih.gov/ molecularlibraries/). As part of the NCGC’s technology development program, a platform for automated testing of hundreds of thousands of compounds in titration-based format over a short period of time was developed [13,19], and this quantitative highthroughput screening (qHTS) platform has become a central aspect of the Tox21 program. Traditional biological assays have been low throughput, employing animal models and labor-intensive testing of samples. Furthermore, the growth of small-molecule collections required the development of HTS technologies to test a large number of compounds in a timely manner [20]. Although HTS has successfully enabled the screening of large chemical libraries to generate hits for medicinal chemistry optimization in the setting of drug discovery, HTS as traditionally practiced is not suitable for toxicity testing because it assays each compound at only single concentration [19] and, thus, generates large numbers of false positives (FPs) and false negatives (FNs) [21]. By contrast, the qHTS paradigm tests each compound at multiple (7–15) concentrations across an approximately four-log concentration range, thus producing concentration–response-based activity profiles of all compounds from the primary screen with greatly reduced FN and FP rates. Miniaturized assay volumes (<10 mL/well) in a 1536-well-plate format provides the throughput to generate concentration–response curves (CRCs) for every compound library member tested [22]. Curve fitting and CRC classification characterizes each curve based on parameters, such as curve fit and efficacy after the primary screening in a qHTS format, enabling the identification of structure–activity relationships (SARs). The NCGC makes its screening data publicly available through PubChem (http://pubchem.ncbi.nlm.nih.gov) and its software available on its website (http:// www.ncgc.nih.gov/pub/openhts/) to enable the scientific community to utilize the data in their own research [23]. The ability of qHTS to produce reliable activity profiles of chemicals has also enabled the NCGC to profile large libraries of chemicals for their propensity to produce assay artifacts, which would otherwise be interpreted as true biological effects [24]. NCGC has taken advantage of titration-based screening to identify
REVIEWS
compounds that produce a wide variety of different artifactual activities, including apparent enzyme inhibition through compound aggregation [25], compound autofluorescence [26] and firefly luciferase inhibition [27]. These profiling examples demonstrate the utility of qHTS in distinguishing true effects from artifacts for more reliable toxicity screening and efficient chemical probe development.
NCGC chemical library collection used for Tox21 assays An essential component of NCGC’s qHTS paradigm is the availability of large chemical libraries in a titration-based format. The availability of several concentrations across different plates gives the user flexibility to use concentrations relevant to the assays. In total, the NCGC has well over 400,000 compounds from the NIH Molecular Libraries Small Molecule Repository and NCGC-specific compound collections. The latter currently includes approximately 1400 compounds each from the NTP and EPA compound libraries and 2816 clinically used drugs in the NCGC Pharmaceutical Collection (NPC). Overall, compound selection is based on having a defined chemical structure and known purity, in addition to the extent of each compound’s solubility in dimethylsulfoxide (DMSO) [13]. One limitation of compound storage in DMSO is precipitation (augmented by DMSO water content and number of freeze–thaw cycles) [28]. Compound integrity studies using P450 assays and qHTS at NCGC revealed decreased compound potency over time and lower efficacy of older samples stored in DMSO [29]. For this reason, compounds are used in screening collections at the NCGC for no longer than four to six months. The current NTP compound collection consists of 1408 compounds, with more than 50 of the compounds represented twice to assess assay reproducibility. The NTP collection includes solvents, fire retardants, dyes, preservatives, plasticizers, therapeutic agents, inorganic and organic pollutants, drinking water disinfection byproducts, pesticides and natural products [3]. Selection of the 1408 compounds was partly based on the availability of toxicological data from standard tests of carcinogenicity, genotoxicity, immunotoxicity and/or reproductive and developmental toxicity [3]. Compounds were prepared as 10 mM stock solutions in DMSO and 14 plates representing 2.23-fold dilutions in 1536-well compound plates from 384-well plates [30]. The current EPA collection consists of 1462 compounds prepared similarly to the NTP compound collection. Compounds were primarily selected based on the need to screen and prioritize environmental chemicals to which humans are exposed through the environment or food. These chemicals include those known to be bioactive, those manufactured or used in large quantities and those to which humans are exposed on a routine basis [31]. In the near future, approximately 1400 additional compounds will be added to each of the NTP and EPA libraries for testing as an integrated Tox21 library [14]. The NPC collection (R.H. et al., unpublished) was prepared at the NCGC and currently contains 2816 small molecules, 52% of which are approved by the Food and Drug Administration for human or animal use in the United States. The remaining drugs are either approved for use in other countries, such as Europe, Canada or Japan, or are compounds that have been tested in clinical trials. The majority of the NPC collection is prepared as a 10 mM stock in DMSO and prepared as 15 2.23-fold dilution plates in 1536-well format [30]. Currently, an additional 1400 compounds are being www.drugdiscoverytoday.com
999
Reviews FOUNDATION REVIEW
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
added to the NPC collection. The next phase of Tox21 testing will begin later this year, using the combined NTP, EPA and NPC compound sets, totaling more than 10,000 chemicals.
NCGC technology Reviews FOUNDATION REVIEW
The NCGC characterizes toxicity endpoints in cell-based assays utilizing integrated robotic systems combined with batteries of in vitro assays and computational analysis [32]. The NCGC robotic platform stores large compound collections, performs distinct assay steps and measures user-defined assay outputs in an integrated manner [23]. The compound storage unit is capable of storing approximately 300,000 compounds in seven-point titrations, which correlates to more than 2.2 million compound samples [23]. A pin transfer station performs the transfer of 23 nL of compound from a 1536-well compound plate to a 1536-well assay plate, with each plate holding up to 1408 compounds (located in columns 5–48). Assay-specific controls (located in columns 1–4) are located on an additional 1536-well compound plate and transferred simultaneously with the test compounds to the assay plate [23]. Solenoid dispensers, having the capability of dispensing volumes ranging from 200 nL to 20 mL, are used for reagent and cell dispensing. Furthermore, up to eight tips can be used for dispensing in either 908 direct dispense or 458 angled head dispense with regard to the well. This allows for the modification of straight head and angled dispense, depending on the reagent type and condition of cells (i.e. if they are grown in a delicate monolayer, then it might be suitable to use the angled head dispense). For the aspiration of liquid, each dispenser comes equipped with an aspiration head made of 32 stainless-steel tubes for columnwise removal of reagents or media from the plate. The aspirator head enables cell washing and fixing in 1536-well format [33] for cell-cycle protocols or protocols involving antibody steps. There are several factors that can be optimized with the dispenser and aspirators, such as dispense volumes, aspiration depth and aspiration speed [23]. There are four different types of detectors that are currently integrated into the robotic system. These detectors essentially enable a wide variety of assays to be performed at NCGC and accommodate various assay technologies. Furthermore, these readers cover the entire spectrum of speed and information content. Although charged-coupled-device-based camera imagers are capable of very fast read times per 1536-well plate (<1 min/plate), they provide the least information regarding characteristics of individual cells. The converse is true for confocal-based imaging readers, which can provide detailed information on subcellular structures with longer read times (1 hour/plate). Specifically, the EnVision and ViewLux (PerkinElmer) are photomultiplier-tubeand charged-coupled-device-based instruments, respectively, which cover a wide range of fluorescence, absorbance and luminescence [3,15,34,35] bulk well readouts commonly used in highthroughput assays [23]. The ViewLux can be used for luminescence, fluorescence, absorbance, time-resolved fluorescence resonance energy transfer (TR-FRET) [36] and fluorescence polarization assays [23]. The EnVision is best suited for AlphaScreen assays and b-lactamase reporter assays [37,38] and can be customized for the detection of multiple wavelength regions [23] and TR-FRET assays [36]. Each assay format and readout has its own set of advantages. For example, the use of b-lactamase as a reporter has several 1000
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
advantages, such as ratiometric readouts from dual emissions (460 and 530 nm), which minimizes well-to-well and plate-toplate variation caused by differences in plating density. In addition, the 530 nm fluorescent signal can be used as an indication of cell viability (and a proxy for compound cytotoxicity) and auto fluorescence [37]. For imaging assays, the user must sacrifice speed to obtain more information about individual cells and characterized cell populations. Two imaging platforms used at the NCGC are the Acumen Explorer (TTP Labtech) and the IN Cell Analyzer 1000 (GE Healthcare). The Acumen Explorer is a photomultiplier-tube-based laserscanning microplate cytometer that is equipped with three excitation and four emission lasers for enumeration and characterization of fluorescent objects [39]. The Acumen is able to provide total well and individual cell fluorescence readings. Compared to the ViewLux, where the entire plate is read in less than 1 min, Acumen read times can vary between 10 and 20 min per plate, depending on the number of wavelengths required by the assay of interest. Thus far, the Acumen has been used in several assays performed at NCGC, such as GFP-based assays [33] and multiplexing of dual fluorescent drug-sensitive and drug-resistant cell lines [40]. For higher resolution automated fluorescent imaging, the IN Cell Analyzer is designed to collect data either at the singlecell or at the subcellular level. The data collected are often complementary to those collected from the Acumen because additional orthogonal phenotypes can be identified. Furthermore, the instrument comes with own algorithm to analyze the data acquired [41]. Once data have been obtained for each assay, the CRCs for each compound are analyzed and classified as previously described [3,19,36]. Briefly, raw plate reads for each titration point are normalized relative to an assay-specific positive control (100% or 100%) and DMSO-only wells (0%), then corrected by applying a pattern correction algorithm using DMSO-only plates at the beginning and end of each stack [3]. Half-maximal inhibition or activation concentration (AC50) and efficacy values are obtained from fitting the concentration–response titration points to the Hill equation [42]. Compounds are classified as curve classes 1–4 according to the characteristics of the CRC, such as efficacy and quality of curve fit (R2). Class 1 curves display two asymptotes, whereas class 2 curves display one asymptote. Class 1 and 2 curves are further subdivided into subclasses a (efficacy 6SD) and b (efficacy < 6SD). These curves have statistically significant curve fits and are usually selected for follow-up analyses. Compounds in curve class 3 only display activity at the highest concentration tested, and compounds with class 4 curves show no concentration response and are deemed inactive. The ability to decipher curves using qHTS for every compound tested is important because many responses, such as toxicity, are measured over broad concentration ranges (typically between 0.5 nM and 92 mM), which might greatly decrease the FP and FN rates.
Assay implementation for Tox21 Various assays (Table 1) in different cell types or lines (Table 2) have been successfully developed, miniaturized and validated for 1536-well plate format at NCGC and screened against the initial Tox21 compound collection. For the majority of assays, compound incubation durations were limited to 48 hours because
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
TABLE 1
Assay
Assay endpointa
Cell type
Assay readout
Refs
Cell viability Apoptosis
Intracellular ATP content Caspase-3/7
Hek293; Jurkat; HepG2; SH-SY5Y; SK-N-SH; BJ; HUV-EC-C; MRC-5; mesangial; kidney proximal tubules; N2a; H-4-II-E; NIH3T3
Luminescence
[3,15]
Membrane integrity
LDH release Protease release
Hek293; mesangial
Fluorescence Luminescence
[34]
Mitochondrial toxicity
Membrane potential
HepG2
Fluorescence
DNA damage
Micronucleus
CHO
Fluorescence
Cytokine
IL-8; TNF-a
THP-1
Homogeneous time-resolved fluorescence
Nuclear receptor
AR; ERa; FXR; PPARd; PPARg; RXR; TRb; VDR GR hPXR; AhR; rPXR
Hek293
b-Lactamase reporter
AP-1; HIF-1a; SIE; NFkB HSR; ESRE ARE/Nrf2 CREB p53 ARE/Nrf2; HSR; ESRE
ME-180 HeLa HepG2 Hek293, CHO HCT-116 HepG2
b-Lactamase reporter
Luciferase reporter
[58]
Thallium influx
U-2OS
Fluorescence
[45]
Toxicity pathway
hERG channel
HeLa HepG2
Reviews FOUNDATION REVIEW
Tox21 assays currently available at NCGC
Luciferase reporter [37,38,59,60] [61] [53]
a
AhR, aryl hydrocarbon receptor; AP-1, activator protein-1; AR, androgen receptor; ARE/Nrf2, antioxidant response element/NF-E2 related factor 2; CREB, cAMP response element binding; ERa, estrogen receptor a; ESRE, endoplasmic reticulum stress response element; FXR, farnesoid X receptor; GR, glucocorticoid receptor; HIF-1a, hypoxia-inducible factor-1a; hPXR, human pregnane X receptor; HSE, heat shock response element; IL-8, interleukin-8; LDH, lactate dehydrogenase; NFkB, nuclear factor kappa B; PPARd, peroxisome proliferator-activated receptor d; PPARg, peroxisome proliferator-activated receptor g; rPXR, rat pregnane X receptor; RXR, retinoid X receptor; SIE, sis-inducible element; TNFa, tumor necrosis factor a; TRb, thyroid hormone receptor b; VDR, vitamin D receptor.
of evaporation-induced edge effects observed in 1536-well plates [3]. Stainless-steel assay lids with rubber gaskets were also used to enable air exchange and minimize edge effects [23]. The assays described below demonstrate the adaptation of existing low-
TABLE 2
Cell lines tested Cell type
Origin
Species
BJ
Foreskin fibroblasts
Human
CHO
Chinese hamster ovary
Hamster
HCT-116
Colorectal carcinoma
Human
Hek293
Embryonic kidney cells
Human
HeLa
Cervical carcinoma
Human
HepG2
Hepatocellular carcinoma
Human
HUV-EC-C
Vascular endothelial cells
Human
H-4-II-E
Hepatoma
Rat
Jurkat
T-cell leukemia
Human
Kidney proximal tubules
Freshly isolated from kidney
Rat
MRC-5
Lung fibroblasts
Human
Mesangial
Renal glomeruli
Human
ME-180
Cervical carcinoma
Human
N2a
Neuroblastoma
Mouse
NIH3T3
Embryonic fibroblasts
Mouse
SH-SY5Y
Neuroblastoma
Human
SK-N-SH
Neuroblastoma
Human
THP-1
Monocytic leukemia
Human
U-2OS
Osteosarcoma
Human
throughput assays to higher throughput, reliable 1536-well format assays. These studies show the ability to modify existing assays to profile larger numbers of compounds for toxicity-based safety studies. To assess chemical effect on cell membrane integrity, a newly developed cytotoxicity assay that measures released intracellular proteases upon membrane damage with a bioluminescent assay readout was evaluated [34]. Although there have been similar assays developed for lower density formats, few have been miniaturized and validated in a high-throughput format with a robust assay signal [34]. This protease-release assay for membrane damage detection was miniaturized in 1536-well format and was screened against the initial NTP compound collection in HEK 293 and human renal mesangial cells [34] (Tables 1 and 2). All compounds were tested in 14-point titration series to identify compounds that disrupt membrane integrity. The assay performed well in miniaturized format, with high reproducibility of the control compound across every plate in both cell lines, high signal-to-background ratios and high Z0 values (a statistical measure of assay performance) [43]. In addition, replicate compounds within the NTP compound collection demonstrated high intra-experimental reproducibility, further indicating the reliability of the qHTS assay. The compounds identified from this assay were known membrane disrupters, including a-solanine and zinc pyrithione. The majority of compounds active in both cell lines were detergents such as digitonin, tetra-N-octylammonium bromide and p-n-nonylphenol, which are known to disrupt membrane integrity; additional non-detergent compounds known to be membrane disrupters were also identified in the assay. Furthermore, some compounds were shown to be uniquely active in one cell line or the other, thus revealing cell-line-specific membrane disruption potential. www.drugdiscoverytoday.com
1001
REVIEWS
Reviews FOUNDATION REVIEW
Overall, this study demonstrated the successful miniaturization of an existing cytotoxicity assay using a luminescent readout. Furthermore, the application of qHTS to this assay format validated the need to characterize the biological activities of compounds over a broad concentration range [34]. Cardiotoxicity has been commonly examined in the human ether-a-go-go-related gene (hERG) potassium channel. The hERG channel is responsible for the repolarization of cardiac action potential, which is associated with certain forms of inherited and acquired long QT syndrome (LQTS) [44,45]. LQTS can lead to sudden death through a rare ventricular arrhythmia [45]. Some drugs have been removed from the market because of their potential to induce LQTS by inhibiting the hERG channel, which warrants the need for premarketing screening of drugs to minimize the risk of sudden death in the treatment of non-life-threatening diseases [45,46]. Patch-clamp electrophysiology technique is still the gold standard for hERG activity in drug development [47,48], but this assay is low throughput and costly and requires specialized training for personnel [45]. The radioligand-binding assay is also commonly used to test compound binding to the hERG channel, but this assay gives little or no information on the functional effect of the ligand on the channel (blocker, activator or no effect) and the allosteric effect of the ligands [49]. To overcome these limitations, a functional assay was developed for the hERG channel by measuring thallium influx into the cells and was validated in a 1536-well plate format. The assay principle is shown in Fig. 2, where thallium ions enter the cells through open hERG channels after stimulation and bind to the dye, yielding an increase in fluorescence. This fluorescence signal is inhibited in the presence of hERG channel blockers [45]. The qHTS screen identified a group of known hERG inhibitors, such as pimozide, amiodarone and verapamil, from a library of 1280 pharmacologically active compounds (LOPAC1280). Furthermore, the activities of the hERG channel inhibitors in the thallium influx assay are well correlated
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
with those obtained from automated patch-clamp experiments [45].
In vitro assays for cytotoxicity One of the goals of the Tox21 collaboration is to establish in vitro signatures of in vivo human and rodent toxicity. To create in vitro signatures of compound cytotoxicity across species, 1408 compounds from the initial NTP collection were profiled for cytotoxicity across 13 different human and rodent cell types [3]. These human and rodent cell types were derived from six tissue types that are common targets of xenobiotic toxicity (Tables 1 and 2); thus, this study aimed to develop species- and cell-specific cytotoxicity profiles for each compound [3]. Each compound was tested at 14 concentrations (0.5 nM–92 mM) in a luminescent cell viability assay that measures adenosine triphosphate (ATP) levels of metabolically active cells. The luminescent ATP quantitation assay worked well in 1536-well format with robust Z0 , signal-tobackground ratio and coefficient of variation values for the positive control compound (tamoxifen). Tamoxifen CRCs for each cell line were consistent across the plates; however, the response pattern was cell-line specific, with Jurkat cells being most sensitive and mesangial cells being least sensitive [3] (Fig. 3). Furthermore, the correlation of IC50 values for the 55 duplicate compounds present in the NTP compound collection across all 13 cell lines was significant (0.71, P < 0.001). There were 428 compounds that displayed cytotoxicity in at least one cell type, and clustering analysis was performed to decipher cytotoxicity profiles across cell types. Within the subgroup of active compounds, multiple effects from the compounds were identified within and across compound types, cell types and species. For example, human- and rodent-derived cells including SH-SY5Y, Jurkat, H-4-II-E, NIH 3T3, N2a, HEK293 and rat renal proximal tubule cells were most sensitive to compound-induced cytotoxicity, whereas human fibroblast and skin cells were least sensitive. Overall, the rodent cells used in
[(Figure_2)TD$IG]
FIGURE 2
Principle of the thallium flux assay. At resting state, cells expressing hERG channels are loaded with dye from the assay kit. Upon stimulation, thallium ions enter the cells through open hERG channels and bind to the dye, yielding green fluorescence upon excitation, proportional to the bound dye. 1002
www.drugdiscoverytoday.com
[(Figure_3)TD$IG]
20
% Inhibition
0 HEK293 HepG2 SH-SY5Y SK-N-SH Jurkat BJ HUV-EC-C MRC-5 Mesangial Proximal tubules H-4-II-E N2a NIH 3T3
-20 -40 -60 -80 -100 -6.5 -6.0
Lo
g -5.5 [T am -5.0 ox -4.5 ife n] (M -4.0 )
250 200 150 100 50
P
e la t
er mb
Nu
Drug Discovery Today
FIGURE 3
Positive control titration across human and rodent cell lines. The reproducibility of tamoxifen, used as a positive control in ATP-mediated cytotoxicity testing, is shown for each cell line for 234 plates tested. Jurkat cells were most sensitive to tamoxifen, and NIH3T3, HEK293, BJ and mesangial cells were least sensitive.
this study demonstrated more sensitivity to the compounds tested than the human cells. Compounds that showed activity in at least one cell type were clustered according to their IC50 values, revealing clusters and specific compounds that were selectively cytotoxic
[(Figure_4)TD$IG]
REVIEWS
in a particular cell type and species. For example, digoxin was more cytotoxic in human HEK293 cells than rat renal proximal tubule cells. Actinomycin D, however, was much more cytotoxic in rat renal proximal tubules than in human HEK293 cells (Fig. 4). Overall, a striking finding was the lack of concordance in the patterns of compound activity in cells derived from the same tissue but from different species (there were also instances in which cells with similar tissue origin in the same species showed discordance in compound activity profiles), highlighting inter-species differences in response. Thus, an important finding from the study is that in vitro cytotoxicity in a particular cell type, even if from the same tissue and/or species, does not necessarily predict cytotoxicity in another cell type [3]. Thus, the combination of in vitro profiling with qHTS enables the generation of hypotheses related to mechanisms of toxicity and prioritization for more intense toxicological investigation related to in vivo toxicity. The application of clustering to data with multiple endpoints can help uncover underlying mechanisms involved in broad phenotypes such as cytotoxicity. To examine the mechanism of compound-induced cytotoxicity in various cell types, two different endpoints (cytotoxicity and caspase-3/7 activation) were assessed by testing the 1408 NTP compounds for both endpoints across 13 different cell types [15]. The cytotoxicity and caspase-3/7 assays performed well in a 1536-well format and the quality of the data was suitable for use in computational efforts. The overall active rate for the 13 caspase assays (0.4–3.5%) was lower than the rate for the 13 cytotoxicity assays (4–11%). Hierarchical clustering
FIGURE 4
Species-selective compounds. Compound activity patterns were obtained through hierarchical clustering of compound IC50 values. Shown are compound activity patterns for human HEK 293 cells and rat renal proximal tubule cells. Two compounds, actinomycin D and digoxin, illustrate species-specific cytotoxicity for those particular compound clusters. www.drugdiscoverytoday.com
1003
Reviews FOUNDATION REVIEW
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews FOUNDATION REVIEW
based on compound cytotoxicity and caspase EC50/IC50 patterns revealed similar clustering based on endpoints rather than cell type, indicating that cytotoxicity and caspase activation assays provide distinct sets of information, and that most compounds induce cytotoxicity through mechanisms other than caspase-3/7 activation. The only exception was the Jurkat cell line, where the caspase and cytotoxicity assays clustered together. One explanation might be that the cell death induced by most compounds in Jurkat cells is dependent on caspase-3/7 activation [15]. The N2a cell line seemed to have the least number of active compound overlap between the cytotoxicity and caspase assays, indicating the contribution of mechanisms outside of caspase activation for cytotoxicity. This approach will be useful for generating hypotheses for compound mechanism of action; however, hypothesis generation will be strengthened by the inclusion of more compounds and endpoints to build stronger models predictive of in vivo toxicity.
Computational modeling Because of the rapidly increasing number of environmental chemicals that need to be tested and the need for prioritization of those compounds for in vivo studies, more computational modeling is needed to complement experimental approaches to decrease the time associated with testing and accelerate prioritization of the data [50,51]. Some challenges associated with computational modeling of toxicity data include the diversity of compounds and structures that can produce the same outcome [50]. However, the production of CRCs for every compound tested provides a data-rich resource for SAR analysis, computational modeling and
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
chemical prioritization for more extensive toxicological evaluation. The NCGC recently developed a weighted feature significance (WFS) algorithm, a fragment-based approach that does not rely on whole molecule similarity to model toxicity (Fig. 5), which is designed to achieve good prediction with structurally diverse sets of compounds [50]. Such approaches can be applied to generate testable hypotheses on mechanisms of compound toxicity. Starting with the structure of a compound, one could model and predict its toxicity in one assay or cell type and in multiple cell types, which essentially forms the activity pattern or signature that indicates the compound’s mechanism of toxicity. Models were developed for two aforementioned [3,15] assays, with rigorous performance evaluation of all models using receiver operating characteristic curves [52]. One advantage of the WFS approach is its ability to identify structural features responsible for toxicity [50]. For example, structural features significantly enriched in the pan-cytotoxic compounds include substituted benzenes, 1,3-dienes, heavy metals and imines [50]. Toxic features were also identified for caspase-3/7-activating compounds [15], such as cyclic alkyl ketones and alkyl halides. Thus, the significant toxic features present in compounds could be used to predict a particular mechanism of toxicity, such as caspase-3/7 activation [50]. Overall, the WFS approach can be applied to model other toxicity endpoints such as mutagenicity and hepatotoxicity and might be applicable to a larger array of compounds. Unlike other modeling methods, WFS can be used even when compound structures are highly diverse. In addition, WFS was shown to have comparable or better predictive power when compared to Native Bayesian clustering or a support vector machine approach in most
[(Figure_5)TD$IG]
FIGURE 5
Weighted feature significance (WFS) algorithm. The algorithm has been developed to build fragment-based models to predict various toxicity endpoints, such as cell viability, caspase-3/7 activation, mutagenicity and hepatotoxicity, based on compound structure. The sensitivity and specificity of these models have been rigorously tested using receiver operating characteristic curves. Activity or toxicity profiles can be generated by testing compounds against a battery of cell lines or assays measuring the same toxicity endpoint. The activity pattern of a compound across such a battery of assays can be viewed as the compound signature, which can be used subsequently to group compounds into different activity clusters, each representing a distinct toxicity mechanism or mode of action. The underlying assumption is that compounds exhibiting similar activity patterns or signatures are likely to share the same biological target or mode of action. Such approaches can be applied to generate testable hypotheses on mechanisms of compound toxicity. Starting with the structure of a compound, one could then model and predict its toxicity in one assay or cell type and in multiple cell types, which essentially forms the activity pattern or signature that indicates the compound’s mechanism of toxicity. 1004
www.drugdiscoverytoday.com
test cases [50]. An analysis of the initial Tox21 collection of 2800 compounds revealed that additional chemicals are required for enhancement of compound diversity in these collections to increase the number of robust structural predictors of the WFS, which validates the previously described initiative to expand the compound collection to more than 10,000 chemicals.
Cellular pathway assays Although attractive, target-based screens can lead to the identification of active compounds that do not retain their activity in a physiological environment [53]. Thus, cell-based assays offer an alternative assay format in which the readout is dependent on specific components acting on a single signaling pathway. Furthermore, the combination of toxicity pathways associated with adverse health events with engineered cellular assays designed to measure the perturbation of these pathways in response to a
REVIEWS
chemical is a crucial implementation of the National Academy of Sciences Tox21 report [54]. As an example of such an approach, a b-lactamase reporter gene assay was employed to identify compounds that inhibit [37] or induce [38] hypoxia-inducible factor1a (HIF-1a) activity (Fig. 6). Hypoxia, the reduction in the normal level of tissue oxygen tension within a tissue, is associated with several pathologies including cancer and inflammation [55]. Under hypoxic conditions, HIF-1 subunits heterodimerize and translocate into the nucleus before binding to a hypoxia-response element (HRE) upstream of target genes that activate angiogenesis and vascular endothelial growth factor (VEGF) [56]. Hypoxic conditions attenuate the degradation of HIF-1a, leading to the transcription of survival genes in many solid tumors and poor cancer prognosis [57]. Thus, compounds that inhibit HIF-1a responsive tumor hypoxia might be a valuable chemotherapeutic approach [37]. Furthermore, a separate screen for inducers of
[(Figure_6)TD$IG]
FIGURE 6
Reporter gene assay for HIF-1 activity. During normoxia, the HIF-1a subunit is degraded by the ubiquitin–proteosome pathway. In this case, the absence of blactamase expression leaves the fluorescent substrate molecule, which contains coumarin and fluorescein. Excitation of the coumarin results in fluorescence resonant energy transfer to the fluorescein moiety, resulting in the emission of green fluorescent signal (530 nm). Under hypoxic conditions, however, HIF-1a heterodimerizes with the HIF-1b subunit and translocates to the nucleus. Next, the HIF-1 complex binds to HRE regulatory sequences upstream of target genes. In this assay, stimulation under hypoxic conditions results in the transcription of b-lactamase, which cleaves the fluorescent substrate molecule, disrupting energy transfer. Excitation of the coumarin molecule in the presence of b-lactamase enzyme activity results in a blue fluorescence signal (460 nm). The ratio of the blue:green signals provides a normalized reporter response.
www.drugdiscoverytoday.com
1005
Reviews FOUNDATION REVIEW
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews FOUNDATION REVIEW
hypoxia is also valuable to identify those compounds that can serve as hypoxia mimetics [38]. To identify inhibitors of hypoxia, 73,000 compounds from the MLMSR compound collection [37] were screened between 7 and 15 concentrations in an HRE-bla assay performed in ME-180 cells (Tables 1 and 2). In addition, to identify HIF-1a inducers, 1408 compounds from the NTP collection were screened at 14 concentrations also utilizing the HRE-bla assay. The screening for both assays performed well and indicated the suitability for qHTS to identify inhibitors and activators of HIF-1a. Three hundred and fifty inhibitors with reliable curve classes were identified and SAR analysis of these compounds yielded 18 structural series sharing a common scaffold. Several follow-up studies, such as the evaluation of compound effects on low-oxygen-induced HIF-1 signaling and VEGF secretion, were employed to ensure the specificity of compound activity in the HIF-1a assay [37]. Overall, the primary qHTS and follow-up compounds identified from SAR analysis demonstrated specificity for inhibition of HIF-1a activity and little to no cytotoxicity and thus seem to be good candidates for further testing in other cancer cell lines or animal models [37]. Conversely, ten compounds were identified and confirmed as inducers of HIF-1a activity from the primary screening using the NTP compound collection [38]. In the follow-up studies, five of ten compounds notably induced VEGF secretion in human ME-180 cells in a concentration-dependent manner. These five compounds were further tested for their dependence on HIF-1 with regard to VEGF secretion by testing them in HIF-1a wild-type and knockout mouse embryonic fibroblast cell lines. Compounds involved in VEGF secretion dependently (such as phenathroline) or independently (such as 7,12-DMBA) of HIF-1a were identified. Finally, these five compounds were tested against a battery of reporter genes driven by hypoxia-responsive gene promoters [38,58] to establish the promoter activity profiles. For example, three compounds (including phenathroline) produced promoter activity profiles very similar to those produced by standard hypoxic conditions (1% O2) used in cell-based studies [38,58]. Furthermore, this study highlights the use of biological profiling data with hierarchical clustering to group compounds that operate under a similar mode of action [58].
Concluding remarks and future directions The Tox21 collaboration is combining technology, biology and computational methods to advance in vitro testing for toxicology [12]. The NCGC is working with its Tox21 partners to develop next-generation testing methods and alternative approaches to existing methods and to model in vitro and in vivo responses.
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
The examples given here are only a few of the assays that have been utilized to date to study specific endpoints or pathways in human and rodent in vitro assays; in total, the NCGC has generated more than six million data points and more than 400,000 CRCs for Tox21 chemicals in specific assays. The qHTS-driven production of CRCs for every compound tested provides a data-rich resource for SAR analysis, computational modeling and chemical prioritization for more extensive toxicological evaluation. This directly points to the advantages of using qHTS with regard to compound hazard identification; qHTS will enable a more accurate assessment of compound-induced toxicity using cell-based studies and an idea of starting doses to use in in vivo studies. SAR analysis will also enable the identification of toxic compounds with similar structures for follow-up testing. Thus, a basis of hazard characterization with regard to toxicity will emerge before in vivo studies. Furthermore, in vitro toxicity tests performed in human-derived cell lines might provide important biomarkers of exposure that can be directly tested in human populations [2]. Human risk assessment from some in vitro studies might prove difficult; thus, a step-wise approach starting with qHTS, computational modeling and carefully designed tissue- and species-specific cell-based assays will provide a stronger and mechanistically predictive approach for in vivo testing and human risk assessment [2]. Building on the solid foundation described here, future Tox21 goals include the inclusion of new platforms for qHTS (such as high-content screening and nanotechnology), assessment of genetic variation involved in human and rodent toxicity, incorporation of metabolism and biotransformation capability into the current and future assays, identification and prioritization of crucial cellular pathways and key targets for screening, expansion of the compound libraries including compounds that are DMSO or water insoluble, discerning the link between observed perturbations in vitro and pathologies in exposed humans and the creation of relational public databases and tools to interrogate the screening data. Table 1 comprises some of the current and future Tox21 assays at the NCGC, such as those for oxidative stress response [54]. Data production in Tox21 is now moving into its exponential growth phase, and over the next several years the interdisciplinary Tox21 collaboration will continue to innovate in assay biology, screening and computation, to usher in a new era of efficient, mechanistic and predictive chemical toxicology.
Acknowledgements We gratefully acknowledge Paul Shinn for compound management. We also thank Raymond Tice for crucial reading of the manuscript and Darryl Leja for illustrations.
References 1 Andersen, M.E. and Krewski, D. (2009) Toxicity testing in the 21st century: bringing the vision to life. Toxicol. Sci. 107, 324–330 2 Krewski, D. et al. (2009) Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 29, 474–479 3 Xia, M. et al. (2008) Compound cytotoxicity profiling using quantitative highthroughput screening. Environ. Health Perspect. 116, 284–291 4 Goldberg, A.M. and Frazier, J.M. (1989) Alternatives to animals in toxicity testing. Sci. Am. 261, 24–30 5 Zurlo, J. et al. (1993) Animals and Alternatives in Testing: History, Science, and Ethics. Mary Ann Liebert, Inc.
1006
www.drugdiscoverytoday.com
6 Rowan, A.N. (1983) Alternatives: interaction between science and animal welfare. In Product Safety Evaluation (Goldberg, A.M., ed.), pp. 113–133, Mary Ann Liebert, Inc. 7 Williams, G. and Weisburger, G. (1993) Chemical carcinogenesis. In Toxicology. The Basic Science of Poisons. McGraw-Hill 8 Beniashvili, D. (1994) Experimental Tumors in Monkeys. CRC Press 9 Rangarajan, A. and Weinberg, R.A. (2003) Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 3, 952–959 10 National Toxicology Program, (2004) A National Toxicology Program for the 21st Century: A Roadmap for the Future.
11 Dix, D.J. et al. (2007) The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95, 5–12 12 National Research Council (NRC), (2007) Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academy Press 13 Austin, C.P. et al. (2008) Tox21: Putting a Lens on the Vision of Toxicity Testing in the 21st Century. 14 Kavlock, R.J. et al. (2009) Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 29, 485–487 15 Huang, R. et al. (2008) Characterization of diversity in toxicity mechanism using in vitro cytotoxicity assays in quantitative high throughput screening. Chem. Res. Toxicol. 21, 659–667 16 Collins, F.S. et al. (2008) Toxicology. Transforming environmental health protection. Science 319, 906–907 17 Austin, C.P. et al. (2004) NIH molecular libraries initiative. Science 306, 1138–1139 18 Seidle, T. and Stephens, M.L. (2009) Bringing toxicology into the 21st century: a global call to action. Toxicol. In Vitro 23, 1576–1579 19 Inglese, J. et al. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U. S. A. 103, 11473–11478 20 Schnecke, V. and Bostrom, J. (2006) Computational chemistry-driven decision making in lead generation. Drug Discov. Today 11, 43–50 21 Malo, N. et al. (2006) Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24, 167–175 22 Thomas, C.J. et al. (2009) The pilot phase of the NIH Chemical Genomics Center. Curr. Top. Med. Chem. 9, 1181–1193 23 Michael, S. et al. (2008) A robotic platform for quantitative high-throughput screening. Assay Drug Dev. Technol. 6, 637–657 24 Thorne, N. et al. (2010) Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr. Opin. Chem. Biol. 14, 315–324 25 Feng, B.Y. et al. (2007) A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50, 2385–2390 26 Simeonov, A. et al. (2008) Fluorescence spectroscopic profiling of compound libraries. J. Med. Chem. 51, 2363–2371 27 Auld, D.S. et al. (2008) Characterization of chemical libraries for luciferase inhibitory activity. J. Med. Chem. 51, 2372–2386 28 Oldenburg, K. et al. (2005) High throughput sonication: evaluation for compound solubilization. Comb. Chem. High Throughput Screen. 8, 499–512 29 MacArthur, R. et al. (2009) Monitoring compound integrity with cytochrome P450 assays and qHTS. J. Biomol. Screen. 14, 538–546 30 Yasgar, A. et al. (2008) Compound management for quantitative high-throughput screening. JALA Charlottesv Va 13, 79–89 31 Judson, R. et al. (2009) The toxicity data landscape for environmental chemicals. Environ. Health Perspect. 117, 685–695 32 Schmidt, C.W. (2009) TOX 21: new dimensions of toxicity testing. Environ. Health Perspect. 117, A348–A353 33 Auld, D.S. et al. (2006) Fluorescent protein-based cellular assays analyzed by laserscanning microplate cytometry in 1536-well plate format. Methods Enzymol. 414, 566–589 34 Cho, M.H. et al. (2008) A bioluminescent cytotoxicity assay for assessment of membrane integrity using a proteolytic biomarker. Toxicol. In Vitro 22, 1099–1106 35 Tanega, C. et al. (2009) Comparison of bioluminescent kinase assays using substrate depletion and product formation. Assay Drug Dev. Technol. 7, 606–614 36 Shukla, S.J. et al. (2009) Identification of pregnane X receptor ligands using timeresolved fluorescence resonance energy transfer and quantitative high-throughput screening. Assay Drug Dev. Technol. 7, 143–169 37 Xia, M. et al. (2009) Identification of small molecule compounds that inhibit the HIF-1 signaling pathway. Mol. Cancer 8, 117
REVIEWS
38 Xia, M. et al. (2009) Identification of chemical compounds that induce HIF-1alpha activity. Toxicol. Sci. 112, 153–163 39 Bowen, W.P. and Wylie, P.G. (2006) Application of laser-scanning fluorescence microplate cytometry in high content screening. Assay Drug Dev. Technol. 4, 209–221 40 Brimacombe, K.R. et al. (2009) A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev. Technol. 7, 233–249 41 Norton, J.T. et al. (2009) Automated high-content screening for compounds that disassemble the perinucleolar compartment. J. Biomol. Screen. 14, 1045–1053 42 Hill, A.V. (1910) The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. 40, 4–7 43 Zhang, J.H. et al. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73 44 Sanguinetti, M.C. et al. (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299–307 45 Titus, S.A. et al. (2009) A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal. Biochem. 394, 30–38 46 De Ponti, F. et al. (2002) Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 25, 263–286 47 Diaz, G.J. et al. (2004) The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K+]o. J. Pharmacol. Toxicol. Methods 50, 187–199 48 Tao, H. et al. (2004) Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev. Technol. 2, 497–506 49 Leishman, D. and Waldron, G. (2006) Assay technologies: techniques available for quantifying drug–channel interactions. In Voltage-Gated Ion Channels as Drug Targets (Triggle, D.J. et al. eds), pp. 37–63, Wiley-VCH 50 Huang, R. et al. (2009) Weighted feature significance: a simple, interpretable model of compound toxicity based on the statistical enrichment of structural features. Toxicol. Sci. 112, 385–393 51 Pritchard, J.F. et al. (2003) Making better drugs: decision gates in non-clinical drug development. Nat. Rev. Drug Discov. 2, 542–553 52 Schoonjans, F. et al. (1996) Presentation of receiver-operating characteristics (ROC) plots. Clin. Chem. 42, 986–987 53 Xia, M. et al. (2009) Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory. Proc. Natl. Acad. Sci. U. S. A. 106, 2412–2417 54 Simmons, S.O. et al. (2009) Cellular stress response pathway system as a sentinel ensemble in toxicological screening. Toxicol. Sci. 111, 202–225 55 Mole, D.R. and Ratcliffe, P.J. (2008) Cellular oxygen sensing in health and disease. Pediatr. Nephrol. 23, 681–694 56 Forsythe, J.A. et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604–4613 57 Redell, M.S. and Tweardy, D.J. (2005) Targeting transcription factors for cancer therapy. Curr. Pharm. Des. 11, 2873–2887 58 Simmons, S.O. (2009) Hypoxia response: a model toxicity pathway for highthroughput screening. Toxicol. Sci. 112, 1–3 59 Johnson, R.L. et al. (2009) A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical libraries. Mol. Biosyst. 5, 1039–1050 60 Miller, S.C. et al. (2010) Identification of known drugs that act as inhibitors of NFkappaB signaling and their mechanism of action. Biochem. Pharmacol. 79, 1272– 1280 61 Hancock, M.K. et al. (2009) HTS-compatible beta-lactamase transcriptional reporter gene assay for interrogating the heat shock response pathway. Curr. Chem. Genomics 3, 1–6
www.drugdiscoverytoday.com
1007
Reviews FOUNDATION REVIEW
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews GENE TO SCREEN
Epigenetic therapies for non-oncology indications Jonathan D. Best and Nessa Carey CellCentric, Chesterford Research Park, Little Chesterford, Cambridge CB10 1XL, UK
Chronic and degenerative disorders are a major, and growing, human health burden, and current treatments are in many cases inadequate or very expensive. Epigenetic therapies are attractive options for treating such disorders because they manipulate the processes that maintain cells in an abnormal transcriptional state. The challenges lie in identifying the most appropriate diseases and the enzymes that should be targeted. This review describes the different approaches that can be used to address this problem, focusing particularly on CNS disorders (especially mental retardation, neurodegenerative disease, psychiatric disorders and drug addiction), diabetes and diabetic complications, and autoimmunity and inflammatory diseases.
Epigenetic traits have been defined operationally as ‘stably heritable phenotypes resulting from changes in a chromosome without alterations in the DNA sequence’ [1]. Epigenetic modifications (also known as epigenetic marks) form a network of covalent alterations to DNA and histone proteins, which, in turn, interacts with other cellular proteins, typically in multi-component mediator complexes. The end result is the regulation of gene expression. This regulation can be short-term and dynamic or exceptionally stable if the chromatin modifications lead to the hypermethylated DNA state associated with the formation of transcriptionally silent heterochromatin. Several excellent reviews cover the underlying modification mechanisms [2–4], and Fig. 1 summarizes our current knowledge of these modifications. It is impossible in one figure to demonstrate the complexity of histone modifications present on even one histone molecule at a single genomic locus in a single cell. In some cases, modifications are mutually exclusive (e.g. it is not possible for a single histone H3K4 residue to be methylated and acetylated simultaneously). A single residue can be modified to varying degrees – many lysine residues can be mono-, di- or trimethylated. Different combinations of modifications can only occur in certain situations. The combination of methylation on H3K4 and H3K27 only occurs in pluripotent cells and, even then, only at the promoters of certain key regulatory genes [5].
Corresponding author:. Carey, N. (
[email protected])
1008
www.drugdiscoverytoday.com
There has been cosiderable progress in the development of epigenetic drugs for the treatment of human cancers [6]. DNA methyltransferase inhibitors and histone deacetylase (HDAC) inhibitors have been licensed by the US Food and Drug Administration. Several companies are now developing inhibitors for second-generation epigenetic targets, focusing on enzymes that mediate restricted histone modifications. Although oncology is the current major focus for most of these programmes, there is optimism that epigenetic drugs will have wider therapeutic applications. It might at first seem counterintuitive that processes involved in the uncontrolled proliferation and transformation that are characteristics of cancer could be useful intervention points in nonproliferative disorders, but in reality this is not so surprising. Epigenetic mechanisms control cell fate. Aberrant epigenetic processes can have several potential outcomes, depending on the enzymes and pathways involved, the specific cell type, interactions with the environment and so on. Given the large numbers of enzymes involved in epigenetic processes, a role only in cancer would be far more surprising than an involvement in multiple indications.
New therapeutic indications Perhaps the greatest problem in developing epigenetic drugs for non-oncology indications lies in identifying the most relevant diseases to target. In general, it might be helpful to think of
1359-6446/06/$ - see front matter ß 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2010.10.006
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
[()TD$FIG]
H C
C
CH3
HN2 C
C
DNMTs
C
HN2
C
Tet family
OH CH2 C
C
p300 Tip60 Hat1
USP22 Bmi1 Ring1b
NHK-1
HN2
C
T120
N C N
N C N
N C N
O Cytosine
O 5-Methyl cytosine
O 5-Hydroxy methyl cytosine
USP22 RNF20/40 UbcH6
p300 ATF2
p300
K20
H2B
K120
K5
H2A
K119
S1
p300 ATF2
Mst1
K15
MSK1
S14
Reviews GENE TO SCREEN
(a)
ATF2
K12
K5
DNAMethylation (b) SUV39h1-2 CLL8 SETDB1 RIZ1 G9A Glp EZH2 MSK1-2
G9A EZH2
PCAF P300 Tip60 SRC-1 hTFIIIC90 TAF1 Gcn5
P300 CBP
PRMT4
PRMT4
SUV39h1-2 CLL8 SETDB1 RIZ1 G9A Glp EZH2
JHDM2a/b JMJD2A-D JMJD3A
MSK1-2 Aurora B TG2
ASH1 MLL1-5 SET1A-B SET7/9
LSD1
HASPIN
PRMT4
DLK/ZIP
PRMT4 JHDM1a/b JMJD2A,C JMJD3A
K27
K23
R26
K18
R17
K14
T11
S10
K9
R8 K4
S28
T3
R2
K36 Gcn5
PCAF SRC-1
Acetylation Methylation
H3
K79
DOT1
SUV4-20H1,2 Pr-SET7/8
Phosphorylation
Tip60 ATF2 Gcn5
HBO1 Hat1 Tip60
PCAF Tip60 p300 ATF2 Gcn5
p300 ATF2 Hat1 HBO1 Tip60 PRMT1,4,5
Ubiquitination
CKII
H4 Histone Modifications
K20
K16
K12
K8
K5 R3 S1
Drug Discovery Today
FIGURE 1
Schematic representation of major chromatin modifications. (a) The chemical structures of the major modification of DNA, cytosine methylation. This modification is mediated by a family of DNMTs. (b) A schematic representation of the major modifications of the four canonical histones that create the nucleosomal octamer. The enzymes generating or removing the modifications are shown in the boxes, and their effects are indicated by the arrows. Methylation of lysine residues can be mono, di or tri, but for clarity this has not been shown. Lysine acetylation is removed by HDACs. Unlike the specific nature of demethylase enzymes, most HDACs can remove acetyl groups from any or all accessible histone lysine residues. For the sake of clarity, the HDACs have been excluded from the schematic representation. The schematic representation has been annotated with the most widely used names for the enzymes – for a more structured nomenclature, refer to Ref. [54].
epigenetic processes serving to stabilize a response to an external stimulus, such that in disease states they act to maintain a cell in an abnormal transcriptional programme. This leads to the hypothesis that epigenetic interventions might be most useful in chronic and developmental disorders, and the limited data available support this theory. Epigenetic effects are also attractive mechanisms for accounting for discordance between monozygotic twins. Within the broad category of chronic and developmental disorders, there are two complementary and intersecting approaches that have been useful in identifying human diseases that might be amenable to epigenetic therapies: biology (both human and animal models) and drug repositioning. Figure 2 lists some of the major disorders beyond oncology for which an epigenetic component or therapeutic approach has been proposed. Several Mendelian disorders have been shown to be the result of mutations in
genes encoding epigenetic enzymes or mediators. This has been particularly fruitful in the field of mental retardation. Angelman’s syndrome and Prader-Willi syndrome were recognized many years ago as associated with parent-of-origin and imprinting deficits, extreme examples of epigenetic regulation and abnormality. Rett’s syndrome, the X-linked neurodevelopmental disorder, is predominantly caused by mutations in MeCP2, a protein that binds methylated DNA residues [7]. This protein might also be implicated in human autism [8]. Elegant work from Adrian Bird’s lab has shown the reversal of the Rett phenotype in engineered mouse strains [9]. Although this cannot yet be directly replicated in human patients, because the mouse work required a genetic approach, it suggests that neurodevelopmental defects can be reversed, offering considerable encouragement to the field. PHF8 is a histone demethylase, and mutations in this gene have www.drugdiscoverytoday.com
1009
REVIEWS
[()TD$FIG]
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Reviews GENE TO SCREEN FIGURE 2
Major non-oncology disease areas for epigenetic interventions. Major indications for which there might be a tractable epigenetic therapeutic approach are shown. For the majority of the indications, supporting evidence is given in the text. See, in addition, Refs. [54–57].
been identified in several families with a history of X-linked mental retardation [10,11]. The majority of chronic human disease is not associated with Mendelian inheritance patterns, however, so how can the pharmaceutical industry use biology to identify other disorders that might be amenable to epigenetic therapies? One tantalizing approach is to identify epigenetic fingerprints characteristic of disease (i.e. to identify marks present in disease states that are absent in health). This is a huge undertaking, fraught with difficulties. As described above, the large numbers of epigenetic enzymes can result in an enormous number of possible combinations of modifications, and identifying those that are associated with a disorder and demonstrate a causal relationship with disease aetiology will require a step-change in detection technologies and bioinformatics. Researchers are taking steps towards this on a global scale (the Thousand Epigenomes project is one example; see http://nihroadmap.nih.gov/epigenomics), and intriguing data already exist in the literature for several disorders. Alzheimer’s disease (AD) is marked by a loss of cholinergic neurons, along with the formation of Abeta protein plaques and neurofibriliary tangles [12]. Research into therapeutics for AD has focussed on either cleavage of the amyloid precursor protein or hyperphosphorylation of the tau protein, which forms neurofibriliary tangles [13]. Developing effective therapeutics using these approaches has met with limited success, and studies have begun to investigate epigenetic changes in animal models of AD. Regional variations in methylation and acetylation of histone proteins have been seen in the brains of the familial AD mutant Tg2576 mouse, suggesting that compounds targeting methylation and acetylation might be useful [14]. Other findings have suggested that HDAC inhibitors might play a part in ameliorating learning 1010
www.drugdiscoverytoday.com
and memory deficits [15]. These studies are at a very early stage, however, and further work is required. This includes analyses of human samples to determine whether the same patterns of epigenetic modifications are present as in the mouse model and whether they genuinely distinguish Alzheimer’s pathology from general ageing effects. It is also necessary to investigate whether these fingerprints are causal effectors of the disease or merely markers of disease progression. In addition to neurodegenerative disorders, epigenetics is an increasing focus in the investigation of psychiatric disorders. One of the most intensively explored has been the long-term effects of childhood abuse or neglect, which is associated with several adult health deficits including increased risk of depression, drug addiction and suicide. The most commonly used rodent model of early life stress is built around periodic mother–infant separation. The offspring maintain elevated levels of glucocorticoid secretion throughout life, and this overactivation of the hypothalamic– pituitary–adrenal axis is also found in affected humans [16]. This seems to be underpinned by epigenetic misregulation at several levels. The arginine vasopressin (AVP) protein is a key stimulator of adrenocorticotrophin release from the pituitary. A specific AVP enhancer is hypomethylated in the paraventricular nucleus of mice subjected to early life stress, and this leads to persistent overexpression of the gene [17]. Other studies have demonstrated increased DNA methylation, and concomitant decreased expression, of the neuron-specific glucocorticoid receptor promoter (Nr3cl) in the same model system [18]. Because the hypothalamic–pituitary–adrenal system is usually controlled by a positive feedback loop, the combined effects of the altered (hypo- and hyper-) methylation at each ‘end’ of the axis would be continual overstimulation of this hormonal response.
There are always questions over the applicability of animal models to human psychiatric disorders. In this instance, the Nr3cl effects reported in the rodent model are also reported in human adult suicides with a history of childhood abuse [19]. The changes were not seen in suicides with no abuse history or in unaffected controls. It is unclear from the literature whether the early events establishing a hypomethylated state at the AVP enhancer occur in mitotic or post-mitotic neurons. If it is the latter, it will be important to identify which, if any, of the recently identified putative active DNA demethylases are present in these cells, because there is no opportunity for passive DNA demethylation in post-mitotic cells [20–22]. At least some of the hypomethylation at the AVP enhancer is reported to be driven by the dissociation of the repressive MeCP2 protein from the locus. MeCP2 can act to drive the continued recruitment of DNA methyltransferases to a silenced chromatin region, and hence loss of this binding protein will lead to long-term hypomethylation. MeCP2 has been reported recently to be a key protein in animal models of drug addiction. Knockdown of MeCP2 in the rat striatum led to decreased cocaine intake in an animal model of unrestricted drug access [23]. Manipulation of MeCP2 levels in the nucleus accumbens of mice altered locomotor responses to amphetamines [24]. The details of the models and the mechanisms postulated for the effects of MeCP2 vary between the two studies (for discussion, see Ref. [25]), but both are supportive of a major role of DNA methylation. Additional support for the importance of DNA methylation in response to drugs of addiction comes from the finding that manipulating levels of the DNMT3a DNA methyltransferase in the nucleus accumbens of mice markedly affected their response to cocaine [26]. DNA methylation is an exceptionally stable epigenetic modification and might be difficult to manipulate for psychiatric disorders because even the licensed DNA methyltransferase inhibitors are unlikely to have side-effect profiles that would be acceptable for these indications. Many gene responses become initially transiently stabilized via histone modifications before more permanent DNA methylation changes are established. These histone modifications might, in the future, become useful targets for the development of drugs that target acute stresses, to prevent long-lasting psychiatric disturbances such as post-traumatic stress disorder. Moving away from psychiatric disease, the HDAC inhibitors MS275 and SAHA (vorinostat) have been shown to relieve pain in the second phase of the formalin rat pain model, causing upregulation of the brain mGlu2 receptors. This suggests a role for histone acetylation in the transcriptional activity of the mGlu2 receptor gene [27]. Neurological disorders are not the only diseases in which there is an ongoing interest in epigenetic therapies. There are expected to be 285 million cases of diabetes worldwide in 2010, 90% of which will be Type 2. This number is increasing, predominantly because of lifestyle changes (http://www.diabetesatlas.org). Affected individuals have an increased risk of cardiovascular disease and a wide range of other pathological conditions, creating a major human health burden. Currently, primary management of both Type 1 and Type 2 diabetes centres on glycaemic control and insulin therapy, along with weight control strategies and the use of statins and treatments for hypertension [28–30]. Early studies have
REVIEWS
begun to show links to epigenetic effects, both in the insulin release and insulin response pathways themselves and in the inflammatory pathways, which are mediators of morbidity and mortality. Hyperacetylation of histone H4 under high-glucose conditions has been reported at the insulin gene promoter in the insulinoma cell line MIN6. DNA hypomethylation of the same promoter was shown in the beta cells of the pancreas in murine and human samples. Experimental methylation of this promoter suppressed expression of the insulin gene [31]. Vascular endothelial cells cultured under hyperglycaemic conditions showed persistently increased levels of the activating H3K4me1 mark in the promoter of the pro-inflammatory NF-kB-p65 gene. This was probably mediated by the SET7 methyltransferase [32]. In the same study, it was observed that levels of the inhibitory H3K9me2 and H3K9me3 marks at the same promoter were reduced. Investigations of the inflammatory aspects of diabetes demonstrated the involvement of H3 methylation in the inflammation of vascular smooth muscle [33,34], where H3K9me3 was purported to play a part in the repression of inflammatory genes [34]. High glucose levels were seen to increase the expression of inflammatory genes and the levels of H3K4me2, reducing the recruitment of the repressive histone demethylase LSD1 [33]. Several additional studies have demonstrated the association of histone H3 methylation events with diabetic end-points, indicating that histone methylation and acetylation pathways could both be potential candidates for small-molecule epigenetic therapeutics in this disease [35,36]. In addition to Type 1 diabetes, several autoimmune diseases are being investigated for underlying epigenetic mechanisms, particularly systemic lupus erythematosus, rheumatoid arthritis (RA) and multiple sclerosis [37]. Changes in histone and DNA modifications are associated with inflammatory responses [27,38,39]. Decreased DNA methylation at a specific CpG motif in the IL-6 promoter of patients’ peripheral blood mononuclear cells has been linked to RA [40]. Systemic lupus erythematosus patients have been reported to have decreased DNA methylation in the promoter of the CD5-E1B gene, a key regulator of the same interleukin [41]. In both clinical conditions, the end-point of these DNA methylation events increased the expression of IL-6, a key inflammatory cytokine. The alternative approach for identifying disorders that might be amenable to epigenetic therapies is a repositioning strategy. Drug repositioning is the process by which drugs (usually marketed drugs) are assessed in diseases for which they were not originally developed. The potential advantage is that marketed drugs have been through safety and toxicology testing in humans and thus can be fast-tracked into clinical trials in alternative indications [42]. In this instance, it involves epigenetic drugs originally developed to treat cancer – although ironically, from this review’s perspective, one of the first examples of such an approach happened the other way around. Sodium valproate was one of the earliest successful anti-convulsant drugs and has been widely used in epilepsy treatment. It is now known that valproic acid is a lowaffinity HDAC inhibitor with anti-proliferative effects in several cancer models. HDAC inhibitors are generally well tolerated, and many compounds have been made available to researchers working in nononcology areas, using model systems ranging from fruit flies to www.drugdiscoverytoday.com
1011
Reviews GENE TO SCREEN
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews GENE TO SCREEN
mice. They have proved particularly informative in some Mendelian disease models. For example, Huntington’s disease (HD) is an untreatable and invariably fatal dominantly inherited disorder caused by an extension of CAG repeats in the Huntingtin (Htt) gene, with consequent loss of neurons from the striatum being one of the prominent pathologies [43]. There are several mouse models of this disease, of which R6/2 is generally accepted as a useful disease phenocopier. Repressed transcription is a common feature in HD tissues, and HDAC inhibitors generally act as transcriptional activators. R6/2 HD mice treated with the HDAC inhibitor SAHA showed improved motor function and increased longevity [44]. Later papers also demonstrated symptomatic improvements in HD models using the less potent HDAC inhibitors sodium valproate and phenylbutyrate [45,46]. Surprisingly, in all cases the symptomatic improvement that followed administration of HDAC inhibitors was not accompanied by changes in underlying cellular pathology, suggesting more investigation is needed to fully understand the mechanism of action of these drugs in the model systems. EnVivo Pharmaceuticals entered an HDAC inhibitor (ENV0334) licensed from MethylGene into phase I clinical trials with HD as a named indication. The most recent statements from the company, however, suggest that this compound is being positioned as a cognitive enhancer for other neurological indications, including AD and Parkinson’s disease (http://www.envivopharma.com/template/2_18_5.html). ENV-0334 inhibits the class I and class II zinc-dependent HDACs. Recently, an inhibitor of the class III NAD-dependent Sirtuin 1 HDAC, EX-527/SEN0014196 (generated by Elixir Pharmaceuticals and partnered with Siena Biotech), has entered phase Ia clinical trials for HD (http://www.sienabiotech.com/portfolio.jsp). In addition to acetylation, recent studies have shown that the HTT protein interacts with the polycomb repressive complex 2, which possesses methyltransferase activity targeted at H3K27 [47]. The significance of this finding in the disease aetiology is unclear. The importance of understanding the biology is further demonstrated by work on dopaminergic neuronal cell lines, where treatment with the HDAC inhibitor trichostatin A (TSA) resulted in decreased cell survival and increased apoptosis [48]. This suggested that HDAC inhibition might not be appropriate for the treatment of Parkinson’s disease. However, this is in contrast to observations of Wu et al. [49], who noted that administration of valproic acid or TSA to dopaminergic neurons in rat neuron–glia cultures upregulated GDNF and BDNF and had a neuroprotective effect against the neurotoxin MPTP. Other studies investigating the effects of HDAC inhibitors have also shown positive effects. Kim et al. [50] observed that the HDAC inhibitors sodium butyrate and TSA seemed to stimulate neurogenesis in the brains of rats with induced ischaemia. The effect was mediated by the BDNF tyrosine kinase signalling pathway. AD mouse models showed restoration of contextual memory with the chronic administration of different HDAC inhibitors [51]. This study was supported by Smith et al. [52], who demonstrated that administration of valproic acid to microglial cell lines led to increased phagocytic activity for Abeta deposits. An intriguing application of epigenetic approaches has been the use of HDAC inhibitors to drive re-expression of developmentally silenced genes, to compensate for the loss of function in Mende1012
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
lian disorders. Spinal muscular atrophy is caused by inactivating mutations in the SMN1 gene [53]. The human genome also contains a highly homologous gene, SMN2, which is usually epigenetically repressed in postnatal tissues. Treatment with HDAC inhibitors leads to reactivation of the SMN2 gene in model systems [54]. A parallel approach might be possible in inherited haemoglobinopathies. Some patients with inherited mutations in the bglobin gene that lead to either sickle cell disease or b-thalassemia fare better than expected clinically [55]. Frequently, this is due to the persistence of foetal haemoglobin gene (HbF) expression. The HbF gene is usually epigenetically repressed postnatally, but studies with HDAC inhibitors in model systems have shown that the gene can be de-repressed by drug treatment [56].
Concluding remarks With epigenetic-focussed therapeutics being a promising avenue for non-cancer indications, the questions of how to assess prospective therapeutics in vivo become key. The majority of animal models are centred around either genetic manipulations, such as the transgenic mice used to model neurodegenerative disorders [57,58], or pharmacologically induced behavioural phenotypes, such as the pilocarpine epilepsy model [59]. In monogenic disorders such as HD, the epigenetic changes seen in the animal models are likely to reflect those seen in humans, although even here the disconnect between behavioural improvements and cellular pathology leads to questions around behavioural testing and whether this is appropriate or linked closely enough to the underlying pathology [60]. For the more complex diseases such as AD, the current animal models mainly mimic inherited diseases [57], so being able to determine effects on the sporadic elements of the disease will require understanding from different mechanisms of the pathology. There is often surprisingly little consensus within the pharmaceutical industry on the most reliable animal models for the majority of complex diseases (including AD, schizophrenia and depression), which will only add to the difficulties. One frequent issue, which has been indicated to some degree above, is the extent to which epigenetic therapies will genuinely alter disease progression or even cure a disorder entirely, rather than simply delay symptomatic presentation. For some diseases with an unequivocally grim prognosis such as HD or AD (particularly the early onset form), current therapies are so inadequate that even a few extra years of good-quality healthy life would represent a major improvement. This will affect the risk–benefit equation in favour of repositioning of broad-acting drugs with a side-effect profile that is less than optimal, such as HDAC inhibitors. This is less likely to be true of less catastrophic human disorders, especially where there are existing therapeutic options. A clear example would be a disease such as RA, which – although debilitating – is rarely directly life-threatening, and for which effective but expensive antibody-based therapeutics are available. In such cases, more precisely targeted epigenetic therapies will be required, with strong mechanism-of-action rationales and sideeffect profiles that are, at the very least, no worse than those of existing drugs. It seems to us improbable that this can be achieved by targeting promiscuous chromatin modifiers represented by the HDACs and the DNA methyltransferases. Success is more probable through the selective second-generation chromatin targets and requires extensive collaborations in basic research, disease model-
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
academic laboratories and the commercial sector have the potential to bring major benefits to patients through the development of second-generation epigenetic interventions.
Acknowledgements The authors thank Neil Pegg and Will West for helpful discussions.
References 1 Berger, S.L. et al. (2009) An operational definition of epigenetics. Genes Dev. 23, 781– 783 2 Kouzarides, T. (2007) Chromatin modifications and their function. Cell 128, 693– 705 3 Cheng, X. and Blumenthal, R.M. (2010) Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry 49, 2999– 3008 4 Ikegami, K. et al. (2009) Interplay between DNA methylation, histone modification and chromatin remodeling in stem cells and during development. Int. J. Dev. Biol. 53, 203–214 5 Bernstein, B.E. et al. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 6 Best, J.D. and Carey, N. (2010) Epigenetic opportunities and challenges in cancer. Drug Discov. Today 15, 65–70 7 Amir, R.E. et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185–188 8 Lasalle, J.M. and Yasui, D.H. (2009) Evolving role of MeCP2 in Rett syndrome and autism. Epigenomics 1, 119–130 9 Guy, J. et al. (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143–1147 10 Laumonnier, F. et al. (2005) Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate. J. Med. Genet. 42, 780–786 11 Loenarz, C. et al. (2010) PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an Nepsilon-dimethyl lysine demethylase. Hum. Mol. Genet. 19, 217–222 12 Jurgensen, S. and Ferreira, S.T. (2010) Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer’s disease. J. Mol. Neurosci. 40, 221–229 13 Citron, M. (2010) Alzheimer’s disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387–398 14 Chouliaras, L. et al. (2010) Epigenetic regulation in the pathophysiology of Alzheimer’s disease. Prog. Neurobiol. 90, 498–510 15 Abel, T. and Zukin, R.S. (2008) Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8, 57–64 16 De Bellis, M.D. et al. (1994) Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J. Clin. Endocrinol. Metab. 78, 249–255 17 Murgatroyd, C. et al. (2009) Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat. Neurosci. 12, 1559–1566 18 Weaver, I.C. et al. (2004) Epigenetic programming by maternal behavior. Nat. Neurosci. 7, 847–854 19 McGowan, P.O. et al. (2009) Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 12, 342–348 20 Tahiliani, M. et al. (2009) Conversion of 5-methylcytosine to 5hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 21 Okada, Y. et al. (2010) A role for the elongator complex in zygotic paternal genome demethylation. Nature 463, 554–558 22 Popp, C. et al. (2010) Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 463, 1101–1105 23 Im, H.I. et al. (2010) MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat. Neurosci. 13, 1120– 1127 24 Deng, J.V. et al. (2010) MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. Nat. Neurosci. 13, 1128–1136 25 Feng, J. and Nestler, E.J. (2010) MeCP2 and drug addiction. Nat. Neurosci. 13, 1039– 1041 26 LaPlant, Q. et al. (2010) Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat. Neurosci. 13, 1137–1143 27 Chiechio, S. et al. (2009) Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol. Pharmacol. 75, 1014–1020
28 Aschner, P. et al. (2010) Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. Int. J. Clin. Pract. 64, 305–315 29 Palumbo, P.J. and Wert, J.M. (2010) Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus. Vasc. Health Risk Manage. 6, 17–26 30 Prato, S.D. et al. (2010) Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int. J. Clin. Pract. 64, 295–304 31 Kuroda, A. et al. (2009) Insulin gene expression is regulated by DNA methylation. PLoS One 4, 6953 32 Brasacchio, D. et al. (2009) Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with geneactivating epigenetic marks that coexist on the lysine tail. Diabetes 58, 1229–1236 33 Reddy, M.A. et al. (2008) Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ. Res. 103, 615–623 34 Villeneuve, L.M. et al. (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl. Acad. Sci. U. S. A. 105, 9047–9052 35 Miao, F. et al. (2008) Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 57, 3189–3198 36 Cavener, D.R. (2009) Sleeping Beauty, awake! Regulation of insulin gene expression by methylation of histone H3 Diabetes 58, 28–29 37 Hewagama, A. and Richardson, B. (2009) The genetics and epigenetics of autoimmune diseases. J. Autoimmun. 33, 3–11 38 Barnes, P.J. (2009) Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6, 693–696 39 Strietholt, S. et al. (2008) Epigenetic modifications in rheumatoid arthritis. Arthritis Res. Ther. 10, 219 40 Nile, C.J. et al. (2008) Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 58, 2686–2693 41 Garaud, S. et al. (2009) IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J. Immunol. 182, 5623–5632 42 Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683 43 HDCRG, (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 72, 971–983 44 Hockly, E. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc. Natl. Acad. Sci. U. S. A. 100, 2041–2046 45 Zadori, D. et al. (2009) Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington’s disease. Pharmacol. Biochem. Behav. 94, 148–153 46 Gardian, G. et al. (2005) Neuroprotective effects of phenylbutyrate in the N17182Q transgenic mouse model of Huntington’s disease. J. Biol. Chem. 280, 556– 563 47 Seong, I.S. et al. (2010) Huntingtin facilitates polycomb repressive complex 2. Hum. Mol. Genet. 19, 573–583 48 Wang, Y. et al. (2009) HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells. Neurosci. Lett. 467, 212–216 49 Wu, X. et al. (2008) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 11, 1123–1134 50 Kim, H.J. et al. (2009) The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J. Neurochem. 110, 1226–1240
www.drugdiscoverytoday.com
1013
Reviews GENE TO SCREEN
ling, compound development and clinical testing. Whether successful interventions will require monotherapy or combination therapies (as seems the most promising avenue for epigenetic drugs in oncology) also remains to be established. No one sector or organization holds all the skills necessary for success in this endeavour, but effective collaborations between cutting-edge
REVIEWS
REVIEWS
Reviews GENE TO SCREEN
51 Kilgore, M. et al. (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 35, 870–880 52 Smith, A.M. et al. (2010) Valproic acid enhances microglial phagocytosis of amyloid-beta(1–42). Neuroscience 169, 505–515 53 Lefebvre, S. et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 54 Riessland, M. et al. (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet. 19, 1492–1506 55 Thein, S.L. et al. (2009) Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum. Mol. Genet. 18 (R2), R216–R223
1014
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
56 Gabbianelli, M. et al. (2000) Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate. Blood 95, 3555–3561 57 Elder, G.A. et al. (2010) Transgenic mouse models of Alzheimer’s disease. Mt. Sinai J. Med. 77, 69–81 58 Kumar, P. et al. (2010) Huntington’s disease: pathogenesis to animal models. Pharmacol. Rep. 62, 1–14 59 Scorza, F.A. et al. (2009) The pilocarpine model of epilepsy: what have we learned? Ann. Acad. Bras. Cienc. 81, 345–365 60 Sadri-Vakili, G. and Cha, J.H. (2006) Mechanisms of disease: histone modifications in Huntington’s disease. Nat. Clin. Pract. Neurol. 2, 330–338
REVIEWS
Reviews GENE TO SCREEN
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Pharmacoproteomics: a chess game on a protein field Angelo D’Alessandro and Lello Zolla Department of Environmental Sciences, Tuscia University, Largo dell’Universita` snc, 01100, Viterbo, Italy
The application of proteomics in the field of drug discovery development and the assessment of drug administration is known as pharmacoproteomics. As a branch of proteomics – perhaps the most promising and rapidly evolving field of the post-genomic era – pharmacoproteomics has inherited all the promises that pharmacogenomics has hitherto left unfulfilled. On the road to tailor-made drugs, whole protein profiles of healthy individuals have been progressively expanded, either qualitatively or quantitatively. In this review article, we provide general information about technical advancements in the field of proteomics (the pieces of this intriguing chess game) and show how this progress has furthered our understanding of biological systems. Pitfalls on the field of biomarker individuation and drug discovery and/or testing are also discussed. Functional proteomics: the pharmacoproteomic promise The application of proteomic technologies in the field of drug discovery development and assessment of drug administration is known as pharmacoproteomics [1]. Pharmacoproteomics directly stems from proteomics, the most rapidly evolving field since the end of the post-genomic era, and holds the potential to fulfill all the promises that pharmacogenomics has hitherto left unfulfilled. Although individualized medicine treatments still remain an ongoing objective, pharmacoproteomics seems to be more suited for providing valuable information in either the design or the toxicity assessment of new drugs because it sheds light on the effects of their interactions with the actual bioactive product, the protein. This is particularly evident when considering the field of biomarker discovery, in which mere genome-oriented or in silicoonly approaches have so far failed to gather conclusive information, whereas the majority of disease diagnosis-related markers have been finally ‘found in translation’, to quote Lockhart and Walther [2]. Notwithstanding the big strides made by proteomeoriented approaches, only a handful of proteins are currently used in routine clinical diagnosis, and the rate of introduction of new protein tests approved by the United States Food and Drug Admin-
Corresponding author:. Zolla, L. (
[email protected]) 1359-6446/06/$ - see front matter ß 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2010.10.002
istration has paradoxically declined over the past two decades to fewer than one new protein diagnostic marker per year [3]. The performance of combinatorial chemistry in filling pharmaceutical pipelines has been lower than anticipated and the tide might be turning back to nature in the search for new drug candidates. Even though diversity-oriented synthesis is now producing molecules that are natural-product-like in terms of size and complexity, these molecules have not evolved to interact with biomolecules: in both cases, the mechanisms of action of these molecules are often unclear. Chemical and reverse chemical proteomics have recently contributed to speeding up the process of individuating new druggable targets and their small-molecule ligands, suggesting an alternative route to follow to overpass undesired drug market stagnancy [4]. New strategies have become necessary to tackle these difficulties. First, the whole protein profiles of healthy individuals have been progressively expanded, from a purely qualitative point of view. This is particularly true for plasma and blood components, the protein lists of which have been continuously improved during the past few years [5]. To this end, the introduction of new technologies enabling sample pre-fractionation, such as combinatorial ligand libraries [6], has allowed a whole hidden proteome to be unveiled. A paradigmatic example is the case of the red blood cell, in which the 98% of the whole cytosolic protein content is characterized by hemoglobin, and the remaining 2% has been www.drugdiscoverytoday.com
1015
REVIEWS
Reviews GENE TO SCREEN
shown to harbor approximately 1578 unique proteins [7]. This amazing list of new proteins has been exploited to update the total map of erythrocyte proteins, from approximately 508 entries to 1989 distinct gene products [8]. In parallel, newly introduced technical caveats have endowed researchers with powerful tools – such as blue and clear native gel-based approaches – to explore the more hydrophobic protein fraction [9]. These approaches are relevant because they shed light on a considerable fraction of proteins that are difficult to separate and analyze with classical investigations, and they could also provide details about the formation of protein complexes, which is a recurring feature of enzymatic machineries in biological systems. These results should be completed or accompanied by in silico modeling, prediction and evaluation of the likely effects of drug– protein interactions, or protein–protein interactions themselves, because the protein itself does not exist in the cell as an independent entity; rather, it takes part in intricate networks of interacting molecules [10]. It is worth underlining that, until recently, approaches to biomarker identification have sought to find single molecules indicative of normal or anomalous conditions (i.e. to distinguish healthy cells from diseased ones, such as progenitors or terminally committed mature cells). Indeed, the molecular complexity is an emerging property of living cells, and reductionist approaches have, so far, restrained an exhaustive understanding of the molecular processes. In this view, ‘omics’-oriented approaches have been gaining momentum in the past two decades. The foremost example is perhaps proteomics, which studies the proteome, the cell-specific protein complement to the genome, and encompasses all the proteins that are expressed in a cell at the given time and under the given conditions (normal, stress, disease and tumor) in which the experiment is performed [1]. Second, new directions have been indicated and included in the ambitious agenda of the Human Proteome Organization (HUPO), in merit of the Plasma Proteome Project, which regroups 35 collaborating laboratories worldwide. In this view, quantitative data should be gathered, along with information about posttranslational modifications, which proteins undergo through consolidated mechanisms of functioning regulation and/or control [11]. Therefore, if on the one hand the accumulation of qualitative information about which proteins are expressed in healthy tissues is fundamental, on the other hand it is also pivotal to determine the fluctuations of quantities and the variations in patterns of post-translational modifications of these proteins in specific tissues under healthy and pathological conditions, before or upon drug assumption. Being this the chessboard, in this Review article we are briefly providing general information about technical advancements in the field of proteomics (the pieces of this intriguing chess game; Fig. 1) and showing how these advancements have furthered our understanding of biological systems. Pitfalls in the field of biomarker individuation and drug discovery and testing are also discussed.
The pawn: qualitative profiles – who, where and when The first step of proteomics analyses is the determination of the specific pattern of protein expression of a given tissue. Tissue proteomic profiling becomes fundamental when it comes to comparing healthy and diseased patients, to determine markers that 1016
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
could be adopted for early diagnoses. In parallel, protein fingerprints of healthy tissues could vary upon drug assumption, thus representing a valuable tool in the assessment of new drug efficiency and effectiveness or to evaluate likely drug targets [12]. The very first phase of the proteomic era has been begun by the need to build up a knowledge body of qualitative databases.
Blood plasma: technical caveats In this respect, relevant results have been obtained in the field of transfusion medicine, as it has been reviewed recently by several authors [5,13]. Indeed, blood components particularly lend themselves to protein-oriented approaches because the enucleated nature of red blood cells and platelets nullifies transcript-oriented analyses. Nonetheless, the analysis of the protein fractions of blood and blood components still represents a challenging task. The high dynamic range spread of blood and blood component proteins hampers a unitary and comprehensive view of both highand low-abundant species, including proteins involved in the most different activities (coagulation, transport, immune system and cell signaling) and protein byproduct from cellular damage of other tissues. Blood samples can be taken at a particular point in time with little burden on patients, and the constituents of the blood samples could reflect a developing or existing illness because tissue-specific proteins might be released into the blood stream from the damaged or dead cells [14]. The latter consideration suggests new scenarios because the qualitative study of minor protein populations in blood components not only is tied to transfusion medicine but could also represent a virgin forest in the field of new biomarker discovery. In this view, blood could constitute a reservoir of proteins suggestive of specific pathological conditions. Nonetheless, blood and blood components are characterized by an extreme dynamic range of proteins, the concentrations of which span more than ten orders of magnitude, from picogram to milligram quantities per milliliter in the case of plasma. Several highabundance proteins, such as albumin, typically constitute greater than 90% of total protein mass. Therefore, the detection of lower abundance proteins, which presumably represents the biologically interesting population, is interfered with by the dominant proteins. Sample preparation and pre-fractionation become pivotal when tackling the complexity of these samples, through the removal of high-abundant species through different approaches.
The bishop: sample fractionation Because of the high complexity of biological samples (especially of blood and blood components), several strategies have been proposed for cutting through the dynamic range of protein concentrations and variability spread. Basically, these methods rely on biochemical and biophysical properties of protein/peptide molecules, viz., molecular weight, density, hydrophobicity, surface change and isoelectric point, and inter-molecular affinity (e.g. protein–protein complex formation). Although samples could be split through preliminary electrophoresis pre-fractionation, most of the methods are based on the removal of high-abundant species. Immunoaffinity depletion [14], centrifugal ultrafiltration [15] and combinatorial ligand libraries [6] are three of the most widely diffused strategies to tackle dynamic concentration rangerelated analytical issues.
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews GENE TO SCREEN
[()TD$FIG]
FIGURE 1
Pharmacoproteomics as a chess game. Proteomic strategies and chess game pieces are briefly enlisted and described.
Resin-based (e.g. Cibacron blue, blue dye) and antibody-based (e.g. IgY directed towards multiple high-abundant protein species) depletion are probably the most widely diffused pre-fractionation methods in biological analyses. Commercial kits enable the removal of the 6 (albumin, transferrin, IgG, IgA, haptoglobin and antitrypsin) [16], 20 [17] and 89 [18] most abundant protein species, thus cutting the analytical noise by more than 97%. Alternatively, avian immunoglobulin yolk (IgY) kits are available, displaying higher avidity and less cross-reactivity with heterologous human proteins. High-abundant protein removal has its drawback as well, owing to the so-called ‘albumin sponge effect’, which implies that up to 210 different minor protein species (potential candidate biomarkers) are found to be associated with the six most abundant plasma proteins (in particular with albumin) [19]. For example, the removal of albumin using a resin causes a considerable loss of several cytokines. The sponge effect could be tackled through salt-
out preparation and molecular sieve filtration [20]. It might also be possible to design a non-protein binding resin or membrane containing small peptides to selectively remove albumin, but not albumin-bound proteins, from plasma [21]. Nonetheless, immunodepletion-based technology still has some considerable technical issues, which include short life span (<200 runs), progressive reduction of antibody binding capability towards specific proteins or altered specificity through high-molecular-weight compound-induced absorption through hydrophobic interactions [14], altered proportion of quantitative outputs and small sample loading capacity (25–100 ml), not to mention the elevated costs for columns and buffers. Combinatorial hexapeptide ligand libraries have emerged recently as a valuable alternative to immunodepletion [6]. The combinatorial peptide ligand library is a mixture of porous beads on which hexapeptides are chemically attached. Each bead carries billions of copies of the same peptide bait; the beads are thus www.drugdiscoverytoday.com
1017
REVIEWS
Reviews GENE TO SCREEN
different from each other, and all combinations of hexapeptides are present. Depending on the number of amino acids used, a library contains a population of millions of different ligands (e.g. 11, 24, or 64 millions starting respectively from 15, 17 or 20 different amino acids). When a complex protein extract is exposed to such a ligand library in large overloading conditions, each bead with affinity to an abundant protein will rapidly become saturated, and the vast majority of the same protein will remain unbound. By contrast, trace proteins will not saturate the corresponding partner beads but are captured in progressively increasing amounts as the beads are loaded with additional protein extract. Thus, a solidphase ligand library enriches for trace proteins, while reducing the relative concentration of abundant species [22]. Indeed, the combinatorial hexapeptide ligand library approach has contributed to dramatically delving into the complexity of a wide series of biological samples. 2-DE gels upon treatment with combinatorial peptide ligand libraries revealed a far greater number of protein species, as in the case of urine (from 184 to 385 [23]), plasma (from 115 to 790 [24]) and platelets (from 197 to 435 [25]), as well as in other biological fluids, such as milk fractions or in egg yolk and white [26]. A reduced percentage of the proteins that are visible with common methods gets lost; however, 7% in the case of urine, 5% for red blood cells and 13% for platelets [24]. The continuous expansion of the proteomes of biological samples holds that a wider basis is available for statistical and in silico analyses to determine molecular species of interest for human health (novel candidate biomarkers, drug-like molecules, anti-microbial peptides, etc.). Organellar proteomics and subcellular fractionation: A further level of complexity is introduced by the precisely controlled spatial organization of these proteins, namely where they are actually expressed, not only in terms of tissues or cells but also in terms of subcellular compartment [27]. A simple hierarchy of cellular organization would include cellular compartments, such as the cytosol and nucleus, membrane-enclosed organelles, and large or small multiprotein complexes. Large-scale approaches to organelle proteomes have been increasingly attracting a great deal of interest as Taylor et al. have recently reviewed in the literature [28]. After an organelle has been biochemically purified, it can be analyzed through proteomic approaches: in this respect, 2-DE has been almost completely substituted by approaches involving preliminary 1D-SDS-PAGE, enzymatic digestion of band of interest, chromatographic separation of the resulting peptides and subsequent identification via mass spectrometry [29]. Recently, shotgun proteomics was used to demonstrate the implication of protease inhibition and complement activation in the anti-inflammatory properties of high-density lipoprotein [30]. This workflow enables optimal protein identification, but a validation step is still required to assess whether the identified protein is a genuine component of a specific organelle. Moreover, it should be considered that the protein constituents of most organelles are in constant exchange with the rest of the cell. Several organelles – particularly nuclear subdomains – contain both resident and transient proteins. Perturbations and temporal changes in organelle proteomes could be investigated through stable isotope of amino acid in culture (SILAC) upon blockade of transcription to stabilize the cellular subproteomes at different times (up to nine). 1018
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
The knight: sample preparation Sample preparation and fractionation technologies are two of the most crucial processes to delve into the complexity of solubilized samples. There are, however, considerable limitations in currently available proteomic technologies: none of them allow for the analysis of the entire proteome in a simple step. This is due to the large number of peptides and to the wide concentration dynamic range of the proteomes in clinical blood samples. As a result, it is often observed that one sample preparation approach biases the proteomic outcome towards a slightly different output; therefore, an ideal proteomic analysis would tend to reduce sample preparation steps [31]. Plasma proteins: sample preparation – challenge ups its ante. An adequate analysis generally includes the following steps: (i) sampling, in which the sample is a good statistical representation of the investigated population; (ii) specimen preservation, during which the sample is expected to be kept stable until the analysis is completed; (iii) appropriate sample handling (fractionation); and (iv) statistical analysis and bioinformatics data treatment [31]. Ideally, sample preparation should be as simple as possible to reduce time and avoid the introduction of steps that could lead to sample loss. Studies from literature seem to attribute the most relevant role in proteomic standardization to sampling strategies, whereas handling and storage conditions apparently provoke relatively minor effects [32]. Indeed, minimal changes were observed in the samples stored at room temperature within the first four hours or six hours, whereas noticeable changes were found after eight hours, especially for peaks in the m/z range at 3000 [33], and were more pronounced after 24 h [34]. Nonetheless, these parameters need adequate standardization as well, in particular for plasma- and blood component-derived proteins, to have comparable results between different laboratories [33]. Standardization has also become an urgent issue for the HUPO, which recently started an international standardization program in proteomics (the Proteomics Standardization Initiative) [11], with the declared intent of defining community standards for data representation in proteomics, which should ease data comparison, exchange and verification. In parallel, the minimum information about a proteomics experiment (MIAPE) initiative has been started to define community standards for data production and representation in proteomics, which should reduce technical variability and ease data comparison, exchange and verification [35]. Other than storage or handling-related changes, proteomic analyses are mainly affected by sample preparation procedures, which include preliminary protein solubilization steps [31].
The rooks and the queen: membrane proteins, protein complexes and protein interactions First rook: membrane proteins. Proteins in biological samples are often insoluble because in their native state they could be found in the form of molecular complexes of associated proteins or in membranes. Solubilization steps vary depending on which kind of protein population is addressed, whether protein complexes or membrane-associated proteins. When promoting solubilization of protein complexes, it is necessary to break interactions involved in protein aggregation (e.g. disulfide and hydrogen bonds, van der Waals forces, ionic and hydrophobic interactions), which enables disruption of proteins
into a solution of individual polypeptides, thereby promoting their solubilization. Sample solubilization can be improved by agitation or ultrasonification, but an increase in temperature must be avoided. The selection of the appropriate solubilization protocol and buffers has especially been facilitated by the availability of commercial kits [36], although it is somewhat more expensive than routine reagent methods. Ionic detergents are strong solubilizing agents that produce protein denaturation. High concentrations of chaotropes such as urea (5–9 M) and thiourea (2 M) help to increase the overall number of solubilized proteins by disrupting hydrogen bonds, whereas charged chaotropic agents such as guanidine hydrochloride should be avoided because they are not compatible with isoelectrofocusing (IEF). Detergents are used to solubilize proteins and consist of a polar head group and a hydrophobic tail, enabling them to solubilize membrane proteins mimicking the lipid environment. The gentleness of detergent is mainly determined by the size of its polar head group and the length of its hydrophobic acyl tail [37]. Detergents could be used at high, medium and low concentrations. When targeting separated proteins, detergents are used within a 1–4% concentration range, to prevent hydrophobic interactions. It is important to know whether the detergent should be removed and, if so, how easy it is to remove it – for example, by dialysis. In sample preparation for 2-DE, only neutral (octylglucoside, dodecyl maltoside and Triton X-100) or zwitterionic (3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-propane sulfonate, CHAPSO, SB 310, SB 3-12 and ABS-14) detergents are used, owing to their compatibility with the separation mechanisms. The anionic detergent sodium dodecyl sulfate (SDS) improves solubilization but interferes with the first electrophoretic dimension separation and must be removed if present in the preparation (e.g. ETTanTM 2D Clean Up kit, GE Health Care; ProteoSpinTM Detergent Clean UP micro and maxi kits, Norgen Biotek Corporation). To protect proteins from protease digestion, inhibitors should also be included during sample preparation phases [38]. Solubilization protocols should be adapted when handling hydrophobic proteins, such as membrane proteins. Membrane proteins represent a large population of the proteome in the form of receptors, transporters, channels and a variety of cellular mechanisms. The importance of membrane proteins is highlighted by the fact that approximately one-third of all genes in various organisms code for this class of proteins [39]. More than two-thirds of all medications exert their effects through membrane proteins [40], which makes them a major target of pharmacological interest. However, membrane proteins are still under-identified and underrepresented during whole-cell proteome analysis. Although membrane proteins with up to 12 transmembrane ahelices have been resolved and identified by 2-DE-MS [41], most membrane proteins have been resistant to this approach. Membrane proteins are often enriched by ultracentrifugation in sucrose gradient, lectin affinity chromatography in combination with centrifugation, silica beads or biotinylation and interaction with immobilized streptavidin [42]. Solubilization of membrane proteins is achieved with different detergents, such as combinations of chloroform and methanol, which were used to extract hydrophobic chloroplast membrane proteins. Alternatively, aqueous two-phase systems (which employ detergent DDM, Triton X-114 or PEG for the selective binding of one or
REVIEWS
more proteins of interest to one of the incompatible aqueous phases) could be used. Second rook: protein complexes. Proteins rarely function in isolation. Rather, they are organized in functional units that are different in size, number of interacting partners and stability, ranging from huge stable ribosomes or nuclear pore domains to small and transient signal transduction complexes. Studying these multiprotein complexes and microdomains provides information about the spatio-temporal organization of signal transduction or metabolic processes within a cell. Moreover, most of these protein complexes involve membrane proteins. However, a major part of this information is lost when cells are lysed and proteins digested before analysis. Isolating protein from complexes enables reduced complexity and eases the identification of low copy number proteins and their specific particular functions [43], although most of the sample pre-fractionation strategies (see the section ‘The bishop: sample fractionation’) tend to disrupt protein complexes by negatively influencing native protein–protein interactions. Protein complexes and hydrophobic protein species can be investigated through different approaches, including affinity-based methods, recombinant pull-downs, liquid chromatography, blue native gel electrophoresis (BN-PAGE), 2DE/LC/CE and FFE methods, followed by MS analysis [41]. Protein denaturing approaches (IEF, SDS-PAGE, 16-BAC-PAGE and CTABPAGE) are not suited to tackle protein complexes [41]. Nevertheless, BN-PAGE is perhaps the gel-based criterion of choice when addressing protein complexes and membrane proteins. BN-PAGE was introduced by Schagger and Von Jagow almost 20 years ago [44] and exploits Comassie G-250 to partially charge proteins to increase their electrophoretic mobility. Native gel-based approaches target protein complexes in their native form, as an alternative to immune co-precipitation [45], against which they enable separation without antibodies at the expense of detergentlabile interacting protein loss. Gel-free platforms particularly lend themselves to shotgun proteomic approaches, such as MudPIT, and minimize the problem of insolubility encountered in membrane protein studies [46].
The queen: protein–protein interactions Protein array information can be exploited to obtain complex maps of proteins involved in disease-specific molecular signatures and could, therefore, be translated to in silico data handling through elaborations of protein–protein interaction maps [47]. Biomolecule interactions are also relevant in that they might elucidate the efficiency and effectiveness of a targeted drug treatment. For example, the extent of drug binding to plasma proteins, determined by measuring the free active fraction, has a notable effect on the pharmacokinetics and pharmacodynamics of a drug. To this end, a vast array of different methods have been developed, viz., equilibrium dialysis, ultrafiltration, parallel artificial membrane permeability assay, high-performance affinity chromatography/zonal elution approach, high-performance affinity chromatography/ frontal analysis approach, affinity capillary electrophoresis, capillary electrophoresis/frontal analysis, spectroscopic assays, isothermal titration calorimetry, competition studies, titration studies, differential scanning calorimetry, surface plasmon resonance-based assays and SILAC [47]. Vice versa, it has been hypothesized that targeted drug treatments should address target protein biomarkers, www.drugdiscoverytoday.com
1019
Reviews GENE TO SCREEN
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Reviews GENE TO SCREEN
which are characterized by specific properties making them eligible interactors of the designed drug (‘drug target-likeness’) [48]. In this respect, in silico modeling becomes pivotal for optimal design of drugs against, for example, specific subclasses of receptors [49]. In parallel, progresses have been made recently in the field of protein–protein interaction mapping and elaboration of networks, pathways and enrichment of gene ontologies for biological and molecular functions, especially upon the introduction of user-friendly software and updated databases [50] (Fig. 2). The ultimate goal of this kind of investigation is to use the software output to focus on specific targets as early biomarkers of pathological conditions or druggable-like targets for medical treatment. In parallel, the in silico approach could be useful in creating models or elaborating data from experimental observations about [()TD$FIG]
changes in pathways and networks upon administration of specific drugs. These methods might reveal drug effects on pathways, which represents the cornerstone of identifying mechanisms of drugs’ efficacy.
The king: quantitative profiles Pre-analytical control Although a wealth of studies are regularly being published about successful proteomic approaches to biological marker (biomarker) discovery, the discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g. assembly of a cohort of patients, sample preparation and the nature of body fluids, and selection of a profiling method and uniform protocols for data analysis) [51]. Most of this gap is due to
Legend Enzyme
AGTRAP
G-protein Coupled Receptor Kinase Peptidase Transcription Regulator Translation Regulator
ATG4A
ATG4B
Transporter
GABARAP
Unknown Relationship
IRGQ
GBAS ATG3*
RNF126 PANK2
LXN
ATG7 PP (1)
CIRBP
GABARAPL2 (includes EG:11345) UBA5 NCBP2
PSMF1*
YARS
EF4G1 EPPK1
KHSRP RBMX NCBP1 HNRNPH1
GSPT1 RPL35A
UBE2O
ARF6 CNBP*
HNRNPA3
IPO11
RPL12 (includes EG:6136)
RPL31
RPL26
LYZ* LTF Drug Discovery Today
FIGURE 2
Network analysis through Ingenuity Pathway Analysis of an experimental dataset. The software graphs proteins as nodes and interactions as connecting hubs (edges). Nodes could vary in color and shape to reflect experimental quantitative fluctuations or indicate different biological functions. Red nodes are overexpressed among two groups under comparison. Highly connected nodes (high-degree) represent the most biologically relevant proteins because they function as regulatory hubs for multiple pathways. Edges could be represented by continuous or interrupted lines, to indicate direct or indirect interactions between two proteins. 1020
www.drugdiscoverytoday.com
the lack of proper quantitative results on large cohorts of patients. As a result, most of the currently available biomarker discovery studies lack the statistical strength for the identification of highconfidence biomarkers and are thus more suited to tailor-made studies, although they lack the statistical strength of large-scale studies [52]. Often, the validation step that follows the discovery phase does not reach desired levels of sensitivity and specificity or reproducibility between laboratories [51]. Identification of the importance of preanalytical factors has implications for the use of large sample banks [53]. Such banks enable many prospective studies, which otherwise would require years for sample acquisition, to be carried out in a timely fashion, but sample banks vary in their adherence to consistent sample processing protocols over time. Many proteins, however, can be unaffected by many of the preanalytical variables. Therefore, any study using or proposing to use such banks should not be instantly condemned, but the way in which the banked samples are used should be examined. A possible, although imperfect, solution to this issue is to restrict the initial phase of biomarker discovery to specimens collected by rigorous adherence to banking protocols. To overcome this hurdle, multi-group efforts are necessary to facilitate the generation of sufficient sample sizes. This is contingent on the ability to collate and cross-compare data from different studies, which will require the use of a common metric or standard.
REVIEWS
be a major contributor to laboratory medicine in the near future. The potential clinical benefits for disease-specific biomarkers (to be tested for in clinical routine practice) include a more rapid and accurate disease diagnosis and a potential reduction in size and duration of clinical drug trials, which would speed up drug development. For example, proteomics in urine analysis could help identify and quantify proteins excreted in urine, which are not only key indicators of diseases associated with renal function but also indicators of the overall health of individuals. The application of biomarkers in the clinical arena of motor neuron disease should determine both whether a drug hits its proposed target and whether the drug alters the course of disease. It is interesting to note that, despite blood lacking direct contact with brain, increasing evidence suggests that there is a blood protein signature, and possibly a transcript signature, that might act to increase confidence in diagnosis and be used to predict progression in either disease or prodromal states. It might also be used to monitor disease progression [56]. These optimistic results come partly from candidate protein studies, from which it emerged that amyloid-beta measures might have value in prediction, and those studies of inflammatory markers that consistently show change in Alzheimer’s disease [56].
In theranostics
Checkmate: biomarker discovery and quantitation The biomarker field has generated various examples of individual biomarkers that can be used as indicators of disease pathophysiology, such as blood pressure, cholesterol levels and viral load in HIV [54]. The complexity of the underlying pathophysiological pathways and interactions makes it desirable to identify shortcuts through the proteome to associate meaningful biomarker-like signatures to specific protein profiles, rather than relying on independent biomolecules alone. The identification of a pattern or profile of several biomarkers (representing, e.g. a combination of genes, proteins, organic molecules, metabolites and/or a physiological response) representative of a given condition might bring a new dimension to disease diagnosis, classification and intervention and the assessment of therapeutic responses. Nonetheless, to be eligible as a valuable biomarker candidate, a protein should be detectable early and quantifiable over disease progression, and its co-occurrence with the disease should be statistically significant in a robust cohort of patients: although most scientific efforts have been put forward to address the first and last concerns, quantification has become a pivotal node in biomarker discovery and validation in recent years, especially in the field of human cancer research. To compare the abundance of proteins in different samples, several quantitative approaches have been developed (such as SILAC, isotope-coded affinity tags, exponentially modified protein abundance index and subtractive proteomic strategies), as Veenstra brilliantly reviewed [55]. Soon enough, quantitation strategies will enable biomarker discovery to meet quality criteria of clinical laboratory medicine.
In clinical laboratory medicine Clinical proteomics consists of discovery proteomics and measurement (quantitative) proteomics. Our current main focus is still discovery proteomics, clinical proteomics will undoubtedly
Non-invasive biomarker strategies based on imaging technologies – including magnetic resonance imaging, single-photon emission computed tomography, positron emission tomography and other techniques – are also progressing quickly in various therapeutic areas [57]. State-of-the-art applications of proteomics in the field of biomarker discovery involve the elaboration of specific signatures in 2DE maps, quantitative approaches [58], the individuation of marker-like post-translational modifications [59] and, recently, the measurement of varying metabolic profiles [60]. Complementary strategies are now adopted to focus on diseaserelevant converging pathways as potential therapeutic intervention points and are accompanied by the individuation of downstream biomarkers, which enable the tracking of drug targeting and seem to correlate with disease mitigation. When putting the pieces together, one is able to envision that a companion diagnostic will be codeveloped along the therapeutic compound. This ‘theranostic’ approach is perfectly positioned to align with the emerging trend toward personalized medicine [61]. In the quest for tailor-made drugs, proteomics has been contributing with previously unexpected results, involving, for example, genderspecific differences in human serum, which could be fundamental to building gender-specific protein biomarker databases to be exploited for targeted treatments.
Protein chips Once individuated, however, it is very unlikely that biomarkers will be monitored with 2-DE or mass spectrometry, which are routine techniques in the academic setting but do not lend themselves to clinical routine practice on large cohorts of samples. Further development of protein arrays might address this issue [51]. A faster approach to biomarker monitoring, using the integration of genomic and proteomic techniques, is based on the prowww.drugdiscoverytoday.com
1021
Reviews GENE TO SCREEN
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews GENE TO SCREEN
duction of protein chips. In this approach, cDNAs encoding tagged proteins are expressed and proteins are isolated and printed on a slide. These slides are then used to examine protein profiling, protein–protein interactions and antibody profiling [62]. These protein array techniques [63] can help not only to detect potential novel biomarkers but also to generate a greater understanding of the signaling pathways associated with the printed proteins. Protein-detecting arrays use a wide variety of capture agents (antibodies, fusion proteins, DNA/RNA aptamers, synthetic peptides, carbohydrates and small molecules) immobilized at high spatial density on a solid surface. Each capture agent binds selectively to its target protein in a complex mixture, such as serum or cell lysate samples. Captured proteins are subsequently detected and quantified in a high-throughput manner, with minimal sample consumption. Furthermore, the first multiplex immunoassay systems have been cleared by the US Food and Drug Administration, signaling recognition of the usefulness of miniaturized and parallelized array technology for protein detection in predictive and/or early diagnosis. Although genetic tests still predominate, with further development protein-based diagnosis will become common in clinical use within a few years [64].
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
components, making it possible to identify protein signatures of diagnostic value and clinical importance. Alternative strategies have been created to target either protein biomarkers (often very low abundance protein) or drug-target-like molecules (often hydrophobic proteins at the membrane level) [65], both needing thorough clinical validation on large cohorts of patients before their widespread diffusion. The real deal is the limited biological variability tested in discovery studies, the current lack of quantitative information and, thus, the need for a proper validation and the absence of quality criteria in alignment to standard clinical practice. These objectives represent the very heart of the ambitious agenda and need to be accomplished in the next few years. The growing need for quantitative information is linked to the opportunity to better understand biological systems as a whole, through the integration of quantitative proteomics, metabolomics and transcriptomics auspicated by systems biology. Whether tailor-made treatments are still far from being a reality, pharmacoproteomics and in silico elaborations have contributed to make this chess game more challenging and intriguing than ever before. As huge amounts of data are being accumulated, the fulfillment of the pharmacoproteomic promises is rapidly approaching; however, the run towards the checkmate is not yet over.
Concluding remarks One square at a time, qualitative protein profiles of healthy and diseased tissues have been thoroughly investigated. Sample preparation and fractionation techniques have been gradually optimized to cut through the biological complexity of blood
Acknowledgements ADA and LZ were supported by founds from the Italian National Blood Centre (Centro Nazionale Sangue – Istituto Superiore di Sanita` – Rome, Italy).
References 1 Zolla, L. (2008) Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins. Drug Discov. Today. 13 (Suppl. 23–24), 1042–1051 2 Lockhart, B.P. and Walther, B. (2009) Biomarkers: ‘found in translation’. Med. Sci. (Paris) 25, 423–430 3 Anderson, N.L. and Anderson, N.G. (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845–867 4 Piggott, A.M. and Karuso, P. (2004) Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery. Comb. Chem. High Throughput Screen. 7, 607–630 5 Liumbruno, G. et al. (2009) Blood-related proteomics. J. Proteomics 73, 483– 507 6 Righetti, P.G. and Boschetti, E. (2009) Blood proteomics and the dynamic range: some light at the end of the tunnel? J. Proteomics 73, 627–628 7 Roux-Dalvai, F. et al. (2008) Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol. Cell. Proteomics 7, 2254–2269 8 D’Alessandro, A. et al. (2010) The red blood cell proteome and interactome: an update. J. Proteome Res. 9, 144–163 9 Braun, R.J. et al. (2007) Two-dimensional electrophoresis of membrane proteins. Anal. Bioanal. Chem. 389, 1033–1045 10 Lee, S. et al. (2009) Structural interactomics: informatics approaches to aid the interpretation of genetic variation and the development of novel therapeutics. Mol. Biosyst. 5, 1456–1472 11 Omenn, G.S. et al. (2009) 7(th) HUPO World Congress of Proteomics: launching the second phase of the HUPOPlasma Proteome Project (PPP-2) 16–20 August 2008, Amsterdam, The Netherlands. Proteomics 9, 4–6 12 Chanda, S.K. and Caldwell, J.S. (2003) Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today 8, 168–174 13 Thiele, T. et al. (2007) Proteomics of blood-based therapeutics. BioDrugs 21, 179–193 14 Ichibangase, T. et al. (2009) Limitation of immunoaffinity column for the removal of abundant proteins from plasma in quantitative plasma proteomics. Biomed. Chromatogr. 23, 480–487
1022
www.drugdiscoverytoday.com
15 Greening, D.W. and Simpson, R.J. (2010) A centrifugal ultrafiltration strategy for isolating the low-molecular weight (25 K) component of human plasma proteome. J. Proteomics 73, 637–648 16 Huang, L. et al. (2005) Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 5, 3314–3328 17 Lin, B. et al. (2009) Deep depletion of abundant serum proteins reveals lowabundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin. Appl. 3, 853–861 18 Qian, W.J. et al. (2006) Advances and challenges in liquid chromatography–mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell. Proteomics 5, 1727–1744 19 Lee, H.J. et al. (2006) Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr. Opin. Chem. Biol. 10, 42–49 20 Hey, J. et al. (2008) Fractionation of complex protein mixtures by liquid-phase isoelectric focusing. Methods Mol. Biol. 424, 225–239 21 Jurgens, M. and Schrader, M. (2002) Peptidomic approaches in proteomic research. Curr. Opin. Mol. Ther. 4, 236–241 22 Righetti, P.G. and Boschetti, E. (2008) The ProteoMiner and the FortyNiners: searching for gold nuggets in the proteomic arena. Mass Spectrom. Rev. 27, 596–608 23 Castagna, A. et al. (2005) Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res. 4, 1917–1930 24 Sennels, L. et al. (2007) Proteomic analysis of human blood serum using peptide library beads. J. Proteome Res. 6, 4055–4062 25 D’Amato, A. et al. (2009) In-depth exploration of cow’s whey proteome via combinatorial peptide ligand libraries. J. Proteome Res. 8, 3925–3936 26 D’Alessandro, A. et al. (2010) The egg white and yolk interactomes as gleaned from extensive proteomic data. J. Proteomics 73, 1028–1042 27 Andersen, J.S. and Mann, M. (2006) Organellar proteomics: turning inventories into insights. EMBO Rep. 7, 874–879 28 Taylor, S.W. et al. (2003) Global organellar proteomics. Trends Biotechnol. 21, 82–88 29 Yates, J.R. et al. (2005) Proteomics of organelles and large cellular structures. Nat. Rev. Mol. Cell Biol. 6, 702–714
30 Vaisar, T. et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117, 746–756 31 Ahmed, F.E. (2009) Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. J. Sep. Sci. 32, 771–798 32 Hsieh, S.Y. et al. (2006) Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 6, 3189–3198 33 Rai, A.J. et al. (2005) HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262–3277 34 Marshall, J. et al. (2003) Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2, 361–372 35 Taylor, C.F. et al. (2007) The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 25, 887–893 ˜ as, B. et al. (2007) Trends in sample preparation for classical and second 36 Can generation proteomics. J. Chromatogr. A 1153, 235–258 37 Reisinger, V. and Eichacker, L.A. (2008) Solubilization of membrane protein complexes for blue native PAGE. J. Proteomics 71, 277–283 38 Tan, S. et al. (2008) Membrane proteins and membrane proteomics. Proteomics 8, 3924–3932 39 Hopkins, A.L. and Groom, C.R. (2002) The druggable genome. Nat. Rev. Drug Discov. 1, 727–730 40 Plewczynski, D. and Rychlewski, L. (2009) Meta-basic estimates the size of druggable human genome. J. Mol. Model. 15, 695–699 41 Helbig, A.O. et al. (2010) Exploring the membrane proteome – challenges and analytical strategies. J. Proteomics 73, 868–878 42 Komatsu, S. et al. (2007) The proteomics of plant cell membranes. J. Exp. Bot. 58, 103–112 43 Pasquali, C. et al. (1999) Subcellular fractionation, electromigrationanalysis and mapping of organelles. J. Chromatogr. B: Biomed. Sci. Appl. 722, 89–102 44 Schagger, H. and von Jagow, G. (1991) Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal. Biochem. 199, 223–231 45 Blonder, J. et al. (2002) Enrichment of integral membrane proteins for proteomic analysis using liquid chromatography–tandem mass spectrometry. J. Proteome Res. 1, 351–360 46 Han, D.K. et al. (2001) Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 19, 946–951
REVIEWS
47 Ong, S.E. et al. (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. U. S. A. 106, 4617–4622 48 Xu, H. et al. (2007) Learning the drug target-likeness of a protein. Proteomics 7, 4255– 4263 49 Sela, I. et al. (2010) G protein coupled receptors – in silico drug discovery and design. Curr. Top. Med. Chem. 10, 638–656 50 Shannon, P. et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 51 Silberring, J. and Ciborowski, P. (2010) Biomarker discovery and clinical proteomics. Trends Analyt. Chem. 29, 128 52 Chao, T.C. et al. (2010) Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery. J. Proteomics 73, 1641–1646 53 Banks, R.E. (2008) Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. Clin. Chem. 54, 6–7 54 Ilyin, S.E. et al. (2004) Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 22, 411–416 55 Veenstra, T.D. (2007) Global and targeted quantitative proteomics for biomarker discovery. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 847, 3–11 56 Thambisetty, M. and Lovestone, S. (2010) Blood-based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark. Med. 4, 65–79 57 Rudin, M. and Weissleder, R. (2003) Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123–131 58 Liu, Y.F. et al. (2009) Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J. Pathol. 217, 54–64 59 Papini, A.M. (2009) The use of post-translationally modified peptides for detection of biomarkers of immune-mediated diseases. J. Pept. Sci. 15, 621–628 60 Wibom, C. et al. (2010) Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. J. Proteome Res. 9, 2909–2919 61 Zhang, Z. et al. (2010) Systems biology and theranostic approach to drug discovery and development to treat traumatic brain injury. Methods Mol. Biol. 662, 317–329 62 Tomizaki, K.Y. et al. (2010) Protein–protein interactions and selection: array-based techniques for screening disease-associated biomarkers in predictive/early diagnosis. FEBS J. 277, 1996–2005 63 Miike, K. et al. (2010) Proteome profiling reveals gender differences in the composition of human serum. Proteomics 10, 2678–2691 64 Tomizaki, K.Y. et al. (2010) Protein–protein interactions and selection:array-based techniques for screening disease-associated biomarkers in predictive/early diagnosis. FEBS J. 277, 1996–2005 65 Lai, Z.W. et al. (2009) Membrane proteomics: the development of diagnostics based on protein shedding. Curr. Opin. Mol. Ther. 11, 623–631
www.drugdiscoverytoday.com
1023
Reviews GENE TO SCREEN
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews INFORMATICS
Connecting the dots: role of standardization and technology sharing in biological simulation Samik Ghosh1, Yukiko Matsuoka1,2 and Hiroaki Kitano1,3,4 1
The Systems Biology Institute, Tokyo 108-0071 Japan JST ERATO Kawaoka Infection-induced Host-response Network Project, Tokyo 108-8639 Japan 3 Okinawa Institute of Science and Technology, Okinawa, Japan 4 Sony Computer Science Laboratories, Tokyo 141-0022 Japan 2
The role of biological modeling and simulation in enhancing productivity across the drug discovery pipeline has been increasingly appreciated over the past decade by the pharmaceutical industry. However, adoption of in silico modeling and simulation techniques has been sparse due to skepticism in the associated pay-offs and knowledge gap in research. While biological simulations have been successfully applied in specific projects, a standardized, community-wide platform is imperative for making the final leap of faith across the domain. This review outlines the issues and challenges involved in fostering a private-public collaborative effort for the development of standard modeling and biosimulation platforms and concludes with insights into possible mechanisms for integrating an in silico pipeline into the drug discovery and development process.
In the spring of 2008, a group of scientists and thought leaders from across academia and industry met in Tokyo [1] to brainstorm future challenges in systems biology and its application to the pharmaceutical industry. While unanimously acknowledging the burgeoning role of systems biology in tackling complex diseases, the researchers laid out a bold objective – ‘to create over the next 30 years a comprehensive, molecule-based, multi-scale, computational model of the human (‘the virtual human’), capable of simulating and predicting, with a reasonable degree of accuracy, the consequences of most of the perturbations that are relevant to healthcare’ [2]. The scale and timeline of the project outlined in the Tokyo Declaration [2] underscore the complexity of the problem facing researchers in life sciences and pharmaceutical companies alike. With the current economic scenario, value of impending major blockbuster drug patent expirations and thinning pipelines for anticipated phase III drug approvals [3,4], the pharma industry is undergoing a paradigm shift in its efforts to develop safe and more efficacious drugs for the complex and life-threatening diseases facing humankind. Recent industry reports on future visions for Corresponding author:. Kitano, H. (
[email protected])
1024
www.drugdiscoverytoday.com
the industry [3,4] have highlighted the need to shift trajectories from target-based drug discovery to more system-oriented, holistic approaches that embrace knowledge from basic academic research and computational and systems engineering techniques. In particular, predictive biosimulation software – based on interconnected sets of mathematical equations with calibrated parameters to represent biological and physiological behaviors – has been successfully applied across the different stages of drug discovery and development, from target identification and validation, lead optimization and candidate selection to clinical trial design and development [5–7]. Simulation is an indispensable tool in all engineering designs and has been successfully applied in the automobile, aerospace and telecommunication industries for decades. Computational fluid dynamics (CFD), for example, is an essential design process in aircraft design, ship design and automobile design. Any highrise building has to carry out a series of structural integrity simulations even to be approved for construction; chipmakers model, modify and simulate their designs on computers before sending them to the fabrication plants; ‘virtual cars’ are driven and ‘virtual aircrafts’ flown under simulated conditions before hitting the manufacturing floor [8]. Although the application of advanced
1359-6446/06/$ - see front matter ß 2010 Published by Elsevier Ltd. doi:10.1016/j.drudis.2010.10.001
modeling and simulation techniques has resulted in immense cost savings and standardized procedures for such R&D-intensive industries, the pharmaceutical industry has historically lacked these approaches, leading to astronomical costs in drug development (25% of its revenue, almost twice that of other knowledgedriven industries [8]). Although appreciation and awareness for the potential benefits of computational approaches in biological sciences and drug design have been on an increasing trajectory in both industry and academic circles, it is important to keep in perspective the unique hurdles and cosiderable challenges of applying in silico techniques in the life sciences. Identification of the specific features desired from computational tools in the pharmaceutical industry, together with an open, collaborative mindset between all players, would form the key stepping stones in the development of safer, efficacious and cost-efficient drugs for complex diseases such as cancer, metabolic and cardiac disorders.
Issues and challenges The adoption of simulation techniques in the life sciences requires careful and detailed consideration of the unique challenges of multi-scale modeling– from cells, to tissues and organs, to whole human body and host–pathogen interactions. A series of issues have to be addressed before simulation can be accepted as normal practice in the industry. First, a set of fundamental technical issues must be solved to further improve accuracy of simulation. Different flavors of simulation technologies exist, from deterministic, differential-equation-based systems to non-deterministic, stochastic techniques, [()TD$FIG]
REVIEWS
agent-based and discrete-event based simulations; each presents a unique set of assumptions and system conditions that need to be considered before successful application to specific biological problems, as elucidated schematically in Fig. 1 [9]. Cellular modeling or physiological modeling with molecular details will require the integration of heterogeneous computational models that are on different spatial and temporal scales, and the basic equations still need to be defined [10]. The purpose and goal of a simulation system applied in drug design should be clearly defined: for example, in Formula 1 aerodynamics design, the goal is to design an aerodynamically optimal body with maximum down force with minimum drag. This forms a key step in defining and determining the eventual success of a biological simulation system. Merrimack Pharmaceuticals [11], for example, used computer simulation to identify a novel drug target for specific cancer sub-types that resulted in the development of a monoclonal antibody for ErbB3, now in clinical trial. Simulation models need to be designed to sufficiently capture essential features to accomplish the task defined, but features that are unlikely to affect prediction accuracy of the given task can be ignored. Sophisticated models with molecular details that can predict cellular behaviors in various conditions are crucial for elucidating system-level properties of cellular systems. Such models should be able to provide predictions on how cells and organs respond when certain perturbations, such as drug administration, are given. Although there are some successful cases of computational modeling of limited-scale biological networks, there is no established method for developing high-precision models.
FIGURE 1
Schematic showing different simulation and modeling approaches. www.drugdiscoverytoday.com
1025
Reviews INFORMATICS
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews INFORMATICS
In establishing such practices, it might be prudent to borrow ideas from other fields with more mature and well-established practices of simulation modeling. In particular, the integration of computational modeling and experimental data acquisition has to be promoted. Delving into the design process of Formula 1 racing cars provides a picture of an iterative design cycle – several designs are tested with CFD and some of these designs are then tested using a wind tunnel, leading to the selection of one or two designs that are actually implemented and tested in a test course before one design is selected for final production. In this process, CFD models are calibrated against wind tunnel data for further improvement of accuracy, instead of data from the test course or from actual racing telemetry data. This comparison delivers two messages. First, we need to develop highly controllable experimental systems comparable to wind tunnels in aerodynamics. This means that we need to be able to precisely control exposure to chemical substances and other environmental conditions. Second, efforts need to be made to create high-precision models against well-controlled experimental systems, instead of uncontrollable systems. The identification and integration of structural, spatial and temporal dynamics of both interaction networks and cellular structures is an essential prerequisite for defining such high-precision models. The dynamics of cellular structure and interaction networks need to be quantified by taking comprehensive, high-resolution, measurements of intracellular status – such as the concentrations, interactions, modifications and localizations of molecules – and of cellular structures in different dimensions and environmental conditions. In addition, the problem of how to identify unknown interactions from such data sets still remains. These problems are fundamental and require collaborative efforts on a community-wide scale. Although various ongoing efforts exist for tackling the problems of building molecular network maps, simulation tools, data resources and web services for sharing information, an open, integrative platform for sharing and exchange of computational approaches is of fundamental importance.
Standards and technologies The sharing of knowledge accelerates progress in science. This is perhaps more true for the biological sciences, in which the complexity and size of the problem domain make it imperative for different research groups to focus on different sections of it. Computational tools have already played an important part in the collection, storage and intelligent retrieval of vast amounts of information in the life sciences. With the adoption of biosimulation tools, the ability to store and share information in a seamless, unambiguous fashion became imperative, leading to the definition of The Systems Biology Markup Language (SBML; http:// www.sbml.org), a set of standards developed to facilitate effective and efficient sharing of models defined as a set of biochemical reactions. The effort was initiated by the ERATO Kitano Symbiotic Systems Project, funded by the Japanese government but soon grew to be a global community-wide initiative. Importantly, the SBML community has evolved a proper procedure to elect editors, implemented voting procedures and formalized discussion forums. Thus, it is no longer a project belonging to any one institution but is truly a community effort. Currently, more than 180 1026
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
pieces of bio-modeling and simulation software comply with SBML [12], enabling the sharing of models across them. Although the definition of a common lingua franca is an important step in the standardization of in silico technologies, biology has traditionally been a descriptive science, in which the role of pictures and diagrams cannot be overstated. Keeping in mind the need for a common graphical representation standard in the life sciences, a community-wide effort has been undertaken to define The Systems Biology Graphical Notation (SBGN; http:// www.sbgn.org/) [13]. The SBGN community is working to formulate a set of rules for human-readable visual representations of biological networks. The goal of SBGN is to define a set of visual glyphs and syntax so that anyone can understand exactly what each diagram means (Fig. 2), in the same vein as the electrical circuit diagrams used by chip designers. With SBML and SBGN, standards for computational modeling and representation languages are being defined that will have a notable impact on standardization and model sharing. For models to be informative, they must be properly annotated; sufficient information must be attached with the models to enable third parties to use them. With the objective of proper model annotation, the MIRIAM project (http://www.ebi.ac.uk/miriam/) defines the minimum information that has to be attached to a model so that model can be informative by itself. A series of standard formation efforts are now underway to cover the whole process of modeling development and analysis. Although standardization is an integral part of the process of computational systems biology, the development of a suite of software tools for model building, distribution and running simulations is another important dimension. In this direction, a plethora of modeling building and simulation tools such as Cellarator [14], Copasi [15] and Dizzy [16] in the academic community and SimBiology1 from Mathworks Inc. (http:// www.mathworks.com/products/simbiology) and PhysioLab1 (Entelos Inc; http://www.entelos.com) exist, each catering to different modeling techniques (see Ref. [12] for comprehensive coverage of systems biology tools). One of the most popular and widely used tools in this space [12] is CellDesignerTM [17] – a modeling and simulation tool to visualize, model, and simulate gene regulatory and biochemical networks. Two major characteristics embedded in CellDesigner boost its usability to create, import and export models: the solidly defined and comprehensive graphical representation (SBGN) of network models and SBML as a model-describing basis, which function as inter-tool media to import and export SBML-based models. Moreover, CellDesigner provides the ability to embed – or smoothly connect via Systems Biology Workbench (http:// www.sys-bio.org/research/sbwIntro.htm) – different simulation and analysis packages, which enable the simulation of the pathways using various simulation techniques (Copasi, SBML ODE solver, and so on), as shown in Fig. 3a. With the explosive growth in proliferation and adoption of the Internet and web services, knowledge in the life sciences has shifted to the World Wide Web with online access to scientific literature, biological databases, and knowledge-sharing and/or discussion forums. As more biological information comes online, it is important to develop an infrastructure that enables the community to leverage the vast web resources. This online, com-
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
[()TD$FIG]
SYSTEMS BIOLOGY GRAPHICAL NOTATION REFERENCE CARD Entity Pool Nodes
Auxiliary units
Process Nodes transition
LABEL
unspecified entity
simple chemical
LABEL
macromolecule
Marker
N
Target EPN
production
Target PN
modulation
association
Target PN
stimulation
Target PN
catalysis
Target PN
inhibition
Target PN
trigger
dissociation
nucleic acid feature
N:5
consumption
uncertain process
clone marker LABEL
LABEL
N
state variable
val@var
?
LABEL
Source EPN
unit of information
pre:label
omitted process LABEL
Connecting Arcs
Reviews INFORMATICS
(a)
Container Nodes
LABEL
multimer INFO
N:2
N:2
LABEL
INFO
LABEL
varZ
LABEL
Source EPN
complex
LABEL
Logical operator
logic arc
LABEL varY
INFO
source/sink
e:INFO
LABEL
varX
compartment AND
LABEL
LABEL
(b)
equivalence arc
Logical Operators
LABEL
tag
LABEL
EPN
observable EPN or CN
perturbation
A
B
EPN or CN
C
EPN or CN
and operator
OR
or operator
OR
not operator
submap
LABEL
Synaptic button ChAT
vAChT
Synaptic vesicle
cholin
ACh
ACh SNARE
CHT1
acetyl CoA
AChE
synaptic cleft
ACh
cholin
nAChR
muscle cytosol
nAChR open
closed
Ca2+
ER
ATP myosin ATP myosin
Ca2+
actin
tense
ADP
Pi
relaxed
ATP actin
myosin
actin
myosin
muscle contraction
Drug Discovery Today
FIGURE 2
(a) The Systems Biology Graphical Notation (SBGN) glyphs and (b) sample model representation.
www.drugdiscoverytoday.com
1027
REVIEWS
[()TD$FIG]
Reviews INFORMATICS FIGURE 3
(a) CellDesigner snapshot and (b) Payao web interface snapshot.
1028
www.drugdiscoverytoday.com
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
munity collaboration paradigm motivated the development of Payao [18], a web-based biological pathway sharing and tagging service (http://www.payaologue.org). A snapshot of the interface is shown in Fig. 3b. The goal of Payao is to provide a Google Maps equivalent for biological pathways, wherein researchers can share large-scale, curated and annotated (MIRIAM-compliant) network maps (SBGN and SBML compliant) using software such as CellDesigner and publish it to the community online. With the built-in tagging and collaborative system, the community can participate in enhancing the biological entities in the map or navigate their specific areas of interest. Other important assets for online community collaboration are the databases that provide pathway models fully curated and compliant with standards. Two major online data resources providing access to biological pathway models are the BioModels.net Initiative (http://www.biomodels.net), which provides a one-stop shop for SBML-compliant simulation models of biological pathways published in various literature, and The Panther Pathways database [19], which provides a database of annotated pathways created in CellDesigner (SBML and SBGN compliant). We have provided a slice of the spectrum of activities initiated by different research groups in developing biosimulation tools and technologies. Whereas each of these tools provides a niche solution to a particular biological problem in isolation, an integrative framework leveraging the advantages of the diverse techniques holds the promise of providing a comprehensive computational pipeline.
Community collaboration and open flow model The standards and technologies in systems biology, as elucidated in the previous section, represent various pieces of a comprehensive computational pipeline for the pharmaceutical industry. Crucial to the success of such a pipeline, however, is the clarification of the promises and pitfalls of the different components and the identification of a cohesive set of strategies to add value to the drug discovery process. In June 2008, a representative group of systems biology scientists from academia, biotechnology and the pharmaceutical sector gathered in Portofino, Italy [20], with the goal of brainstorming a set of recommendations for such a strategic path to systems biology. While identifying various action items like setting data standards, modeling drug actions and toxicity, the leaders proclaimed that a ‘network solution’ [20] (i.e. community-wide collaboration, communication and outreach) was the key to solving complex biological network problems. As outlined in the ‘Issues and challenges’ section, the size and complexity of living systems present several challenges to the systems biology community. Overcoming the obstacles of simulation speed, accuracy, high-precision experiments and knowledge sharing would require the expertise of scientists and engineers from diverse backgrounds and disciplines. Thus, developing an ecosystem of communication and information sharing empowered by powerful computational simulation tools and web services can provide the right plan for advancing biosimulation approaches in the pharmaceutical domain. Concomitant with the development of a community ecosystem is the need for an open flow model of research, in which researchers from industry and academia share knowledge in a collective
REVIEWS
commons of data, analytical tools, information technology, biospecimens and disease models [21]. The past decade has seen several efforts in open-source biomedical science – the Cancer Genome Atlas (http://www.cancergenome.nih.gov/), Pathway Commons (http://www.pathwaycommons.org) and World Community Grid (http://www.worldcommunitygrid.org). Efforts for establishing collaboration and outreach through joint projects have also been launched in North America and Europe, including the Alliance for Cellular Signaling by the NIH (http://www.afcs.org) and the HepatoSys project (http://www.hepatosys.de) in Germany. The Open Source Drug Discovery project (http://www.osdd.net), initiated by the Council of Scientific and Industrial Research, India, is a uniquely novel effort dedicated to developing drugs for neglected tropical diseases (Mycobacterium tuberculosis) that plague developing countries and have very thin pipelines (in terms of the number of candidate drug compounds in development) in the pharmaceutical industries. An open innovation strategy has also gained traction recently in the pharmaceutical industry, fueled by a need to reconfigure and streamline the drug discovery pipeline, particularly in the early phases of target biology and biomarker development [22]. An industry–academic consortium involving researchers from The University of California at San Diego, the California Institute of Technology, the Massachusetts Institute of Technology, the University of Massachusetts, Entelos, and several research groups from Pfizer has initiated a collaborative project on insulin-resistive pathways [23]. More recently, in May 2010, London-based GlaxoSmithKline and Novartis deposited over 300,000 structures of chemical compounds active against the malaria parasite Plasmodium falciparum in an open database archive, ChEMBL Neglected Tropical Disease from the European Bioinformatics Institute (http://www.ebi.ac.uk/chemblntd) [22]. Several socioeconomic obstacles to leveraging the power of an open-source approach exist, however – participant willingness to share data, incompatibility of formats, quality control of data, intellectual property conflicts and sustainable funding avenues. To develop a generic model for collaboration, it is necessary to develop a framework that is open, providing standardized, license-free access to biological data; integrative, providing common sets of pathway curation, annotation, modeling, analysis and simulation tools; and ‘share-and-care’, an incentive system for providing pre-competitive, early access to the results and data to participants.
An open, integrative, share-and-care model The goal of an open, integrative, share-and-care framework is to provide a common set of tools, principles and practices for the application of biosimulation techniques in a systematic and cohesive manner. It would involve a standardization platform that enables the incorporation of standards and interfaces for the systems biology community; a computational bio-networking platform that provides a suite of network building tools, databases and web services for sharing information in a standards-compliant, interoperable manner; and an advanced simulation platform that incorporates the different simulation tools and technologies and is capable of encompassing information from the standard compliant biological network resources and databases. A schematic representation of such a scheme is shown in Fig. 4. www.drugdiscoverytoday.com
1029
Reviews INFORMATICS
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
[()TD$FIG]
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
Reviews INFORMATICS FIGURE 4
An open, integrative, share-and-care model for systems biology.
Although the technical components of such a framework are all or mostly in place, the success of the model hinges on being able to foster a bi-directional flow of knowledge between academia and industry. An open access paradigm for information and data sharing would enable the fast and effective dissemination of knowledge and the identification and filling in of information gaps in crucial biological processes and pathways. A standard-driven, integrative framework would enable a plugand-play model for diverse simulation and modeling tools, providing researchers with the freedom to test various tools and techniques. The most important part, perhaps, is ensuring the flow of information between diverse research groups. In this respect, a share-and-care model would provide incentives to all participants: academic researchers would gain access to specific data on drugs and clinical trials (e.g. access to failed drugs from phase II trial databases [24]), enabling them to develop models with higher predictive powers, whereas the business imperatives of pharmaceutical companies would be respected through early, pre-competitive access to model predictions and insights. Such a system would work in a positive feedback loop, because high-precision data from the drug industry would drive the precision of biosimulation models, which, in turn, would be able to provide better decision-making conditions for the drug companies. In a recent development, a Boston, MA based startup called 1030
www.drugdiscoverytoday.com
EnlightBio (http://www.enlightbio.com), working on similar paradigms, started operations focused on developing breakthrough innovations through partnership with multiple drug companies. Another effort initiated in early 2010 is Sage Bionetworks (http:// www.sagebase.org), a non-profit, open-source research organization that aims to develop and share large-scale network models of diseases. Such initiatives would foster collaborative research while paving the way for systems biology to empower the life sciences industry.
Future perspectives The value of applying systems biology techniques to the different stages of the drug design and development process has been demonstrated through various academic–industry collaborations spanning projects of different scales and sizes. Although such isolated success stories further motivate the large-scale adoption of in silico biosimulation practices, the development of a structured and coherent route to facilitate and accelerate the process is imperative. As outlined in this review, collaboration is the key to achieving the goal – not only in terms of joint projects but also – in developing a suite of standards-compliant platforms for sharing domain-specific knowledge and expertise. It might not be a distant dream that the community will develop a set of recommendations for good simulation practices (GSP), as already exists for good manufacturing practices (GMP) and good engineering practices (GEP) – standards and protocols accepted and complied with in the
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
application of computational simulation tools for drug design and development.
Acknowledgements This research is, in part, supported by the ERATO-SORST Program of the Japan Science and Technology Agency (JST); the Genome
REVIEWS
Network Project of the Ministry of Education, Culture, Sports, Science, and Technology; the NEDO Fund for International Standard Formation from the New Energy Development Organization; and the Okinawa Institute of Science and Technology.
1 Editorial, (2008) All systems go. Nat. Rev. Drug Discov. 7, 278–279 2 FCSB, (2008) The Tokyo Declaration, International Workshop on Future Challenges for Systems Biology. http://www.systems-biology.org/myukiko/FCSB2008/ doku.php?id=workshop:statement 3 PriceWaterhouseCoopers, (2008) Pharma 2020: Virtual R7D – which path will you take? http://www.pwc.com/extweb/pwcpublications.nsf/docid/ 91BF330647FFA402852572F2005ECC22 4 Futurology, P. (2007) Joined-up healthcare, 2016 and beyond. British Telecommunications http://www2.bt.com/static/i/media/pdf/ BT_Pharma_Lowres.pdf 5 Kansal, A.R. and Trimmer, J. (2005) Application of predictive biosimulation within pharmaceutical clinical development: examples of significance for translational medicine and clinical trial design. Syst. Biol. (Stevenage) 152, 214–220 6 Rullmann, J.A.C. et al. (2005) Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. Syst. Biol. (Stevenage) 152, 256–262 7 Sams-Dodd, F. (2006) Drug discovery: selecting the optimal approach. Drug. Discov. Today 11, 465–472 8 No authors listed. (2005) Models that take drugs. The Economist June, S23–S24. 9 Michelson, S. and Scherrer, D. (2003) Predictive biosimulation for lead optimization. Curr. Drug Discov. 1, 18–22 10 Kitano, H. (2010) Grand challenges in systems physiology. Frontiers in Physiology. doi:10.3389/fphys.2010.00003. 11 No author listed. (2008) Merrimack Pharmaceuticals initiates enrollment in a phase 1 study of MM-121, an ErbB3 antagonist. Medical News Today August.
12 Klipp, E. et al. (2007) Systems biology standards – the community speaks. Nat. Biotechnol. 25, 390–391 13 Le Nove`re, N. et al. (2009) The systems biology graphical notation. Nat. Biotechnol. 27, 735–741 14 Shapiro, B.E. et al. (2003) Cellerator: extending a computer algebra system to include biochemical arrows for signal transduction simulations. Bioinformatics 19, 677–678 15 Hoops, S. et al. (2006) COPASI – a complex pathway simulator. Bioinformatics 22, 3067–3074 16 Ramsey, S. (2005) Dizzy: stochastic simulation of large-scale genetic regulatory networks. J. Bioinform. Comput. Biol. 3, 415–436 17 Funahashi, A. et al. (2008) CellDesigner 3.5: a versatile modeling tool for biochemical networks. In Proceedings of the IEEE 96 pp. 1254–1265 18 Matsuoka, Y. et al. (2010) Payao: a community platform for SBML pathway model curation. Bioinformatics 26, 1381–1383 19 Thomas, P.D. et al. (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 20 Henney, A. and Superti-Furga, G. (2008) A network solution. Nature 455, 730–731 21 Patlak, M. (2010) Open-source science makes headway. J. Natl. Cancer Inst. 102, 1221–1223 22 Strauss, S. (2010) Pharma embraces open source models. Nat. Biotechnol. 28, 631– 634 23 No authors listed. (2008) The Insulin Resistance Pathways Project. http:// www.pfizercambridge.com/home.php?id=groups/tgu/focus_insulin 24 Petsko, G.A. (2010) When failure should be the option. BMC Biol. 8, 61
www.drugdiscoverytoday.com
1031
Reviews INFORMATICS
References
Drug Discovery Today Volume 15, Numbers 23/24 December 2010
REVIEWS
Reviews POST SCREEN
Lyotropic liquid crystal systems in drug delivery Chenyu Guo1, Jun Wang1, Fengliang Cao1, Robert J. Lee2,3, and Guangxi Zhai1, 1
Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 250012, People’s Republic of China Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA 3 Center for Affordable Nanoengineering of Polymeric Biomedical Devices, an NSF Nanoscale Science and Engineering Center, The Ohio State University, Columbus, OH 43210, USA 2
Lyotropic liquid crystal systems, such as reversed bicontinuous cubic and hexagonal mesophases, are attracting more and more attention because of their unique microstructures and physicochemical properties. Various bioactive molecules such as chemical drugs, peptides and proteins can be solubilized in either aqueous or oil phase and be protected from hydrolysis or oxidation. Furthermore, several studies have demonstrated sustained release of bioactive molecules from reversed cubic and hexagonal mesophases. This article gives an overview of recent advances and current status of reversed cubic and hexagonal mesophases, especially with respect to their preparation methods and applications in the field of drug delivery. In addition, potential problems and possible future research directions are highlighted.
Introduction Lyotropic liquid crystal (LLC) systems that commonly consist of amphiphilic molecules and solvents can be classified into lamellar (La), cubic, hexagonal mesophases, and so on. In recent years, LLC systems have received considerable attention because of their excellent potential as drug vehicles. Among these systems, reversed cubic (Q2) and hexagonal mesophases (H2) are the most important and have been extensively investigated for their ability to sustain the release of a wide range of bioactives from low molecular weight drugs to proteins, peptides and nucleic acids [1–5]. Reversed cubic and hexagonal mesophases are often formed by polar lipids in an aqueous environment. The structure-forming lipids can absorb a certain amount of water and then spontaneously form gel-like phases with unique internal structures, into which drugs can be incorporated. Moreover, non-toxic, biodegradable and bioadhesive properties also contribute to their applications for drug delivery [6]. Owing to infinite swelling capability, reversed cubic and hexagonal mesophases can also be dispersed in equilibrium with excess water and form colloidal dispersions with superior thermodynamic stability [7,8]. At present, reversed cubic and hexCorresponding authors:. Zhai, Lee, R.J. (
[email protected]), G. (
[email protected])
1032
www.drugdiscoverytoday.com
agonal mesophases are being investigated as candidates for aural, buccal, gastrointestinal, intravenous, lung, nasal, oral, rectal and vaginal administration of drug with considerable progress [1]. In the following sections, we briefly introduce the cubic and hexagonal mesophases based on recent literature, including their textures, preparation methods, phase behaviors and applications in drug delivery. This article is not meant to provide an exhaustive review but rather to present some highlights. In particular, we discuss the current status of investigations with respect to the applications of cubic and hexagonal mesophases as drug vehicles and then propose new or promising directions of research.
Structures of reversed cubic and hexagonal mesophases For reversed bicontinuous cubic and hexagonal mesophases, three macroscopic forms are typically encountered: precursor, bulk gel and particulate dispersions.
Structure of cubic mesophase The structure of cubic mesophases is unique and comprises a curved bicontinuous lipid bilayer (with an estimated thickness of 3.5 nm) extending in three dimensions and two interpenetrating, but non-contacting, aqueous nano-channels (with a fully
1359-6446/06/$ - see front matter ß 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2010.09.006
swollen diameter of approximately 5 nm), with a high interfacial area of 400 m2/g [1,7,8]. At present, the cubic mesophases prepared by unsaturated monoglycerides or phytantriol (PT) are the most frequently investigated liquid crystal structures for drug delivery [9–11]. The compartmentalization in cubic mesophases can be used to introduce guest drugs of hydrophilic, lipophilic or amphiphilic nature (Fig. 1a). Hydrophilic drugs will be located close to the emulsifier polar head or in the water channels, whereas lipophilic drugs will be localized within the lipid bilayer and amphiphilic drugs